



Cecelia B. Moore
Chief Financial Officer and Treasurer
VUMC Finance

August 27, 2018

Donna L. Seger, M.D.
Executive Director
Tennessee Poison Center
3319 West End Avenue
Suite 460
Nashville, TN 37203-1059

Dear Dr. Seger,

This letter will describe the relationship between the Tennessee Poison Center, located at Vanderbilt University Medical Center (VUMC), and the financial oversight process that exists to ensure a well-managed operation.

The Tennessee Poison Center is a program of the department of Pharmaceutical Services of VUMC Adult Hospital, and as such, does not have an individual financial audit by an independent accounting firm. The Poison Center's revenue, expenses and budget are overseen by Poison Center Management that is accountable to the CEO of the Adult Hospital and are required to follow VUMC financial guidelines and policies that are monitored by VUMC Finance. Activities of the Poison Center are also subject to review by Vanderbilt Internal Audit.

I can attest to the fact that strict accounting measures are applied to the financial management of the Poison Center. The monthly performance of the Center's financial activity is approved by the Center's program director and monitored by VUMC Finance.

A financial audit is performed every year for Vanderbilt University Medical Center and a separate audit is completed for the Vanderbilt University Hospital and Clinics by an independent accounting firm. A copy of the fiscal 2016 Hospital audit is enclosed. Although the Poison Center is not specifically identified in the audit, please note on page 1 of the Independent Auditor's Report, that the Hospital's financial statements fairly present the financial position of the Adult Hospital.

You are free to photocopy this letter and send it along with your funding applications to area foundations and to United Way. If any questions about the procedures should arise, I will be glad to address them.

Sincerely,

A handwritten signature in cursive script, reading "Cecelia B. Moore".

Cecelia B. Moore
Chief Financial Officer and Treasurer
VUMC Finance

Vanderbilt University Medical Center

**Consolidated Financial Statements and
Uniform Guidance Reports and Schedule
Years Ended June 30, 2022 and 2021**

Ernst & Young LLP



Vanderbilt University Medical Center
Index to Consolidated Financial Statements
June 30, 2022 and 2021

Page

Other Information

Roster of VUMC officials

Report of Independent Auditors 1

Consolidated Financial Statements

Consolidated Balance Sheets 3

Consolidated Statements of Operations 4

Consolidated Statements of Changes in Net Assets 5

Consolidated Statements of Cash Flows 6

Notes to Consolidated Financial Statements 7

Supplementary Information

Schedule of Expenditures of Federal Awards and State Financial Assistance 46

Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance 103

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on
Compliance and Other Matters Based on an Audit of Financial Statements Performed
in Accordance With *Government Auditing Standards* 104

Report of Independent Auditors on Compliance for Each Major Federal Program and
Report on Internal Control Over Compliance Required by the Uniform Guidance 106

Schedule of Findings and Questioned Costs 110

Roster of VUMC officials

The members of our Board, Board Advisors, Audit Committee and Management Officials responsible for the financial statements are reflected below.

VUMC Board Members:

Edie Johnson (Chair)
John Stein (Vice Chair)
Jeff Balser
Cindy Baier
Daniel Diermeier
Sara Finley
John Ingram
Mike Johns
Sam Lynch
Alex Taylor
Makeba Williams

VUMC Board Advisors:

Mike Burry
Colin Reed
Gail Williams

Audit & Compliance Committee Members:

Sam Lynch (Chair)
Cindy Baier
Sara Finley
John Ingram
Edie Johnson
Jeff Balser (non-voting)

Management Officials Responsible for the Financial Statements

Cecelia Moore (Chief Financial Officer and Treasurer)
Scott Phillips (Chief Accounting Officer and Corporate Controller)

Report of Independent Auditors

Senior Management and the Board of Directors
Vanderbilt University Medical Center

Opinion

We have audited the consolidated financial statements of Vanderbilt University Medical Center (VUMC), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of VUMC at June 30, 2022 and 2021, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of VUMC, and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such

procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of VUMC's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for a reasonable period of time.


We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to September 30, 2022. The *Schedule of Expenditures of Federal Awards and State Financial Assistance* as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* and the State of Tennessee Audit Manual is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated September 30, 2022, on our consideration of VUMC's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of VUMC's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering VUMC's internal control over financial reporting and compliance.



September 30, 2022, except for our report on the Schedule of Expenditures of Federal Awards and State Financial Assistance for which the date is February 3, 2023

Vanderbilt University Medical Center
Consolidated Balance Sheets
June 30, 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
Assets		
Current assets:		
Cash and cash equivalents	\$ 651,720	\$ 837,312
Current investments	255,090	215,484
Patient accounts receivable	658,644	553,874
Grants and contracts receivable	88,793	77,365
Inventories	134,557	140,281
Other current assets	122,903	118,259
Total current assets	<u>1,911,707</u>	<u>1,942,575</u>
Restricted cash	18,662	27,404
Noncurrent investments	773,234	779,389
Noncurrent investments limited as to use	150,925	127,414
Property, plant, and equipment, net	1,679,768	1,630,325
Operating lease assets	826,560	839,850
Other noncurrent assets	166,734	96,351
Total assets	<u>\$ 5,527,590</u>	<u>\$ 5,443,308</u>
Liabilities and Net Assets		
Current liabilities:		
Current portion of long-term debt	\$ 18,193	\$ 14,704
Short-term borrowings	—	300,000
Accounts payable and other accrued expenses	404,059	356,171
Medicare accelerated payments	15,956	189,427
Estimated liabilities under third-party programs	89,328	37,669
Accrued compensation and benefits	353,270	316,531
Current portion of operating lease liabilities	68,510	67,343
Current portion of deferred revenue	9,494	4,240
Current portion of medical malpractice self-insurance reserves	15,820	15,820
Total current liabilities	<u>974,630</u>	<u>1,301,905</u>
Long-term debt, net of current portion	1,728,263	1,432,150
Noncurrent portion of operating lease liabilities	783,178	795,330
Fair value of interest rate exchange agreements	45,019	76,864
Noncurrent portion of medical malpractice self-insurance reserves	65,816	56,770
Noncurrent portion of deferred revenue	1,560	2,923
Other noncurrent liabilities	8,856	46,986
Total liabilities	<u>3,607,322</u>	<u>3,712,928</u>
Net assets without donor restrictions:		
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,631,068	1,497,483
Net assets without donor restrictions related to noncontrolling interests	20,768	8,339
Total net assets without donor restrictions	<u>1,651,836</u>	<u>1,505,822</u>
Net assets with donor restrictions	268,432	224,558
Total net assets	<u>1,920,268</u>	<u>1,730,380</u>
Total liabilities and net assets	<u>\$ 5,527,590</u>	<u>\$ 5,443,308</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Operations
Years Ended June 30, 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
Operating revenues		
Patient service revenue	\$ 5,356,273	\$ 4,691,814
Academic and research revenue	705,859	614,611
Other operating revenue	278,736	228,204
Total operating revenues	6,340,868	5,534,629
Operating expenses		
Salaries, wages, and benefits	3,304,333	2,836,544
Supplies and drugs	1,426,939	1,216,203
Facilities and equipment	306,378	296,748
Services and other	919,405	795,287
Depreciation and amortization	172,999	151,454
Interest	59,930	60,530
Total operating expenses	6,189,984	5,356,766
Income from operations	150,884	177,863
Nonoperating revenues and expenses		
(Loss) income from investments	(71,057)	68,201
Gift income	21,477	19,104
Earnings of unconsolidated organizations	9,392	8,100
Unrealized gain on interest rate exchange agreements, net of cash settlements	25,841	17,372
Other nonoperating gains	5,957	—
Total nonoperating revenues and expenses	(8,390)	112,777
Excess of revenues over expenses	142,494	290,640
Excess of revenues over expenses attributable to noncontrolling interests	(8,886)	(6,295)
Excess of revenues over expenses attributable to VUMC	133,608	284,345
Other changes in net assets without donor restrictions		
Change in noncontrolling interests' net assets	12,429	1,704
Net assets released from restriction for capital	6,733	474
Other changes	(6,756)	3,868
Total changes in net assets without donor restrictions	\$ 146,014	\$ 290,391

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Changes in Net Assets
Years Ended June 30, 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
Net assets without donor restrictions		
Net assets without donor restrictions at the beginning of the period	\$ 1,505,822	\$ 1,215,431
Excess of revenues over expenses	133,608	284,345
Change in noncontrolling interests' net assets	12,429	1,704
Net assets released from restriction for capital	6,733	474
Other changes	(6,756)	3,868
Change in net assets without donor restrictions	146,014	290,391
Net assets without donor restrictions at the end of the period	<u>\$ 1,651,836</u>	<u>\$ 1,505,822</u>
Net assets with donor restrictions		
Net assets with donor restrictions at the beginning of the period	\$ 224,558	\$ 186,555
Contributions	73,294	46,824
Restricted investment (loss) income	(8,482)	11,169
Net assets released from restrictions for operations	(15,697)	(15,647)
Net assets released from restriction for capital	(6,733)	(474)
Other changes	1,492	(3,869)
Change in net assets with donor restrictions	43,874	38,003
Net assets with donor restrictions at the end of the period	<u>\$ 268,432</u>	<u>\$ 224,558</u>
Total net assets		
Beginning of the period	\$ 1,730,380	\$ 1,401,986
Change in total net assets	189,888	328,394
End of the period	<u>\$ 1,920,268</u>	<u>\$ 1,730,380</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Cash Flows
Years Ended June 30, 2022 and 2021

(\$ in thousands)	2022	2021
Cash flows from operating activities		
Change in total net assets	\$ 189,888	\$ 328,394
Adjustments to reconcile change in total net assets to net cash provided by operating activities:		
Depreciation and amortization	172,999	151,454
Gain on acquisition of equity method investment	(14,669)	—
Investment losses (gains)	102,832	(64,917)
Purchases of trading securities	(289,027)	(391,959)
Sales of trading securities	306,081	363,454
Unrealized gain on interest rate exchange agreements	(31,845)	(23,478)
Implementation costs incurred on hosting arrangements	(18,108)	—
Restricted contributions for endowments and property, plant, and equipment	(24,323)	(21,755)
Noncash lease expense	76,325	77,755
Other noncash activities	(2,805)	(3,852)
(Decrease) increase in cash due to changes in:		
Patient accounts receivable	(102,805)	(83,324)
Accounts payable and other accrued expenses	51,693	44,666
Medicare accelerated payments	(174,428)	(33,018)
Other assets and other liabilities, net	(42,617)	(31,344)
Net cash provided by operating activities	199,191	312,076
Cash flows from investing activities		
Purchases of property, plant, and equipment	(213,532)	(236,244)
Acquisition of hospitals	—	(15,600)
Acquisition of equity method investment	—	(36,927)
Acquisition of additional investment interest	(7,660)	—
Purchases of long-term securities	(399,028)	(437,281)
Sales and maturities of long-term securities	221,191	295,673
Proceeds on sale of property, plant, and equipment	—	15
Net cash used in investing activities	(399,029)	(430,364)
Cash flows from financing activities		
Proceeds from issuance of long-term debt	361,666	200,000
Draws on lines of credit	—	100,000
Debt issuance costs	(3,160)	(459)
Repayment of long-term debt and lines of credit	(359,292)	(510,267)
Principal payments under finance lease obligations	(7,333)	(5,766)
Restricted contributions for endowments and property, plant, and equipment	24,323	21,755
Distributions to noncontrolling interests	(10,700)	(4,591)
Net cash provided by (used in) financing activities	5,504	(199,328)
Net change in cash, cash equivalents, and restricted cash	(194,334)	(317,616)
Cash, cash equivalents, and restricted cash		
Beginning of the period	864,716	1,182,332
End of the period	\$ 670,382	\$ 864,716

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

1. Description of Organization

Vanderbilt University Medical Center (“VUMC”) is a Tennessee not-for-profit corporation incorporated in March of 2015 to operate an academic medical center including a comprehensive research, teaching, and patient care health system (the “Medical Center”). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (the “University” or “VU”), as a part of the University’s administrative structure, with the same governing board, legal, financial, and other shared services. VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the “Acquisition”).

VUMC owns and operates three hospitals located on the main campus (“Medical Center Main Campus” or “MCMC”) of the University in Nashville, Tennessee: Vanderbilt University Hospital (“VUH”), Monroe Carell Junior Children’s Hospital at Vanderbilt (“MCJCHV”), and Vanderbilt Psychiatric Hospital (“VPH”). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital (“VSRH”), also located on the main campus of the University, through a joint venture with Encompass Health Corp. in which VUMC holds a 50% interest, including a 1% interest held by Vanderbilt Health Services, LLC, (“VHS”), a VUMC wholly owned subsidiary. Effective August 1, 2019, VUMC acquired from Community Health Systems, Inc. (“CHS”): Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”). Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital (“VBCH”) and Vanderbilt Tullahoma-Harton Hospital (“VTHH”), respectively. At the same time as the acquisition of VBCH and VTHH, VUMC acquired a noncontrolling ownership interest in CHS’s affiliated Tennova Healthcare – Clarksville (“VMH”). VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH are licensed for 1,664 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration (“MCA”).

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of the Vanderbilt Medical Group (“VMG”), and technical revenues and associated expenses for the operation of VUMC’s hospitals and clinic facilities, including VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH. The Clinical Enterprise also includes VHS.

- VUH is a quaternary care teaching hospital licensed for 726 acute care and specialty beds. VUH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center. As of June 30, 2022, VUMC held a temporary license provided under the Board for Licensing Health Care Facilities (“BLHCF”) Policy 82 to license 49 additional beds in response to COVID-19. This licensure increase is comprised of 34 observation beds and 15 double occupancy beds. The beds associated with this temporary license are not included in the above VUH bed count.
- MCJCHV is a pediatric quaternary care teaching hospital licensed for 343 beds (159 acute and specialty, 65 pediatric intensive care, and 119 neonatal intensive care). MCJCHV is the region’s only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- VPH is a psychiatric hospital licensed for 106 beds and provides inpatient care to pediatric, adolescent, adult, and geriatric patients. Also, VPH provides partial hospitalization programs to both adult and adolescent patients, psychiatric assessment services, adult intensive outpatient programs, pediatric and adult ambulatory outpatient treatment, and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.
- VWCH is a two-campus facility licensed for 245 beds and is a substantial provider of both inpatient and outpatient medical services in Lebanon, Tennessee. Services offered include an accredited chest pain center, a stroke center, and a comprehensive total joint program for orthopedics. In addition, Vanderbilt Ingram Cancer Center extended services to this campus in 2020, and it includes a state-of-the-art linear accelerator.
- VBCH is a 60 licensed bed, Joint Commission-accredited hospital, which offers a range of inpatient and outpatient medical and surgical services, along with urgent care services.
- VTHH is a 135 licensed bed Joint Commission-accredited hospital, which offers a full range of inpatient and outpatient surgical and specialty services including a sleep center, cardiac rehabilitation, and physical rehabilitation. The hospital also features an accredited Chest Pain Center.
- VMG is the practice group of physicians and advanced practice practitioners employed by VUMC, many of whom, when appropriate and required, have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician's compensation. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. VMG members are "board certified" or eligible for board certification, as required by bylaws. All VMG members are re-credentialed every two years in accordance with the Centers for Medicare and Medicaid Services, The Joint Commission, and the National Committee for Quality Assurance Standards. The majority of the specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.
- VHS serves as a holding company for 16 first-tier health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network ("VHAN"). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.
- Health Professional Solutions, LLC ("HPS") is a holding company that holds interest in five VUMC subsidiaries that engage in or support various health care related activities in order to improve the quality and availability of health care services in the community. These subsidiaries include businesses focused on pharmacy, supply chain, and clinically integrated support services.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

- Nashville Biosciences, LLC (“NashBio”) operates exclusively in support of VUMC’s non-academic medical research activities. NashBio deploys the biospecimens and genomic data and de-identified medical records of VUMC known as “BioVU”, along with other information, to provide commercial services and products to life science industry customers in connection with pharmaceutical, biotechnology, and medical research and development activities.

The Academic Enterprise division includes all research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC’s research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the Department of Defense, the National Science Foundation, and other federal agencies. Sponsored research awards, including multi-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

VUMC has entered into debt agreements further discussed below. Certain of these debt agreements contain required disclosures outlining annual and quarterly reporting requirements. In addition, certain of these debt agreements require notices of the occurrence of significant events which include but are not limited to delinquencies, bond calls, rating changes, bankruptcies, and mergers or acquisitions. The Obligated Group includes the wholly-owned hospitals located on the MCMC along with all associated on-campus and off-campus ambulatory clinics, the Academic Enterprise, MCA, VWCH, and VMG.

The terms “Company,” “VUMC,” “we,” “our,” or “us” as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by VUMC and its affiliates, and the term “employees” refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term “Fiscal” preceding a year refers to a particular VUMC fiscal year.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC’s share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC’s

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

investment (i.e., dividends) are reported as cash flows from operating activities in VUMC's consolidated statements of cash flows.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bears a risk of loss.

Liquidity and Availability

As of June 30, 2022, VUMC has \$2,338.6 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$651.7 million, patient accounts receivable of \$658.6 million, and unrestricted investments of \$1,028.3 million. As of June 30, 2021, VUMC had \$2,386.1 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$837.3 million, patient accounts receivable of \$553.9 million, and unrestricted investments of \$994.9 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditures within one year of the balance sheet date.

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificates of deposit and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has committed lines of credit in the amount of \$150.0 million, which it could draw upon in the event of an unanticipated liquidity need, with no amount drawn as of June 30, 2022 and \$100.0 million drawn as of June 30, 2021.

Revenue Recognition – Patient Services

VUMC contracts with patients to provide healthcare services that are tailored to each patient's medical needs and health conditions. VUMC recognizes patient service revenue over time as performance obligations are ultimately satisfied. Performance obligations related to inpatient services are generally satisfied as the healthcare services are rendered to the patient, which generally begins at the time of patient admission and extends through the time of patient discharge. Performance obligations for outpatient services are generally satisfied on the same day that services are rendered to the patient. VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Patient service revenue is recognized on an accrual basis using a best estimate of the transaction price for the type of service rendered to the patient. The transaction price ultimately represents the estimated amount to be received from the patient and third-party payors in exchange for the services rendered by VUMC. VUMC estimates the transaction price based on standard charges, reduced for estimated price concessions. The price concessions include items that are explicit, such as contractual adjustments provided to third-party payors and discounts provided to uninsured and underinsured patients in accordance with VUMC policy, and also implicit in nature, such as the estimated uncollectible amounts from uninsured or underinsured patients. VUMC regularly reviews transactional data for the major revenue categories to evaluate the reasonableness of the transaction price, including any price concessions, and takes into consideration recent experience by payor category and payor agreement rate changes among other factors.

VUMC carries the value of the related patient accounts receivable balances at the transaction price, inclusive of all estimated price concessions. Given the complexities involved in determining amounts ultimately due to VUMC under reimbursement arrangements with third-party payors, which are often subject to interpretation, VUMC may receive reimbursement for healthcare services authorized and provided that differs from these estimates. If actual results differ from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC has elected to apply the optional exemption provided in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which is typically within a week.

In addition to reimbursement received in fee-for-service arrangements, VUMC participates in certain federal healthcare programs, as well as state and commercial payor programs, through which VUMC may be entitled to additional payments. These arrangements are complex and may extend over multiple accounting periods. The arrangements are subject to the interpretation of federal and state-specific reimbursement rules, new or changing legislation, and final cost report settlements. Any changes to reimbursement rules or the introduction of new or changing legislation could impact levels and timing of reimbursements received from these programs. As a participant in these programs, VUMC is also required to meet certain financial reporting requirements which include the filing of an annual cost report for each hospital. Each annual cost report is also subjected to an audit performed by the regulatory agency and may extend several years before ultimate settlement becomes known. Therefore, determining the actual amounts earned under these programs involves judgement and estimates that may extend into future periods. These estimates are frequently evaluated and subsequently may be adjusted based on new developments or the receipt of new information related to these settlements. If actual results vary from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Revenue Recognition – Non-Patient Services

Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative ("F&A") costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

Deferred Revenue

Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

Gift Income and Pledges

VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the consolidated statements of operations. Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2022 and 2021.

Concentrations of Risk

VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare (both traditional fee-for-service and Managed Medicare), or TennCare agreements. Medicare, Blue Cross Blue Shield ("BCBS"), and TennCare (which includes BCBS of Tennessee, United, and Amerigroup) represent VUMC's significant concentrations of credit risk from payors.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

The collection of revenue and accounts receivables from Medicare, TennCare, Blue Cross, other third-party payors, and patients is a significant source of operating cash flow. The payor composition of patient service revenue and related accounts receivable portfolio may fluctuate from time to time and generally correlate to the prevailing economic conditions, such as periods of economic expansion or recession or changes in unemployment levels, and those fluctuations may impact the realization of patient service revenue and collectability of accounts receivable. Other factors such as unexpected disruptions to business office operations or trends in federal or state governmental and private employer healthcare coverage could affect the ultimate collectability of accounts receivable balances. As a result, VUMC may be exposed to gains or losses in future periods that could affect the financial position and operating cash flows of the organization and may be material to its financial position, operating income and cash flow from operations.

Inventories

VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

Restricted Cash

VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment and restricted cash associated with our self-insurance trust.

Investments

VUMC reports investments held at fair value in the consolidated balance sheets. Private equity investments, multi-strategy hedge funds, and hedged equity funds are reported based on net asset value ("NAV"), provided by the respective fund manager, as a practical expedient to estimate fair value. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Property, Plant, and Equipment, Net

VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (5 to 18 years), buildings and leasehold improvements (2 to 40 years), and equipment (2 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 3 to 12 years.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Costs Associated with Hosting Arrangements under Service Contracts

Costs associated with hosting arrangements under service contracts are presented in other noncurrent assets on our consolidated balance sheets. These assets total \$18.1 million and \$0 as of June 30, 2022 and June 30, 2021, respectively. The related capitalization policy is consistent with the policy described above for internal use software. Once placed into service, these assets will be amortized over their respective estimated useful lives. Currently these assets largely consist of costs associated with the implementation of an enterprise resource planning system, which has not yet been placed into service.

Impairment of Long-Lived Assets

VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations

VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total \$7.0 million and \$6.7 million as of June 30, 2022 and 2021, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2022 and 2021. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2022 and 2021, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

Long-Term Debt

The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs and bond premiums and discounts.

Interest Rate Exchange Agreements

VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves

VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. For Fiscal 2022 and 2021, the maximum annual self-insurance retention was \$6.0 million per occurrence, up to \$46.0 million in the aggregate. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2022 and 2021. For both Fiscal 2022 and 2021, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims exceeding the retention limits, up to \$175.0 million. These policies would also provide coverage up to \$175.0 million if any claims in the aggregate exceeded the retention limits.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers' compensation was \$0.8 million per occurrence for both Fiscal 2022 and 2021. There is no stop loss insurance on health plan claims.

Income Taxes

VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the "Code") and is generally exempt from federal income taxes under Section 501(a) of the Code.

Excess of Revenues Over Expenses

The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders' share of consolidated entities, net assets released from restrictions used for capital, and certain other items.

Statement of Cash Flows

For VUMC's consolidated statements of cash flows, cash, cash equivalents, and restricted cash is defined as those amounts included in the cash and cash equivalents caption and restricted cash caption on the consolidated balance sheets.

Reclassifications

Certain reclassifications have been made to the Fiscal 2021 consolidated financial statements to conform to the Fiscal 2022 presentation. The reclassifications had no effect on net assets or changes in net assets as previously reported.

Recent Accounting Pronouncements

Periodically, the FASB issues Accounting Standards Updates ("ASUs") that may impact the recognition, measurement, and presentation of balances and activity in VUMC's consolidated financial statements or the disclosures contained within those statements. As part of preparing consolidated financial statements, VUMC evaluates the effects of the ASUs and applies the updated guidance within the required effective dates.

Adopted

- Effective July 1, 2021, VUMC adopted FASB ASU 2018-15, Intangibles – Goodwill and Other, Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. The primary effect of adopting this ASU is the capitalization of implementation costs incurred in hosting arrangements that are service contracts and subsequent amortization expenses in the consolidated statements of operations. The ASU was adopted prospectively and resulted in \$18.1 million of implementation costs being capitalized during Fiscal 2022, which are recorded in other noncurrent assets on the consolidated balance sheet.
- Effective July 1, 2021, VUMC adopted FASB ASU 2020-07, Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958). This ASU requires presentation of nonfinancial assets as a separate line in the consolidated statement of operations, apart from contributions of cash or other financial assets. The adoption of this ASU did not materially impact the consolidated financial statements.
- Effective July 1, 2021, VUMC adopted FASB ASU 2021-03, Intangibles – Goodwill and Other (Topic 350): Accounting Alternative for Evaluating Triggering Events. This ASU provides private companies and not-for-profit entities with an accounting alternative to perform the goodwill

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

impairment triggering event evaluation as required in Subtopic 350-20 as of the end of the reporting period. An entity that elects this alternative is not required to monitor for goodwill impairment triggering events during the reporting period but, instead, should evaluate the facts and circumstances as of the end of each reporting period to determine whether a triggering event exists and, if so, whether it is more likely than not that goodwill is impaired. VUMC has elected this alternative and evaluates goodwill, recorded in other noncurrent assets on the consolidated balance sheet, for impairment as of the end of each annual reporting period. The adoption of this ASU did not have a material impact on our consolidated financial statements.

3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University's owned and operated Medical Center through the Acquisition.

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement ("MTSA"). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement ("AAA"), a Trademark License Agreement ("TMLA"), a Ground Lease, and a Reciprocal Master Services Agreement ("MSA"). The agreements are described below.

- The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all the University's degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU's academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index ("BRDPI") in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$79.8 million and \$78.5 million, respectively, in connection with fees due under the AAA.

- Under the TMLA, VU grants, subject to certain consents and approvals, a perpetual license to use various VU-owned licensed marks in connection with VUMC's fundamental activities after the Acquisition date. The licensed marks, which VUMC continues to use as its primary brands, include virtually all those previously in use by VUMC. This agreement requires VUMC to pay VU royalties consisting of a monthly payment equal to 1% of all operating revenue of VUMC and 15% of income from operations. During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$88.0 million and \$83.7 million, respectively, in connection with the 1% of operating revenue and 15% of operating income payments due under the TMLA. Also, VUMC is required to pay in equal monthly installments an annual TMLA base fee royalty, which increases 3% annually, but is also reduced by the amount of principal payments made under a subordinated note discussed in Note 11 Long-Term Debt (the "Fixed TMLA Royalty Payment"). During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$66.6 million and \$64.6 million, respectively, in connection with this base fee royalty. In Fiscal 2018, VU sold its rights to future base fee royalty payments to a third party. In Fiscal 2019, VU sold its rights to future 1% of operating revenue payments to a third party. The TMLA is in force in perpetuity under certain mutually agreed-upon termination or default clauses.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC's campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2114, with the option to extend the lease for two additional terms of up to 50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal 2022 and 2021, VUMC recorded operating expense totaling \$20.4 million and \$19.6 million, respectively, in connection with fees due under the Ground Lease.
- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU provides services to VUMC, such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC provides various operational services for the University, such as a student health clinic and animal care. Additionally, the MSA encompasses an Employee Matters Agreement ("EMA") and specific Employee Service Agreements ("ESAs"). The EMA and ESAs govern employee transactions and ongoing sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to predetermined cancellation notification periods. In connection with the MSA, during Fiscal 2022 and 2021, VUMC recognized revenue totaling \$44.5 million and \$43.4 million, respectively, and recorded operating expense totaling \$121.2 million and \$119.5 million, respectively.
- Also, as part of the Acquisition, VUMC issued to VU a \$100.0 million subordinated promissory note payable, which is further described in Note 11 Long-Term Debt, with a balance of \$69.6 million as of June 30, 2022, and \$74.6 million as of June 30, 2021. VU sold its rights to future principal and interest payments on this note to a third party.

The impact of these agreements in the consolidated statements of operations during Fiscal 2022 and 2021 is as follows:

<i>(\$ in thousands)</i>	2022	2021
Academic and research revenue	\$ 13,540	\$ 15,816
Other operating revenue	30,958	27,565
Total operating revenues	<u>\$ 44,498</u>	<u>\$ 43,381</u>
Operating expenses		
Salaries, wages, and benefits	\$ 9,111	\$ 8,223
Facilities and equipment	58,610	56,910
Services and other	308,290	300,656
Interest	2,336	2,498
Total operating expenses	<u>\$ 378,347</u>	<u>\$ 368,287</u>

Other current assets include amounts receivable from VU, which totaled \$7.0 million as of June 30, 2022, and \$8.0 million as of June 30, 2021. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled \$58.5 million as of June 30, 2022 and 2021.

In the normal course of business, members of VUMC's Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all individual members of the VUMC community (including Board of Directors, VUMC officials, full-time, part-time, temporary faculty and staff). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC's best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit and Compliance Committee of the Board of Directors.

4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements

The sources of patient service revenue by payor for Fiscal 2022 and 2021 are as follows:

<i>(\$ in thousands)</i>	2022	2021
Other third-party payors, primarily commercial carriers	\$ 3,307,671	\$ 2,961,480
Medicare/Managed Medicare	1,262,330	1,084,216
TennCare/Medicaid	724,030	608,791
Uninsured (self-pay)	62,242	37,327
	<u>\$ 5,356,273</u>	<u>\$ 4,691,814</u>

Patient accounts receivable comprise amounts due from the following sources as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Medicare/Managed Medicare	\$ 119,626	\$ 95,382
TennCare/Medicaid	87,357	70,487
Blue Cross	134,528	115,028
Other third-party payors, primarily commercial carriers	260,034	219,643
Patient responsibility ⁽¹⁾	57,099	53,334
Patient accounts receivable	<u>\$ 658,644</u>	<u>\$ 553,874</u>

⁽¹⁾ Includes self-pay after insurance.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Estimated third-party settlements by major payor category as of June 30, 2022 and 2021 are as follows:

<i>(\$ in thousands)</i>	2022	2021
Receivables under third-party programs		
Tricare/Champus ⁽¹⁾	\$ 5,338	\$ 4,635
Total receivables under third-party programs	<u>\$ 5,338</u>	<u>\$ 4,635</u>
Liabilities under third-party programs		
TennCare/Medicaid	\$ 88,296	\$ 33,781
Medicare ⁽¹⁾	6,370	8,170
Other	—	353
Total liabilities under third-party programs	<u>\$ 94,666</u>	<u>\$ 42,304</u>

⁽¹⁾ These two federal healthcare programs are combined for presentation purposes on the face of the consolidated balance sheets and are reflected as an obligation in Fiscal 2022 and 2021.

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized. The aggregate liability associated with pay for performance and episode of care settlements at June 30, 2022 and 2021 was \$4.8 million and \$1.1 million, respectively, with the ultimate resolution of such financial arrangements not expected to have a material impact on the operating results of VUMC.

Medicare

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2015. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.

TennCare

TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations ("MCOs"), which offer health maintenance organization ("HMO") and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system ("MS-DRG") for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system ("APC"), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC's share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

In Fiscal 2022 and 2021, patient service revenue includes the following supplemental amounts received in each respective period from TennCare.

<i>(\$ in thousands)</i>	<u>2022</u>	<u>2021</u>
Directed payments	\$ 36,633	\$ —
Charity pool	26,026	26,659
Graduate medical education	14,688	14,618
Trauma fund	1,192	1,560
Workforce development and other	2,621	—
Virtual disproportionate share	7,651	6,400
Changes in prior year virtual disproportionate share reserve estimate	—	20,411
Total supplemental TennCare revenue	<u>\$ 88,811</u>	<u>\$ 69,648</u>

5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or are included as a part of price concessions.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2022 and 2021 totals \$530.5 million and \$474.1 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2022 and 2021 totals \$140.0 million and \$123.6 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

6. Academic and Research Revenue, and Grants and Contracts Receivable

Academic and research revenue comprises the following for Fiscal 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Grants and contracts revenue		
Federally funded	\$ 415,566	\$ 345,745
Non-federally funded	123,825	124,690
	539,391	470,435
Facilities and administrative costs recovery	166,468	144,176
Academic and research revenue	<u>\$ 705,859</u>	<u>\$ 614,611</u>

Grants and contracts receivable comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Federally funded	\$ 47,210	\$ 38,472
Non-federally funded	41,583	38,893
Total grants and contracts receivable	<u>\$ 88,793</u>	<u>\$ 77,365</u>

7. Pledges Receivable, Net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2022 and 2021, were as follows:

<i>(\$ in thousands)</i>	2022	2021
Amounts due		
Within one year	\$ 19,476	\$ 10,660
In one to five years	34,312	26,257
Total pledges receivable	53,788	36,917
Unamortized discount	(1,336)	(1,225)
	52,452	35,692
Allowance for uncollectible pledges	(6,993)	(4,806)
Net pledges receivable	<u>\$ 45,459</u>	<u>\$ 30,886</u>
Net pledges receivable classified as		
Current	\$ 13,349	\$ 6,615
Noncurrent	32,110	24,271
	<u>\$ 45,459</u>	<u>\$ 30,886</u>

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling \$76.6 million and \$79.5 million as of June 30, 2022 and 2021, respectively. Due to their conditional nature, VUMC does not recognize intentions to give as assets. Pledges receivables are presented in other current assets and other noncurrent assets on our consolidated balance sheets, as shown in Note 8.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

8. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Prepaid expenses	\$ 35,547	\$ 44,552
Other receivables	61,043	55,295
Amounts due from VU (see Note 3 Related Parties)	7,017	7,977
Current pledges receivable, net (see Note 7 Pledges Receivable, Net)	13,349	6,615
Expected recoveries from commercial insurance excess coverage	5,947	3,820
Total other current assets	<u>\$ 122,903</u>	<u>\$ 118,259</u>

Other noncurrent assets comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Equity in unconsolidated organizations	\$ 62,080	\$ 63,109
Noncurrent pledges receivable, net (see Note 7 Pledges Receivable, Net)	32,110	24,271
Goodwill	27,028	—
Implementation costs incurred on hosting arrangements	18,108	—
Other	27,408	8,971
Total other noncurrent assets	<u>\$ 166,734</u>	<u>\$ 96,351</u>

Other operating revenues comprise the following for Fiscal 2022 and 2021

<i>(\$ in thousands)</i>	2022	2021
CARES funding	\$ 72,682	\$ 63,045
Clinical contracts	55,645	49,701
Amounts recognized under MSA with VU (see Note 3 Related Parties)	30,958	27,565
VHS other revenue	22,726	21,556
Nonclinical contracts	20,588	16,846
Resident and house staff rotations	9,123	10,151
Royalty revenue	17,612	1,222
Other	49,402	38,118
Total other operating revenue	<u>\$ 278,736</u>	<u>\$ 228,204</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

9. Investments

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	<u>2022</u>	<u>2021</u>
Self-insured malpractice program	\$ 49,290	\$ 46,991
Donor endowments	85,430	65,083
Split-interest trusts	8,515	9,503
Supplemental employee retirement program assets	7,690	5,837
	<u>\$ 150,925</u>	<u>\$ 127,414</u>

VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

The Board of Directors' interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor's intent, as specified in a gift agreement. Donor endowments typically benefit specific programs in clinical departments of the Medical Center, for either, research, directorships, or general program support.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary. Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially a principal amount at some point in the future. Like donor endowments, split-interest trusts typically benefit specific programs as defined in the terms of the trust.

Supplemental executive retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Investments were as follows as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Corporate bonds	\$ 345,781	\$ 336,905
Equity mutual funds	123,707	151,200
Cash and cash equivalents	17,852	27,681
Split-interest trusts	8,515	9,503
Hedged equity mutual funds	137,325	107,548
Fixed income mutual funds	167,261	217,762
Certificates of deposit	18,301	21,162
Asset-backed securities	28,022	28,971
Mortgage-backed securities	6,542	6,503
Commercial paper	22,755	37,040
Government bonds	44,126	53,133
Hedged debt mutual funds	150,056	114,474
Commodities and managed futures mutual funds	42,063	19,802
Target date mutual funds	6,422	5,168
Equity securities	12,033	—
Total investments reported at fair value	1,130,761	1,136,852
Private equity investments recorded at net asset value	31,022	12,839
Multi-strategy funds recorded at net asset value	17,055	—
Hedged equity funds recorded at net asset value	19,073	—
Total investments	<u>\$ 1,197,911</u>	<u>\$ 1,149,691</u>

Investment returns comprise the following elements for Fiscal 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Interest and dividend income	\$ 23,891	\$ 14,910
Net realized gains on sales of securities	9,619	14,922
Realized investment gains	33,510	29,832
Unrealized investment (losses) gains, net	(112,451)	49,995
Total investment returns	(78,941)	79,827
Investment manager, trustee and other fees	(598)	(457)
Restricted investment loss (income)	8,482	(11,169)
Total (loss) income from investments, net	<u>\$ (71,057)</u>	<u>\$ 68,201</u>

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, in various investment pools.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

10. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Land and land improvements	\$ 44,230	\$ 40,800
Buildings and improvements	1,303,474	1,249,125
Equipment and software	813,736	683,108
Leasehold improvements	154,486	141,358
Construction in progress	98,300	94,027
Property, plant, and equipment at cost	2,414,226	2,208,418
Accumulated depreciation and amortization	(734,458)	(578,093)
Property, plant, and equipment, net	<u>\$ 1,679,768</u>	<u>\$ 1,630,325</u>

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

In Fiscal 2022 and 2021, VUMC capitalized interest of \$1.3 million and \$2.3 million, respectively, related to long-term capital projects, primarily the VUH lobby and operating room renovations in Fiscal 2022 and the construction of ambulatory and outpatient facilities in Fiscal 2021.

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:

<i>(\$ in thousands)</i>	2022	2021
Equipment and software	\$ 211,790	\$ 188,334
Construction in progress	3,931	7,095
	215,721	195,429
Accumulated amortization	(85,071)	(58,662)
Internal use software, carrying value	<u>\$ 130,650</u>	<u>\$ 136,767</u>

Depreciation and amortization comprise the following amounts in Fiscal 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Depreciation of tangible assets	\$ 131,677	\$ 117,183
Amortization of finance leases, leasehold improvements, and internal use software	41,322	34,271
Total depreciation and amortization	<u>\$ 172,999</u>	<u>\$ 151,454</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

11. Long-Term Debt

Long-term debt comprises the following as of June 30, 2022 and 2021:

(\$ in thousands)	<u>2022</u> <u>Carrying</u> <u>Amount</u>	<u>2021</u> <u>Carrying</u> <u>Amount</u>	<u>Effective</u> <u>Interest</u> <u>Rate</u> ⁽²⁾	<u>Fiscal</u> <u>Year of</u> <u>Maturity</u>
Series debt				
Fixed-rate debt				
Series 2016A	\$ 476,930	\$ 476,930	4.1%	2047
Series 2016B	300,000	300,000	4.1%	2027
Series 2017A	121,270	121,270	4.1%	2049
Series 2017	100,000	100,000	4.2%	2038
Series 2021A	57,860	—	1.8%	2032
Series 2021B	237,565	—	3.2%	2053
Total fixed-rate debt	<u>1,293,625</u>	<u>998,200</u>	4.1%	
Variable-rate debt				
Series 2016F	21,900	21,900	1.2%	2042
Series 2017B	—	50,000	1.3%	2047
Series 2018	53,385	53,385	0.8%	2050
Series 2021C	50,000	—	1.0%	2047
Total variable-rate debt	<u>125,285</u>	<u>125,285</u>	1.0%	
Total series debt	<u>1,418,910</u>	<u>1,123,485</u>		
Other long-term debt				
2019 Term Loan	35,000	35,000	0.8%	2050
2019 Notes	128,600	128,600	3.9%	2055
2021 Short-Term Loan	—	200,000	0.5%	2022
Subordinated note payable	69,583	74,583	3.2%	2036
Product financing arrangement	20,830	25,121	4.3%	2027
Lines of credit	—	100,000	0.7%	2023
Finance leases	19,388	16,997	2.6%	Various
Total other long-term debt	<u>273,401</u>	<u>580,301</u>	2.3%	
Subtotal ⁽¹⁾	1,692,311	1,703,786	3.4%	
Net unamortized premiums	66,838	53,986		
Net unamortized issuance costs	<u>(12,693)</u>	<u>(10,918)</u>		
Total long-term debt	1,746,456	1,746,854		
Short-term borrowings	—	(300,000)		
Current portion of long-term debt	<u>(18,193)</u>	<u>(14,704)</u>		
Long-term debt, net	<u>\$ 1,728,263</u>	<u>\$ 1,432,150</u>		

(1) The effective interest rate of 3.4% as of June 30, 2022, is presented exclusive of interest rate exchange agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 3.8%.

(2) The effective interest rate for each debt instrument is calculated by dividing each instrument's interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

On April 29, 2016, VUMC issued the Series 2016 A, B, C, D, E, and F bonds ("2016 Series Debt") and notes aggregating \$1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee ("HEFB"). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC's debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$476.9 million and include an original issue premium of \$59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of \$300.0 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 35 basis points above rates for U.S. Treasury securities with comparable maturities.
- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of \$75.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, \$53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below. The renegotiated interest rate on the remaining \$21.9 million of principal outstanding is a variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. During Fiscal 2022, the Series 2016F taxable variable-rate revenue bonds were modified and the renegotiated interest rate is a variable-rate mode at a fixed spread to SOFR of 0.8%. The remaining principal has a mandatory tender date of December 1, 2028. Prior to that, beginning on July 1, 2022, VUMC must pay annual principal payments ranging from \$2.1 million to \$2.7 million. The remaining \$5.3 million of principal is due on December 1, 2028.
- Prior to Fiscal 2022, Series 2016 C, D and E bonds were extinguished.

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued ("2017 Series Debt"), aggregating \$271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUH bed expansion/clinical relocation, which was a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$121.3 million and include an original issue premium of \$5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of \$100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.
- The Series 2017B taxable variable-rate term loan notes were issued in the par amount of \$50 million and placed privately with a bank. The notes bear interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes have a final maturity date of July 1, 2046, a tender date of August 1, 2024, and may be redeemed at any time. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016. During Fiscal 2022, the Series 2017B notes were extinguished using proceeds from the Series 2021C Taxable Revenue Bonds, discussed further below.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds ("2018 Series Debt") aggregating \$53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bear interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049 and can be optionally redeemed on or after July 1, 2025. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds. During Fiscal 2022, the Series 2018 bonds were modified, and the renegotiated interest rate is a fixed spread to 79% of SOFR of 0.6%. The renegotiated bonds have a final maturity date of July 1, 2049 and can be optionally redeemed on or after December 3, 2029.

On July 30, 2019, VUMC entered into a term loan agreement ("2019 Term Loan") with a lender for \$35 million to pay for the acquisition of Tennova – Lebanon (now VWCH) hospital facilities, near term capital expenditures, and costs of issuance. The term loan bears interest at a variable rate plus a fixed spread to one-month LIBOR of 0.50% through the maturity date of August 1, 2029. VUMC has the option to prepay all or a portion of the loan at any time, subject to notice. The 2019 loan is subject to principal amortization commencing on July 1, 2024 and ending July 1, 2049, as defined in the 2019 loan agreement between VUMC and the lender.

On October 22, 2019, the 2019 Taxable Fixed Private Placement Notes ("2019 Notes") aggregating \$128.6 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2019 Notes. The 2019 Notes were placed privately with a bank, and bear interest at a fixed rate of 3.9% per annum. The notes have a final maturity date of July 1, 2054.

On April 9, 2020, the 2020 Taxable Fixed Term Loan ("2020 Loan") aggregating \$300 million was issued to provide additional liquidity during the COVID-19 pandemic. The lender for the 2020 Loan was JPMorgan Chase Bank. The debt bore interest at a fixed rate of 2.1% per annum, had an optional redemption after one year, and had a final maturity date of April 1, 2022. During Fiscal 2021, the 2020 Loan was extinguished using proceeds from the 2021 Short-Term Loan discussed further below, and draws on available lines of credit.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

On April 9, 2021, the 2021 Short-Term Loan was issued in the par amount of \$200.0 million for the purpose of refinancing the 2020 Loan. The lender for the 2021 Short-Term Loan was Royal Bank of Canada. The debt bore interest at a fixed spread to LIBOR of 0.4% and had a maturity of April 8, 2022. During Fiscal 2022, the 2021 Short-Term Loan was extinguished using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds discussed further below.

On November 4, 2021, the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds were issued, and on December 1, 2021, the Series 2021C Taxable Revenue Bonds were issued ("2021 Series Debt"), aggregating \$345.4 million of proceeds for the purpose of refinancing existing debt, funding capital projects, and paying a portion of the costs of issuance associated with the 2021 Series Debt. The 2021 Series was issued by the HEFB.

- The Series 2021A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$57.9 million and include an original issue premium of \$16.2 million. The Series 2021A bonds have a bullet maturity of July 1, 2031, and can be optionally redeemed at par on or after January 1, 2031. The Series 2021A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The 2021B taxable fixed-rate revenue bonds were issued in the par amount of \$237.6 million, bearing interest at 3.2% per annum, which is paid semiannually on July 1 and January 1. The 2021B bonds have a final maturity of July 1, 2052 and are subject to mandatory sinking fund redemption in lots. VUMC is entitled, at its option, to redeem all or a portion of the Series 2021B bonds before January 1, 2052, at a redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 20 basis points above rates for U.S. Treasury securities with comparable maturities.
- The 2021C taxable variable-rate revenue bonds were issued in the par amount of \$50.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 0.5%. The bonds have a final maturity date of July 1, 2046, a tender date of December 1, 2027, and may be redeemed at any time. Proceeds from the issuance of the Series 2021C bonds were used to extinguish the Series 2017B notes.

Each of the bonds, notes, and loans represent separate obligations under a Master Trust Indenture ("MTI") structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the "Security Agreement") within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2022 and 2021.

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of \$100.0 million to VU to finance the Acquisition (the "subordinated note"). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

a fixed rate of 3.25% with monthly principal payments totaling \$5.0 million annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. The annual payment of \$5.3 million is payable in monthly installments, is considered principal and imputed interest, and continues through Fiscal 2027. The balance due under the Product Financing Arrangement is \$20.8 million and \$25.1 million as of June 30, 2022 and 2021, respectively. At June 30, 2022 and 2021, \$4.5 million and \$4.3 million, respectively, was included in the current portion of long-term debt caption, with the remaining balance in long-term debt, net of current portion.

In Fiscal 2022 and 2021, noncash investing and financing activities totaled \$10.5 million and \$6.8 million, respectively, related to finance leases.

VUMC has an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling \$100.0 million, which bears interest at a fixed spread to one-month LIBOR of 0.65% and has no maturity date if the line of credit is renewed annually. The outstanding balance on the line of credit is \$59.5 million as of June 30, 2021. During Fiscal 2022, the outstanding balance of the general use line of credit was paid off using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds, discussed previously. The line of credit accrues a commitment fee of 0.15% per annum on any unused portion of the line of credit. Effective April 4, 2022, the agreement was amended to modify the interest rate and commitment fee and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.60%, accrues a commitment fee of 0.10% on any unused portion of the line of credit, and has a final maturity date of April 3, 2023.

VUMC established one additional line of credit with a bank in Fiscal 2021. A \$50 million line of credit with Royal Bank of Canada, bearing interest at a fixed spread to one-month LIBOR of 0.45%, maturing in Fiscal 2022 with a commitment fee of 0.2% on any unused portion of the line of credit. As of June 30, 2021, this line of credit had an outstanding balance of \$40.5 million. During Fiscal 2022, the outstanding balance of the line of credit was paid off using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds, discussed previously. Effective April 8, 2022, the agreement was amended to modify the interest rate and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.45% and has a maturity date of April 7, 2023.

During Fiscal 2020, VUMC established an additional \$50 million line of credit with Truist, bearing interest at a fixed spread to one-month LIBOR of 1.0%, maturing in Fiscal 2022 with a commitment fee of 0.25% on any unused portion of the line of credit. As of June 30, 2021, this line of credit had no outstanding balance. This line of credit expired during Fiscal 2022.

The total outstanding balance on lines of credit is \$100.0 million as of June 30, 2021. There is no outstanding balance on lines of credit as of June 30, 2022. Commitment fees for the lines of credit totaled \$0.3 million and \$0.4 million in Fiscal 2022 and Fiscal 2021, respectively.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Interest paid on all obligations, including interest rate swap settlements, net of amounts capitalized, was \$62.6 million and \$68.4 million in Fiscal 2022 and 2021, respectively.

Principal retirements and scheduled sinking fund requirements based on nominal maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

(\$ in thousands)

2023	\$ 18,193
2024	17,319
2025	17,009
2026	19,980
2027	317,167
Thereafter	1,302,643
	<u>\$ 1,692,311</u>

12. Interest Rate Exchange Agreements

Key features of VUMC interest rate exchange agreements are summarized below:

<u>Notional Amount</u>	<u>Pay Fixed Rate</u>	<u>Receive Variable Rate</u>	<u>Mandatory Termination Date</u>
\$75.0 million	4.28%	68% of one-month LIBOR	April 29, 2026
\$75.0 million	4.18%	68% of one-month LIBOR	April 29, 2023

VUMC incorporates these interest rate exchange agreements into its debt portfolio management strategy. There are no collateral pledging requirements. The agreements terminate automatically on April 29, 2026 and 2023, if not renegotiated or extended, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2022 and 2021:

(\$ in thousands)

	<u>2022</u>	<u>2021</u>
Mark-to-market adjustments	\$ 31,845	\$ 23,478
Cash settlements	(6,004)	(6,106)
Unrealized gain on interest rate exchange agreements, net of cash settlements	<u>\$ 25,841</u>	<u>\$ 17,372</u>

13. Leases

VUMC has operating and finance leases for real estate, personal property and equipment. VUMC determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded in the consolidated balance sheets.

VUMC has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, VUMC elected the permitted practical expedients to not reassess the

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use assets represent VUMC's right to use an underlying asset during the lease term, and lease liabilities represent VUMC's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. VUMC's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of VUMC's operating leases do not provide an implicit rate, VUMC uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. VUMC considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance and other index adjustments.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2022 and 2021, are as follows:

(\$ in thousands)	Balance Sheet Classification	2022	2021
Assets:			
Operating leases	Operating leases	\$ 826,560	\$ 839,850
Finance leases	Property, plant, and equipment, net	19,412	17,363
Total lease assets		<u>\$ 845,972</u>	<u>\$ 857,213</u>
Liabilities:			
Current:			
Operating leases	Current portion of operating lease liabilities	\$ 68,510	\$ 67,343
Finance leases	Current portion of long-term debt	6,618	5,413
Noncurrent:			
Operating leases	Noncurrent portion of operating lease liabilities	783,178	795,330
Finance leases	Long-term debt, net of current portion	12,770	11,584
Total lease liabilities		<u>\$ 871,076</u>	<u>\$ 879,670</u>
Weighted-average remaining term:			
Operating leases		56.3 years	57.4 years
Finance leases		3.4 years	3.6 years
Weighted-average discount rate:			
Operating leases		3.7%	3.7%
Finance leases		2.7%	2.4%

Included in the tables above is the Ground Lease with VU expiring in 2114 discussed below. Excluding this lease, the weighted average remaining lease term for VUMC's operating leases is 7.5 years as of June 30, 2022 and 8.2 years as of June 30, 2021. As of June 30, 2022 and 2021, the

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

land lease comprises \$488.7 million and \$489.2 million, respectively, of the operating lease asset and \$491.4 million and \$491.9 million, respectively, of the operating lease liability detailed above.

Lease expense for finance and operating leases for the years ended June 30, 2022 and 2021, are as follows:

<i>(\$ in thousands)</i>	2022	2021
Finance lease expense:		
Amortization of leased assets	\$ 8,431	\$ 6,125
Interest on lease liabilities	467	410
Operating lease expense ⁽¹⁾	107,551	109,665
Short-term lease expense ⁽¹⁾	4,551	4,578
Variable lease expense ⁽¹⁾	15,665	16,181
	<u>\$ 136,665</u>	<u>\$ 136,959</u>

⁽¹⁾ Expense is included in "Facilities and equipment" in the consolidated statements of operations.

The following table presents supplemental cash flow information for the years ended June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 105,366	\$ 105,136
Operating cash flows for finance leases	467	410
Financing cash flows for finance leases	7,333	5,766

The following table reconciles the undiscounted minimum lease payments to the operating and financing lease liabilities recorded in the consolidated balance sheet at June 30, 2022:

<i>(\$ in thousands)</i>	Operating Leases	Finance Leases
2023	\$ 96,040	\$ 6,974
2024	87,268	5,733
2025	79,137	4,066
2026	66,484	1,555
2027	51,993	1,569
Thereafter	1,812,846	371
Total minimum lease payments	2,193,768	20,268
Less: amount of lease payments representing interest	(1,342,080)	(880)
Present value of future minimum lease payments	851,688	19,388
Less: current lease obligations	(68,510)	(6,618)
Long-term lease obligations	<u>\$ 783,178</u>	<u>\$ 12,770</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2114, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The annual base rent is payable monthly, and is CPI adjusted annually. VUMC made rental payments totaling \$20.4 million and \$19.6 million in Fiscal 2022 and 2021, respectively. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. Included in the table above are \$1.8 billion in ground lease payments representing future minimum rentals based on the initial annual base rent of \$19.4 million, excluding annual CPI adjustments.
- In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus ("100 Oaks Lease"). VU redeveloped this leased space primarily for medical and office uses. In October 2014, VU agreed to an amendment which extends the original lease term to November 30, 2035, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. VUMC included minimum property rental payments totaling \$104.4 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum lease payments totaling \$56.0 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings owned by both entities. As of June 30, 2022, VUMC's estimated future minimum lease payments to VU totaled \$33.3 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2023, are \$7.9 million, subject to annual renewal.

14. Net Assets

Net asset restrictions relate to the following purposes as of June 30, 2022 and 2021:

<i>(\$ in thousands)</i>	2022	2021
Donor-restricted – time or purpose		
Property, plant, and equipment	\$ 8,294	\$ 13,044
Research and education	150,086	115,897
Operations	11,575	15,087
Total donor-restricted – time or purpose	<u>\$ 169,955</u>	<u>\$ 144,028</u>
Donor restricted – perpetuity		
Research and education	<u>\$ 98,477</u>	<u>\$ 80,530</u>

Net assets without donor restrictions are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures in net assets without donor restrictions since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

Donor restricted – time or purpose contain donor-imposed stipulations that expire with the passage of time or that can be satisfied by the action of VUMC. These net assets may include restricted gifts including unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution. Donor gifts that are restricted for funding capital projects are considered released from restriction once related capital expenditures have been made and the asset is placed in service.

Donor restricted – perpetuity contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as donor restricted – perpetuity and the net accumulated appreciation as donor restricted – time or purpose. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

- | | |
|---------|---|
| Level 1 | Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access. |
| Level 2 | Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
| Level 3 | Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data. |

VUMC's principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and liabilities under third-party programs, grants and contracts receivable, pledges receivable, operating lease assets, accounts payable and other accrued expenses, self-insurance reserves, operating lease liabilities, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

As of June 30, 2022, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.7 billion, respectively. As of June 30, 2021, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.9 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in active markets as of June 30, 2022 and 2021, as applicable. The carrying amounts related to VUMC's variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2022 and 2021. As of June 30, 2022 and 2021, the fair values of the subordinated note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2022 and 2021, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

Fair Value Measurements as of June 30, 2022				
<i>(\$ in thousands)</i>	Level 1	Level 2	Level 3	Total Carrying Amount
Assets				
Corporate bonds	\$ 19,004	\$ 326,777	\$ —	\$ 345,781
Equity mutual funds	19,887	103,820	—	123,707
Cash and cash equivalents	17,055	797	—	17,852
Beneficial interests in split-interest trusts	—	8,515	—	8,515
Hedged equity mutual funds	—	137,325	—	137,325
Fixed-income mutual funds	80,697	86,564	—	167,261
Certificates of deposit	—	18,301	—	18,301
Asset-backed securities	6,680	21,342	—	28,022
Mortgage-backed securities	—	6,542	—	6,542
Commercial paper	—	22,755	—	22,755
Government bonds	10,498	33,628	—	44,126
Hedged debt mutual funds	—	150,056	—	150,056
Commodities and managed futures mutual funds	8,135	33,928	—	42,063
Target date mutual funds	—	6,422	—	6,422
Equity securities	12,033	—	—	12,033
Total assets in the fair value hierarchy	<u>\$ 173,989</u>	<u>\$ 956,772</u>	<u>\$ —</u>	<u>\$ 1,130,761</u>
Investments measured at net asset value				67,150
Total assets reported at fair value				<u>\$ 1,197,911</u>
Liabilities				
Interest rate exchange agreements	\$ —	\$ 45,019	\$ —	\$ 45,019
Total liabilities reported at fair value	<u>\$ —</u>	<u>\$ 45,019</u>	<u>\$ —</u>	<u>\$ 45,019</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Fair Value Measurements as of June 30, 2021				
(\$ in thousands)	Level 1	Level 2	Level 3	Total Carrying Amount
Assets				
Corporate bonds	\$ 38,310	\$ 298,595	\$ —	\$ 336,905
Equity mutual funds	29,174	122,026	—	151,200
Cash and cash equivalents	27,681	—	—	27,681
Beneficial interests in split-interest trusts	—	9,503	—	9,503
Hedged equity mutual funds	—	107,548	—	107,548
Fixed-income mutual funds	114,871	102,891	—	217,762
Certificates of deposit	—	21,162	—	21,162
Asset-backed securities	6,982	21,989	—	28,971
Mortgage-backed securities	—	6,503	—	6,503
Commercial paper	—	37,040	—	37,040
Government bonds	21,884	31,249	—	53,133
Hedged debt mutual funds	—	114,474	—	114,474
Commodities and managed futures mutual funds	10,759	9,043	—	19,802
Target date mutual funds	—	5,168	—	5,168
Total assets in the fair value hierarchy	<u>\$ 249,661</u>	<u>\$ 887,191</u>	<u>\$ —</u>	<u>\$ 1,136,852</u>
Investments measured at net asset value				12,839
Total assets reported at fair value				<u>\$ 1,149,691</u>
Liabilities				
Interest rate exchange agreements	\$ —	\$ 76,864	\$ —	\$ 76,864
Total liabilities reported at fair value	<u>\$ —</u>	<u>\$ 76,864</u>	<u>\$ —</u>	<u>\$ 76,864</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Certain of the investments are reported using a calculated NAV per share. These investments are not expected to be sold at amounts that are materially different from NAV. The following table identifies attributes relating to the nature and risk of investments for which fair value is determined using a calculated NAV as of June 30, 2022 and 2021:

June 30, 2022				
(\$ in thousands)	Carrying Amount	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity	\$ 31,022	\$ 3,500	None	None
Multi-strategy hedge funds	17,055	8,000	Quarterly	65-95 Days
Hedged equity funds	19,073	—	Quarterly	90 Days
Total	\$ 67,150	\$ 11,500		

June 30, 2021				
(\$ in thousands)	Carrying Amount	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity	\$ 12,839	\$ —	None	None

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

16. Retirement Plan

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2022 and 2021, VUMC recognized \$86.4 million and \$76.8 million, respectively, of expense in connection with this plan.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

17. Functional Expense

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expense by nature and function for Fiscal 2022 and 2021 were as follows:

(\$ in thousands)

	For the year ended June 30, 2022			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 2,454,835	\$ 608,296	\$ 241,202	\$ 3,304,333
Supplies and drugs	1,321,793	67,058	38,088	1,426,939
Facilities and equipment	187,646	41,496	77,236	306,378
Services and other	677,021	147,922	94,462	919,405
Depreciation and amortization	150,181	1,140	21,678	172,999
Interest	50,391	9,527	12	59,930
Total operating expense	<u>\$ 4,841,867</u>	<u>\$ 875,439</u>	<u>\$ 472,678</u>	<u>\$ 6,189,984</u>

(\$ in thousands)

	For the year ended June 30, 2021			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 2,021,532	\$ 581,945	\$ 233,067	\$ 2,836,544
Supplies and drugs	1,134,657	56,507	25,039	1,216,203
Facilities and equipment	177,973	44,722	74,053	296,748
Services and other	599,477	107,610	88,200	795,287
Depreciation and amortization	128,181	1,582	21,691	151,454
Interest	49,351	11,163	16	60,530
Total operating expense	<u>\$ 4,111,171</u>	<u>\$ 803,529</u>	<u>\$ 442,066</u>	<u>\$ 5,356,766</u>

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- **Litigation.** VUMC is a defendant in certain lawsuits alleging medical malpractice and civil action.

Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2022 and 2021, which is not material to VUMC's overall financial position.

- **Regulations.** VUMC's compliance with regulations and laws is subject to future government reviews and interpretations, as well as regulatory actions unknown at this time. VUMC believes that the liability, if any, from such reviews will not have a significant effect on VUMC's consolidated financial position.
- **Medical Malpractice Self-Insurance.** The consolidated balance sheets include reserves for medical malpractice, professional, and general liability coverage totaling \$81.6 million as of June 30, 2022, and \$72.6 million as of June 30, 2021. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% at both dates and are classified as current or noncurrent based on the expected timing of cash flows. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling \$5.9 million as of June 30, 2022, and \$3.8 million as of June 30, 2021. During Fiscal 2022 and 2021, VUMC recorded expenses for medical malpractice self-insurance of \$30.4 million and \$22.4 million, respectively.
- **Employee Health and Workers' Compensation Insurance.** Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling \$23.0 million and \$5.7 million, respectively, as of June 30, 2022, and \$21.8 million and \$6.7 million, respectively, as of June 30, 2021. During Fiscal 2022 and 2021, VUMC recorded expenses for self-insured employee health benefit plans, net of employee premiums, totaling \$261.4 million and \$241.9 million, respectively. During Fiscal 2022 and 2021, VUMC recorded expenses for self-insured workers' compensation plans of \$4.9 million.
- **Federal and State Contracts and Other Requirements.** Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue, as well as facilities and administrative costs recovery. VUMC does not expect these costs to impact the consolidated financial position by material amounts.
- **Health Care Services.** In Fiscal 2022 and 2021, 84% and 85%, respectively, of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

- **HIPAA Compliance.** Under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), the federal government has authority to complete fraud and abuse investigations. HIPAA has established substantial fines and penalties for offenders. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other applicable local, state, and federal statutes and regulations.
- **Construction.** VUMC had contractual commitments under major construction and equipment contracts totaling \$53.5 million and \$56.8 million as of June 30, 2022 and 2021, respectively.

19. Other Events

COVID-19

In March of Fiscal 2020, COVID-19, a disease caused by the novel strain of the coronavirus, was designated by the World Health Organization as a global pandemic. A state of emergency was subsequently announced by the State of Tennessee, quickly followed by “stay at home” orders and orders for hospitals and outpatient surgical facilities to stop non-essential procedures. This global health crisis negatively impacted many facets of the business, including lower patient volumes and related revenues, significant increases in certain supply costs (in particular personal protective equipment) as well as difficulties sourcing these supplies, and volatility in the U.S. and global financial markets impacting VUMC’s investment portfolios. Due to new strains and periodic surges in coronavirus cases, VUMC continued to experience negative impacts to its business in Fiscal 2021 and 2022.

Sources of pandemic relief include the federal stimulus package known as The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, signed into law on March 27, 2020, the Coronavirus Response and Consolidated Appropriations Act (“CRCA”) signed into law on December 27, 2020, and the American Rescue Plan (“ARP”), signed into law on March 11, 2021. These laws include a number of provisions: most importantly providing funding through the Public Health and Social Services Emergency Fund (“Provider Relief Fund”) to reimburse eligible health care providers for health care-related expenses or lost revenues not otherwise reimbursed that are directly attributable to COVID-19. These provider relief funds included amounts distributed to providers based on their share of the Medicare fee-for-service reimbursement (“General Distributions”). The funds also included for certain targeted distributions (“Targeted Distributions”) to qualifying providers (primarily rural and high impact areas). For the period ended June 30, 2022, VUMC recognized as revenue approximately \$44.8 million in General Distributions and \$23.4 million in Targeted Distributions, for a total of \$68.2 million, under the Provider Relief Fund. For the period ended June 30, 2021, VUMC recognized as revenue approximately \$46.3 million in General Distributions and \$8.8 million in Targeted Distributions, for a total of \$55.1 million, under the Provider Relief Fund. These amounts are presented in other operating revenue in the consolidated statements of operations.

In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program (“MAAPP”) whereby inpatient acute care hospitals and other eligible providers may request an advance payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments beginning 120 days after receipt. During Fiscal 2020, VUMC received advance payments from Medicare of \$222.4 million.

On October 1, 2020, the Continuing Appropriations and Other Extensions Acts amended the repayment terms for the funds received under the MAAPP. Under the revised repayment terms, the Centers for Medicare and Medicaid Services (“CMS”) began to automatically recoup the advance payments one year from the original date of issuance by offsetting the payments against newly

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

submitted Medicare claims. Once the recoupment period began, for the first eleven (11) months, Medicare automatically recouped payments at a rate of 25% of the Medicare claims amount otherwise owed to VUMC. After the first recoupment period of eleven (11) months, and continuing for the following six (6) months, Medicare automatically recoups payments at a rate of 50% of the Medicare claims amount otherwise owed to VUMC. After this repayment term concludes, any balance that remains outstanding will be subject to interest at a rate of four percent (4%) per annum. In accordance with the repayment terms, CMS began recoupment of VUMC's MAAPP funds in April 2021 and recouped \$33.0 million as of June 30, 2021. CMS recouped an additional \$173.4 million during Fiscal 2022. VUMC expects the remaining liability will be subject to recoupment within the next twelve months, and as such, VUMC has classified the remaining MAAPP liability of \$16.0 million as a current liability in the consolidated balance sheet as of June 30, 2022.

The CARES Act also allows for deferred payment of the employer portion of certain payroll taxes between March 27, 2020 and December 31, 2020, with 50% due December 31, 2021 and the remaining 50% due December 31, 2022. As of June 30, 2022, VUMC had deferred payroll tax payments of \$37.9 million included in accrued compensation and benefits in the consolidated balance sheet. As of June 30, 2021, VUMC had deferred payroll tax payments of \$75.8 million, with \$37.9 million and \$37.9 million included in accrued compensation and benefits and other noncurrent liabilities, respectively, in the consolidated balance sheet.

In addition, the CARES Act suspended the sequestration payment adjustment percentage of 2% applied to all Medicare Fee-for-Service claims from May 1, 2020 through December 31, 2020, with subsequent acts extending through March 31, 2022. Upon conclusion of the suspension period, CMS applied a 1% payment adjustment for the period April 1, 2022 through June 30, 2022, at which time CMS will revert to the 2% payment adjustment for sequestration. This suspension positively impacted patient service revenue in the consolidated statements of operations by approximately \$14 million for Fiscal 2022 and 2021. Beginning, September 1, 2020, the CARES Act also provided for a 20% Medicare supplement for Medicare patients diagnosed with COVID-19 that are admitted to the hospital, reflecting the additional costs of treating a patient with this diagnosis. During Fiscal 2022 and 2021, VUMC recognized an additional \$6 million in patient service revenue in the consolidated statements of operations related to this supplement.

During Fiscal 2022, VUMC received \$73.2 million of supplemental payments directed from the State of Tennessee which covered a uniform increase for inpatient and outpatient services performed for the period January 1, 2022 through December 31, 2022. VUMC recognized \$36.6 million as patient service revenue related to the services performed for the period January 1, 2022 through June 30, 2022. The remaining \$36.6 million of payments received was deferred and is included in the current liability section as an estimated liability under third-party programs in the consolidated balance sheet as of June 30, 2022. This deferred amount will be recognized during Fiscal 2023.

During Fiscal 2022, VUMC recognized as other operating revenue \$4.5 million for Tennessee staffing grants. During Fiscal 2021, VUMC recognized as other operating revenue \$3.1 million for Tennessee staffing grants, \$2.0 million of business interruption insurance payments, \$2.0 million of State of Tennessee CARES funding, and \$0.8 million of other COVID-19 grants.

Acquisition of VBCH and VTHH

Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital ("VBCH") and Vanderbilt Tullahoma-Harton Hospital ("VTHH") for total consideration of \$15.6 million.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

The following table summarizes the fair value of net assets acquired:

(\$ in thousands)

Inventories	\$ 2,808
Other current assets	882
Property, plant, and equipment, net	11,943
Operating lease assets	4,230
Other noncurrent assets	122
Accounts payable and other accrued expenses	(155)
Operating lease liabilities	<u>(4,230)</u>
Total invested capital	<u>\$ 15,600</u>

The results of operations for these acquisitions are included in the consolidated statements of operations and changes in net assets beginning on the acquisition date. Pro forma results of operations and changes in net assets as though these acquisitions occurred on July 1, 2020 are not materially different and accordingly are not provided.

Acquisition of Noncontrolling Interest in VMH

As discussed in Note 1 Description of Organization, effective January 1, 2021, VUMC acquired a noncontrolling ownership interest of 20% in CHS's affiliated Tennova Healthcare – Clarksville for total consideration of \$36.9 million. The noncontrolling interest is accounted for as an equity method investment and is included in other noncurrent assets in the consolidated balance sheets.

Business Combination of Cool Springs Surgery Center

Effective July 1, 2021, VUMC amended the operating agreement related to the noncontrolling ownership interest held in the Cool Springs Surgery Center ("CSSC"). This amendment constituted a change in control event for CSSC and is now consolidated into the financial statements of VUMC. Prior to the change in control event date, VUMC accounted for its noncontrolling ownership interest in CSSC as an equity method investment. In accordance with FASB ASC 805, Business Combinations, the acquisition method was applied to account for this consolidation and CSSC was recorded at its fair value.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

The following table summarizes the fair values of the assets acquired and liabilities assumed:

(\$ in thousands)

Cash	\$	3,319
Patient accounts receivable		1,965
Inventories		832
Other current assets		205
Property, plant, and equipment, net		3,489
Total identifiable assets acquired		<u>9,810</u>
Accounts payable and other accrued expenses		(848)
Medicare accelerated payments		(957)
Accrued compensation and benefits		(408)
Long-term debt		(132)
Total liabilities assumed		<u>(2,345)</u>
Net identifiable assets acquired		7,465
Goodwill		<u>27,028</u>
Net assets acquired	\$	<u><u>34,493</u></u>

The acquisition-date fair value of the previous equity interest was \$18.0 million. VUMC recognized a gain of \$14.7 million as a result of remeasuring its previous equity interest to fair value, which is presented in other nonoperating gains in the consolidated statements of operations.

20. Subsequent Events

Management evaluated events after June 30, 2022 through September 30, 2022, the date on which the consolidated financial statements were issued. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

Supplementary Information

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEPARTMENT OF AGRICULTURE									
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	59-0210-8-184		\$ 92,478	\$ 226,612	RESEARCH AND DEVELOPMENT	\$ 493,731,962
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		89,198	226,612	RESEARCH AND DEVELOPMENT	493,731,962
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-8-184		41,365	226,612	RESEARCH AND DEVELOPMENT	493,731,962
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-8-184		3,571	226,612	RESEARCH AND DEVELOPMENT	493,731,962
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-68001-38846	UNIVERSITY OF KENTUCKY	2017-68001-38846		110,772	110,772	RESEARCH AND DEVELOPMENT	493,731,962
DISTANCE LEARNING AND TELEMEDICINE LOANS AND GRANTS	10.855	TN 754-A17				151,675	151,675	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL DEPARTMENT OF AGRICULTURE						<u>489,059</u>			
DEPARTMENT OF DEFENSE									
COLLABORATIVE RESEARCH AND DEVELOPMENT	12.114	W912HQ-16-C-0033	UNIVERSITY OF PITTSBURGH	W912HQ-16-C-0033		19,454	19,454	RESEARCH AND DEVELOPMENT	493,731,962
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-22-1-2184				29,376	29,376	RESEARCH AND DEVELOPMENT	493,731,962
BASIC SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	12.351	W15QKN-16-9-1002	EMORY UNIVERSITY	W15QKN-16-9-1002		156,159	156,159	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0160	CASE WESTERN RESERVE UNIVERSITY	W81XWH-21-1-0160		12,847	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0540	EPICTRACKER, INC.	W81XWH-20-1-0540		(38,636)	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0003	FLORIDA STATE UNIVERSITY	W81XWH-16-2-0003		96,543	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0405	IDBIOLOGICS, LLC	W81XWH-19-1-0405		6,415	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0620	IOWA STATE UNIVERSITY	W81XWH-20-1-0620		7,852	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0090	JOHNS HOPKINS UNIVERSITY	W81XWH-10-2-0090		28,295	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0067	JOHNS HOPKINS UNIVERSITY	W81XWH-15-2-0067		35,021	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0060	JOHNS HOPKINS UNIVERSITY	W81XWH-16-2-0060		51,402	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0815	JOHNS HOPKINS UNIVERSITY	W81XWH-18-1-0815		11,261	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0062	JOHNS HOPKINS UNIVERSITY	W81XWH-19-2-0062		2,208	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0063	JOHNS HOPKINS UNIVERSITY	W81XWH-20-2-0063		15,796	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0698	MEHARRY MEDICAL COLLEGE	W81XWH-20-1-0698		7,673	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0692	NORTHWESTERN UNIVERSITY	W81XWH-20-1-0692		1,451	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0692	NORTHWESTERN UNIVERSITY	W81XWH-20-1-0692		10,930	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0010				25,184	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0821	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	W81XWH-19-1-0821		27,832	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0017	SOUTHERN ILLINOIS UNIVERSITY	W81XWH-19-1-0017		32,778	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0631	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	W81XWH-17-1-0631		915	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0631	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	W81XWH-17-1-0631		671,178	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0001	UNIVERSITY OF COLORADO	W81XWH-20-2-0001		122,839	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0273	UNIVERSITY OF KENTUCKY	W81XWH-21-1-0273		100,077	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0833	UNIVERSITY OF KENTUCKY	W81XWH-21-1-0833		140,242	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0702	UNIVERSITY OF MARYLAND	W81XWH-17-1-0702		54,584	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0848	UNIVERSITY OF MARYLAND	W81XWH-19-1-0848		17,009	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		27,922	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		65,390	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		35,021	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0790	UNIVERSITY OF ROCHESTER	W81XWH-18-1-0790		964,331	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0061			\$ 14,742	60,532	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0442				228,744	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0503				152,310	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0003			1,151	1,151	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0055			83,367	360,766	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0029				289,614	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0149			\$ 59,041	\$ 722,354	\$ 10,320,865	RESEARCH AND DEVELOPMENT	\$ 493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0536			22,605	192,916	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0683				250,287	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0810			52,648	364,850	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0814			11,105	11,105	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0090				102,523	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0415				439,514	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0580				141,616	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0640				22,277	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0782				39,665	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0812				557,144	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0269			6,419	133,657	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0475			77,544	212,124	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0542			131,286	609,159	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0593				130,389	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0648				276,783	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0691				110,384	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0701			116,129	266,055	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0910				308,883	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0046			124,797	296,611	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-PRORP-CTRA				368,178	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0051			68,767	222,105	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0617				79,195	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0694				68,421	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0765			12,297	150,404	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0786				169,175	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0025				332,955	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-BCRP-BTA12				51,873	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0090				73,503	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0003				(256)	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0814				(10,461)	10,320,865	RESEARCH AND DEVELOPMENT	493,731,962
COMMUNITY INVESTMENT	12.600	W81XWH-15-9-001	UNIVERSITY OF COLORADO	W81XWH-15-9-001		117,016	117,016	RESEARCH AND DEVELOPMENT	493,731,962
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU000-12-1-20002	VANDERBILT UNIVERSITY	HU000-12-1-20002		3,912	3,912	RESEARCH AND DEVELOPMENT	493,731,962
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA8650-16-2-6G02	UNIVERSITY OF CINCINNATI	FA8650-16-2-6G02		12,448	12,448	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-18-2-0001			2,950,400	4,175,430	4,408,417	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-21-2-0011	VANDERBILT UNIVERSITY	HR0011-21-2-0011		232,987	4,408,417	RESEARCH AND DEVELOPMENT	493,731,962
W81XWH-20-C-0031	12.RD	W81XWH-20-C-0031	HENRY M. JACKSON FOUNDATION	W81XWH-20-C-0031		48,886	700,513	RESEARCH AND DEVELOPMENT	493,731,962
47QFWA-20-C-0012	12.RD	47QFWA-20-C-0012	UNIVERSITY OF COLORADO	47QFWA-20-C-0012		24,967	700,513	RESEARCH AND DEVELOPMENT	493,731,962
47QFWA-20-C-0012	12.RD	47QFWA-20-C-0012	UNIVERSITY OF COLORADO	47QFWA-20-C-0012		23,810	700,513	RESEARCH AND DEVELOPMENT	493,731,962
ID07200010-301	12.RD	ID07200010-301	UNIVERSITY OF COLORADO	ID07200010-301		437,457	700,513	RESEARCH AND DEVELOPMENT	493,731,962
W911NF-21-2-0078	12.RD	W911NF-21-2-0078	VANDERBILT UNIVERSITY	W911NF-21-2-0078		26,576	700,513	RESEARCH AND DEVELOPMENT	493,731,962
W81XWH-20-C-0027	12.RD	W81XWH-20-C-0027				6,264	700,513	RESEARCH AND DEVELOPMENT	493,731,962
W909MY-21-C-0023	12.RD	W909MY-21-C-0023				132,553	700,513	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL DEPARTMENT OF DEFENSE					3,732,298	15,768,160			
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575	DOJ-TN HOSP ASSOC	TENNESSEE HOSPITAL ASSOCIATION	DOJ-TN HOSP ASSOC		111,517	376,471	RESEARCH AND DEVELOPMENT	493,731,962
CRIME VICTIM ASSISTANCE	16.575	63811:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	63811:ST TN		264,954	376,471	RESEARCH AND DEVELOPMENT	493,731,962
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM	16.754	64793:ST TN	TN DEPARTMENT OF HEALTH	64793:ST TN		81,647	81,647	RESEARCH AND DEVELOPMENT	493,731,962
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	65987:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	65987:ST TN		10,492	20,095	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	68104:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	68104:ST TN		\$ 2,881	\$ 20,095	RESEARCH AND DEVELOPMENT	\$ 493,731,962
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72816:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	72816:ST TN		791	20,095	RESEARCH AND DEVELOPMENT	493,731,962
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72929:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	72929:ST TN		5,187	20,095	RESEARCH AND DEVELOPMENT	493,731,962
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72930:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	72930:ST TN		744	20,095	RESEARCH AND DEVELOPMENT	493,731,962
15JC1V20P00000511	16.RD	15JC1V20P00000511				56,379	227,929	RESEARCH AND DEVELOPMENT	493,731,962
15JC1V22P00000040	16.RD	15JC1V22P00000040				171,550	227,929	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL DEPARTMENT OF JUSTICE						<u>706,142</u>			
DEPARTMENT OF TREASURY									
COVID-19 CORONAVIRUS RELIEF FUND	21.019	COVID-19 TN CARES STAFFING GRANT	TN CARES STAFFING GRANT	TN CARES ACT		259,200	259,200	N/A	—
CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19 TN	TN CARES STAFFING GRANT	TN CARES ACT		3,095,425	3,095,425	N/A	—
TOTAL DEPARTMENT OF TREASURY						<u>3,354,625</u>			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
EXPLORATION	43.003	80NCCS19M0161	NATIONAL COUNCIL ON RADIATION PROTECTION AND MEASUREMENTS	80NCCS19M0161		91,584	240,434	RESEARCH AND DEVELOPMENT	493,731,962
EXPLORATION	43.003	80NSSC19M0161	NATIONAL COUNCIL ON RADIATION PROTECTION AND MEASUREMENTS	80NSSC19M0161		148,850	240,434	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						<u>240,434</u>			
INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES									
PROMOTION OF THE ARTS _GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1863278-38-20				67,159	67,159	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES						<u>67,159</u>			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	NSF CMMI-2050252				75,857	161,578	RESEARCH AND DEVELOPMENT	493,731,962
ENGINEERING	47.041	NSF IIP-2124578			\$ 33,099	47,821	161,578	RESEARCH AND DEVELOPMENT	493,731,962
ENGINEERING	47.041	2124872	PRAGMADX INC	2124872		17,746	161,578	RESEARCH AND DEVELOPMENT	493,731,962
ENGINEERING	47.041	2124002	VANDERBILT UNIVERSITY	2124002		20,154	161,578	RESEARCH AND DEVELOPMENT	493,731,962
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-2050895				215,912	235,740	RESEARCH AND DEVELOPMENT	493,731,962
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-2029651				4,392	235,740	RESEARCH AND DEVELOPMENT	493,731,962
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-2129909				14,029	235,740	RESEARCH AND DEVELOPMENT	493,731,962
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1952029	VANDERBILT UNIVERSITY	1952029		1,407	235,740	RESEARCH AND DEVELOPMENT	493,731,962
BIOLOGICAL SCIENCES	47.074	NSF MCB-2032016				12,913	369,993	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
BIOLOGICAL SCIENCES	47.074	NSF IOS-2011291				\$ 129,407	\$ 369,993	RESEARCH AND DEVELOPMENT	\$ 493,731,962
BIOLOGICAL SCIENCES	47.074	1845634	UNIVERSITY OF MASSACHUSETTS	1845634		12,133	369,993	RESEARCH AND DEVELOPMENT	493,731,962
BIOLOGICAL SCIENCES	47.074	2120084	UNIVERSITY OF PITTSBURGH	2120084		106,339	369,993	RESEARCH AND DEVELOPMENT	493,731,962
BIOLOGICAL SCIENCES	47.074	1814520	UNIVERSITY OF TENNESSEE	1814520		109,201	369,993	RESEARCH AND DEVELOPMENT	493,731,962
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	NSF BCS-2033896				14,106	19,077	RESEARCH AND DEVELOPMENT	493,731,962
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1840896	VANDERBILT UNIVERSITY	1840896		4,971	19,077	RESEARCH AND DEVELOPMENT	493,731,962
EDUCATION AND HUMAN RESOURCES	47.076	NSF DUE-1926794				189,952	218,569	RESEARCH AND DEVELOPMENT	493,731,962
EDUCATION AND HUMAN RESOURCES	47.076	2116026	OREGON STATE UNIVERSITY	2116026		28,617	218,569	RESEARCH AND DEVELOPMENT	493,731,962
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	9531011	JOHNS HOPKINS UNIVERSITY	9531011		583	66,716	RESEARCH AND DEVELOPMENT	493,731,962
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-20-66590-1	UNIVERSITY OF WISCONSIN	OISE-20-66590-1		40,296	66,716	RESEARCH AND DEVELOPMENT	493,731,962
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	9531011	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	9531011		25,837	66,716	RESEARCH AND DEVELOPMENT	493,731,962
INTEGRATIVE ACTIVITIES	47.083	2033413	VANDERBILT UNIVERSITY	2033413		191,511	217,542	RESEARCH AND DEVELOPMENT	493,731,962
INTEGRATIVE ACTIVITIES	47.083	2040462	VANDERBILT UNIVERSITY	2040462		26,031	217,542	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL NATIONAL SCIENCE FOUNDATION					\$ 33,099	1,289,215			
ENVIRONMENTAL PROTECTION AGENCY									
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83927501	MEHARRY MEDICAL COLLEGE	83927501		11,478	310,807	RESEARCH AND DEVELOPMENT	493,731,962
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	RD-83950101-0			27,075	280,633	310,807	RESEARCH AND DEVELOPMENT	493,731,962
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83950401	VANDERBILT UNIVERSITY	83950401		18,696	310,807	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL ENVIRONMENTAL PROTECTION AGENCY					27,075	310,807			
DEPARTMENT OF ENERGY									
NUCLEAR ENERGY RESEARCH, DEVELOPMENT AND DEMONSTRATION	81.121	DE-NE0008664	VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY	DE-NE0008664		31,279	31,279	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL DEPARTMENT OF ENERGY						31,279			
DEPARTMENT OF EDUCATION									
SPECIAL EDUCATION_GRANTS TO STATES	84.027	45237:ST TN	TN DEPARTMENT OF EDUCATION	45237:ST TN		(6,775)	2,526,602	SPECIAL EDUCATION CLUSTER (IDEA)	2,526,695
SPECIAL EDUCATION_GRANTS TO STATES	84.027	71077:ST TN	TN DEPARTMENT OF EDUCATION	71077:ST TN		1,865,725	2,526,602	SPECIAL EDUCATION CLUSTER (IDEA)	2,526,695
SPECIAL EDUCATION_GRANTS TO STATES	84.027	71430:ST TN	TN DEPARTMENT OF EDUCATION	71430:ST TN		667,652	2,526,602	SPECIAL EDUCATION CLUSTER (IDEA)	2,526,695
REHABILITATION SERVICES_VOCATIONAL REHABILITATION GRANTS TO STATES	84.126	69455:ST TN-VU	VANDERBILT UNIVERSITY	69455:ST TN-VU		9,622	9,622	N/A	—
SPECIAL EDUCATION_PRESCHOOL GRANTS	84.173	49454:ST TN	TN DEPARTMENT OF EDUCATION	49454:ST TN		93	93	SPECIAL EDUCATION CLUSTER (IDEA)	2,526,695
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	62363:ST TN	TN DEPARTMENT OF EDUCATION	62363:ST TN		(132)	1,037,222	N/A	—
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	70785:ST TN	TN DEPARTMENT OF EDUCATION	70785:ST TN		1,037,354	1,037,222	N/A	—
RESEARCH IN SPECIAL EDUCATION	84.324	R324 A160300				23,737	23,737	RESEARCH AND DEVELOPMENT	493,731,962
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190046-21				265,738	812,198	N/A	—
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190064			62,619	230,247	812,198	N/A	—

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190068			\$ 81,312	\$ 280,286	\$ 812,198	N/A	\$ -
<i>SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES</i>	<i>84.325</i>	<i>H325D140087-18</i>	<i>VANDERBILT UNIVERSITY</i>	<i>H325D140087-18</i>		<i>33,816</i>	<i>812,198</i>	<i>N/A</i>	<i>-</i>
<i>SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES</i>	<i>84.325</i>	<i>H325K200036</i>	<i>VANDERBILT UNIVERSITY</i>	<i>H325K200036</i>		<i>2,111</i>	<i>812,198</i>	<i>N/A</i>	<i>-</i>
SPECIAL EDUCATION TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.326	H326 T180048				264,127	264,127	N/A	-
TOTAL DEPARTMENT OF EDUCATION					143,931	4,673,601			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
GLOBAL AIDS	93.067	6 NU2GGH002367-01-05			1,684,352	21,728,511	41,208,584	N/A	-
GLOBAL AIDS	93.067	6 NU2GGH002367-01-05				13,329	41,208,584	N/A	-
GLOBAL AIDS	93.067	6 NU2GGH002367-01-05				622,834	41,208,584	N/A	-
GLOBAL AIDS	93.067	5 NU2 GGH001943-05-00			2,397,330	18,843,910	41,208,584	N/A	-
<i>HOSPITAL PREPAREDNESS PROGRAM (HPP) AND PUBLIC HEALTH EMERGENCY PREPAREDNESS (PHEP) ALIGNED COOPERATIVE AGREEMENTS</i>	<i>93.074</i>	<i>54788:ST TN</i>	<i>TN DEPARTMENT OF HEALTH</i>	<i>54788:ST TN</i>		<i>248,904</i>	<i>248,904</i>	<i>N/A</i>	<i>-</i>
<i>FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH</i>	<i>93.077</i>	<i>5 U54 HL120163-08</i>	<i>AMERICAN HEART ASSOCIATION-HEADQUARTERS</i>	<i>5 U54 HL120163-08</i>		<i>10,608</i>	<i>210,812</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH</i>	<i>93.077</i>	<i>5 U54 HL120163-09</i>	<i>AMERICAN HEART ASSOCIATION-HEADQUARTERS</i>	<i>5 U54 HL120163-09</i>		<i>37,923</i>	<i>210,812</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	1 R21 DA052026-01A1			60,648	140,518	210,812	RESEARCH AND DEVELOPMENT	493,731,962
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	5 R21 DA052026-02				21,763	210,812	RESEARCH AND DEVELOPMENT	493,731,962
<i>BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH</i>	<i>93.080</i>	<i>1 NU 58DD000019-01-00</i>	<i>UNIVERSITY OF MEMPHIS</i>	<i>1 NU 58DD000019-01-00</i>		<i>24,632</i>	<i>109,020</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH</i>	<i>93.080</i>	<i>6 NU58 DD000019-02-00</i>	<i>UNIVERSITY OF MEMPHIS</i>	<i>6 NU58 DD000019-02-00</i>		<i>54,780</i>	<i>109,020</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH</i>	<i>93.080</i>	<i>1 NU27 DD000020-01-00</i>	<i>UNIVERSITY OF NORTH CAROLINA</i>	<i>1 NU27 DD000020-01-00</i>		<i>14,406</i>	<i>109,020</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH</i>	<i>93.080</i>	<i>NU27DD000020-02-00</i>	<i>UNIVERSITY OF NORTH CAROLINA</i>	<i>NU27DD000020-02-00</i>		<i>15,202</i>	<i>109,020</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	5 U01 IP000979-06			617	63,452	81,098	RESEARCH AND DEVELOPMENT	493,731,962
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	6 U01 IP000979-06-03				17,646	81,098	RESEARCH AND DEVELOPMENT	493,731,962
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>1 R01 FD006003-01</i>	<i>BOSTON CHILDREN'S HOSPITAL CUMBERLAND</i>	<i>1 R01 FD006003-01</i>		<i>(3,018)</i>	<i>861,574</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>1 R01 FD006371-01A1</i>	<i>PHARMACEUTICALS, INC.</i>	<i>1 R01 FD006371-01A1</i>		<i>18,396</i>	<i>861,574</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>75F40119D10037</i>	<i>HARVARD PILGRIM HEALTH CARE</i>	<i>75F40119D10037</i>		<i>121,166</i>	<i>861,574</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>75F40119D10037</i>	<i>HARVARD PILGRIM HEALTH CARE</i>	<i>75F40119D10037</i>		<i>172,613</i>	<i>861,574</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>HHSF223201400020I</i>	<i>HARVARD PILGRIM HEALTH CARE</i>	<i>HHSF223201400020I</i>		<i>(128)</i>	<i>861,574</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>1 R01 FD007290-01</i>	<i>MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH</i>	<i>1 R01 FD007290-01</i>		<i>33,317</i>	<i>861,574</i>	<i>RESEARCH AND DEVELOPMENT</i>	<i>493,731,962</i>
<i>FOOD AND DRUG ADMINISTRATION RESEARCH</i>	<i>93.103</i>	<i>5 U01 FD006292-03</i>	<i>MEDICAL DEVICE INNOVATION CONSORTIUM</i>	<i>5 U01 FD006292-03</i>	199,025	224,388	861,574	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 R01 FD004778-05				\$ 5,314	\$ 861,574	RESEARCH AND DEVELOPMENT	\$ 493,731,962
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	1 R01 FD006649-01				(106)	861,574	RESEARCH AND DEVELOPMENT	493,731,962
FOOD AND DRUG ADMINISTRATION_RESEARCH	93.103	5 R01 FD006649-02			\$ 31,100	289,632	861,574	RESEARCH AND DEVELOPMENT	493,731,962
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	64172:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	64172:ST TN		48,717	297,859	N/A	—
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	70832:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	70832:ST TN		2,359	297,859	N/A	—
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	70833:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	70833:ST TN		85,898	297,859	N/A	—
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	72274:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	72274:ST TN		160,885	297,859	N/A	—
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	2 UC4 MC28042-05-00	AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS	2 UC4 MC28042-05-00		28,629	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H30 MC24046-04-00	HEMPHILIA OF GEORGIA, INC.	5 H30 MC24046-04-00		3,432,742	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H30 MC24046-10-00	HEMPHILIA OF GEORGIA, INC.	5 H30 MC24046-10-00		16,337	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	2 H30 MC24046-11-00	HEMPHILIA OF GEORGIA, INC.	2 H30 MC24046-11-00		1,262	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 UA6 MC32492-03-00	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UA6 MC32492-03-00		6,474	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 UA6 MC32492-04-00	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UA6 MC32492-04-00		32,656	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 U24 GM132217-03	UNIVERSITY OF NORTH TEXAS	5 U24 GM132217-03		389,702	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H6M MC33236-02-00				28,664	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H6M MC33236-03-00				326,358	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 T73 MC30767-05-00			65,985	68,252	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	2 T73 MC30767-06-00			45,377	608,825	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 T73 MC30767-07-00				219	4,940,120	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES027845-05	COLUMBIA UNIVERSITY	5 R01 ES027845-05		20,813	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES007331-26	PURDUE UNIVERSITY	5 R01 ES007331-26		15,776	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	2 R01 ES010563-19	PURDUE UNIVERSITY	2 R01 ES010563-19		39,386	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES010563-20	PURDUE UNIVERSITY	5 R01 ES010563-20		11,575	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES031401-03			359,608	587,628	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES019217-09	UNIVERSITY OF LOUISVILLE	5 R01 ES019217-09		13,408	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES019217-10	UNIVERSITY OF LOUISVILLE	5 R01 ES019217-10		4,948	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 R01 ES029846-05	UNIVERSITY OF LOUISVILLE	5 R01 ES029846-05		20,168	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	2 T32 ES007028-46	VANDERBILT UNIVERSITY	2 T32 ES007028-46		8,846	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 T32 ES007028-46	VANDERBILT UNIVERSITY	5 T32 ES007028-46		39,688	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ENVIRONMENTAL HEALTH	93.113	5 T32 ES007028-47	VANDERBILT UNIVERSITY	5 T32 ES007028-47		26,109	788,345	RESEARCH AND DEVELOPMENT	493,731,962
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 K23 DE028010-04				122,549	568,891	RESEARCH AND DEVELOPMENT	493,731,962
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 R01 DE027749-04			110,737	238,490	568,891	RESEARCH AND DEVELOPMENT	493,731,962
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 R21 DE029002-02				38,544	568,891	RESEARCH AND DEVELOPMENT	493,731,962
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 R01 DE029650-03	UNIVERSITY OF KENTUCKY	5 R01 DE029650-03		73,582	568,891	RESEARCH AND DEVELOPMENT	493,731,962
ORAL DISEASES AND DISORDERS RESEARCH	93.121	3 R01 DE029650-03S1	UNIVERSITY OF KENTUCKY	3 R01 DE029650-03S1		77,706	568,891	RESEARCH AND DEVELOPMENT	493,731,962
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R56 DE028302-01A1	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	1 R56 DE028302-01A1		18,020	568,891	RESEARCH AND DEVELOPMENT	493,731,962
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 H33 MC31540-05-00				261,309	296,264	N/A	—

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 H33 MC31540-06-00				\$ 30,942	\$ 296,264	N/A	\$ -
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	2 U03 MC00001-19-00	UNIVERSITY OF CALIFORNIA, DAVIS	2 U03 MC00001-19-00		1,050	296,264	N/A	-
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	2 U03 MC00001-20-00	UNIVERSITY OF CALIFORNIA, DAVIS	2 U03 MC00001-20-00		2,963	296,264	N/A	-
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6 R01 CE003009-03-01	UNIVERSITY OF NORTH CAROLINA	6 R01 CE003009-03-01		35,855	208,724	RESEARCH AND DEVELOPMENT	493,731,962
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	65908:ST TN	TN DEPARTMENT OF HEALTH	65908:ST TN		(219)	208,724	RESEARCH AND DEVELOPMENT	493,731,962
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	69624:ST TN	TN DEPARTMENT OF HEALTH	69624:ST TN		80,134	208,724	RESEARCH AND DEVELOPMENT	493,731,962
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	72944:ST TN	TN DEPARTMENT OF HEALTH	72944:ST TN		92,954	208,724	RESEARCH AND DEVELOPMENT	493,731,962
AIDS EDUCATION AND TRAINING CENTERS	93.145	1 H1L HA37340-01-00				1,265	6,314,960	RESEARCH AND DEVELOPMENT	493,731,962
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U1O HA30535-05-00			\$ 1,079,946	1,095,017	6,314,960	RESEARCH AND DEVELOPMENT	493,731,962
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U1O HA30535-03-00				(4,141)	6,314,960	RESEARCH AND DEVELOPMENT	493,731,962
AIDS EDUCATION AND TRAINING CENTERS	93.145	6 U1O HA030535-04-07				266	6,314,960	RESEARCH AND DEVELOPMENT	493,731,962
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U1O HA30535-06-00			3,492,822	5,222,553	6,314,960	RESEARCH AND DEVELOPMENT	493,731,962
COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	4 H12 HA30750-04-01				61,873	527,159	N/A	-
COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	4 H12 HA30750-05-00				465,286	527,159	N/A	-
HUMAN GENOME RESEARCH	93.172	5 U24 HG010262-03	BROAD INSTITUTE OF MIT AND HARVARD	5 U24 HG010262-03		1,472	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U24 HG010262-04	BROAD INSTITUTE OF MIT AND HARVARD	5 U24 HG010262-04		282,452	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	3 U24 HG010262-04S1	BROAD INSTITUTE OF MIT AND HARVARD	3 U24 HG010262-04S1		34,423	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 U01 HG011723-01	BROAD INSTITUTE OF MIT AND HARVARD	1 U01 HG011723-01		80,229	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG011723-02	BROAD INSTITUTE OF MIT AND HARVARD	5 U01 HG011723-02		2,708	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 R21 HG010952-01	GEORGIA STATE UNIVERSITY	1 R21 HG010952-01		109,811	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 K99 HG010904-02				53,710	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R01 HG006844-09			8,558	8,558	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 RM1 HG009034-06			267,512	898,134	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R01 HG009694-04			565,540	617,991	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	4 R00 HG010493-03				103,733	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R21 HG010652-02			11,466	99,182	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 R35 HG010718-01				(22,850)	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R35 HG010718-02				(5,531)	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R35 HG010718-03				774,688	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R01 HG010863-04			37,994	666,789	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	4 R00 HG010904-03				68,320	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R01 HG011138-03				306,328	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	4 R00 HG011367-02				99,022	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 R01 HG011405-01A1				134,029	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 R01 HG012262-01			48,362	112,129	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 T32 HG008341-05				24	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	2 T32 HG008341-06				201,248	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG008672-04				892	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG010232-03			185,625	185,625	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG010232-04			275,622	1,067,210	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 U01 HG011166-01			63,410	82,846	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG011166-02			547,352	2,149,577	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG011166-03				301,268	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 U01 HG011181-01				(115,272)	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG011181-02				895,828	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	1 R01 HG011598-01A1	UNIVERSITY OF LOUISVILLE	1 R01 HG011598-01A1		42,131	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R01 HG008605-03	UNIVERSITY OF MINNESOTA	5 R01 HG008605-03		(969)	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
HUMAN GENOME RESEARCH	93.172	1 U01 HG011720-01	UNIVERSITY OF NORTH CAROLINA	1 U01 HG011720-01		\$ 108,483	\$ 9,383,108	RESEARCH AND DEVELOPMENT	\$ 493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG011720-02	UNIVERSITY OF NORTH CAROLINA	5 U01 HG011720-02		49,007	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 R01 HG006844-09				(3,362)	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
HUMAN GENOME RESEARCH	93.172	5 U01 HG010232-03				(6,755)	9,383,108	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC016643-05	BOYS TOWN NATIONAL RESEARCH HOSPITAL	5 R01 DC016643-05		94,838	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3 R01 DC018060-02S1	COLUMBIA UNIVERSITY	3 R01 DC018060-02S1		2,015	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R01 DC016680-01A1	CREIGHTON UNIVERSITY	1 R01 DC016680-01A1		149,584	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 F32 DC020347-01				35,548	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R44 DC018491-02	INTELLIGENT HEARING SYSTEMS, INC.	5 R44 DC018491-02		196,549	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 P50 DC015857-04	MASSACHUSETTS EYE AND EAR INFIRMARY	5 P50 DC015857-04		1,088	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 P50 DC015857-05	MASSACHUSETTS EYE AND EAR INFIRMARY	5 P50 DC015857-05		13,541	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017078-04	MASSACHUSETTS EYE AND EAR INFIRMARY	5 R01 DC017078-04		33,348	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R44 DC016780-03	MIMOSA ACOUSTICS, INC	5 R44 DC016780-03		171,159	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015780-05	NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH (NKI)	5 R01 DC015780-05	\$ 25,078	39,988	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 U01 DC018920-01	OHIO STATE UNIVERSITY	1 U01 DC018920-01		4,575	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC018920-02	OHIO STATE UNIVERSITY	5 U01 DC018920-02		52,036	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC008408-14			92,464	135,285	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013270-07			86,784	538,317	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R03 DC015075-03				(300)	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015388-06				106,745	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015988-05			90,718	486,960	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R21 DC016710-02:03				9,772	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R01 DC016977-04			70,408	520,620	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017175-04			153,709	701,753	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017683-03			92,884	590,421	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017926-03			217,869	817,349	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R56 DC019113-01			144,068	394,053	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R21 DC019280-01A1				122,161	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R13 DC020098-01				2,284	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC009404-11				\$ 883	\$ 5,834,672	RESEARCH AND DEVELOPMENT	\$ 493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R21 DC016723-03				86,784	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 T35 DC008763-14			\$ 6,836	13,440	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 T35 DC008763-15				4,744	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC016033-03				209,397	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3 R01 DC015997-02S1	UNIVERSITY OF IOWA	3 R01 DC015997-02S1		15,238	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3 R01 DC015997-03	UNIVERSITY OF IOWA	3 R01 DC015997-03		107,522	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC014706-02	UNIVERSITY OF UTAH	5 U01 DC014706-02		3,555	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2 R01 DC014037-07	VANDERBILT UNIVERSITY	2 R01 DC014037-07		151,056	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1 R01 DC018171-01	VANDERBILT UNIVERSITY	1 R01 DC018171-01		22,364	5,834,672	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001116-02-00	JOHNS HOPKINS UNIVERSITY	5 U01 IP001116-02-00		9,682	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001116-02-00	JOHNS HOPKINS UNIVERSITY	5 U01 IP001116-02-00		76,632	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	6 U01 IP001116-03-01	JOHNS HOPKINS UNIVERSITY	6 U01 IP001116-03-01		103,107	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-04				412	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-05-00				109,650	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-05-00				281,046	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	6 U01 IP001083-03				19,008	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	1 U01 IP001156-01-00				979,944	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	1 U01 IP001156-01-00				428,932	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	6 U01 IP001083-03				(1,318)	2,007,095	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1 U01 AT010598-01A1	CASE WESTERN RESERVE UNIVERSITY	1 U01 AT010598-01A1		3,175	824,727	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 U01 AT010598-02	CASE WESTERN RESERVE UNIVERSITY	5 U01 AT010598-02		61,774	824,727	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1 K23 AT011569-01				77,505	824,727	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 R01 AT010462-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 AT010462-02		26	824,727	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 R34 AT009685-03	NORTHWESTERN UNIVERSITY	5 R34 AT009685-03		8,660	824,727	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1 R01 AT011456-01				\$ 254,050	\$ 824,727	RESEARCH AND DEVELOPMENT	\$ 493,731,962
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 R01 AT009680-04	RUSH UNIVERSITY MEDICAL CENTER	5 R01 AT009680-04		419,537	824,727	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING	93.225	5 T32 HS026122-03				1,878	582,246	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING	93.225	5 T32 HS026122-04			\$ 52,323	580,368	582,246	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025979-03	ATRIUM HEALTH	5 R01 HS025979-03		374	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	7 U18 HS025291-04	KAISER PERMANENTE	7 U18 HS025291-04		3,023	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS026395-03			98,387	242,105	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS026395-04			78,686	515,010	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025910-02			197	278	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025910-03			8,076	313,374	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025931-02				(270)	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025931-03			122,300	194,358	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025931-04				20,650	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025976-03			33,311	66,691	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025976-04			122,642	286,034	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R03 HS026069-02				2,995	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026158-03			110,076	132,940	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026158-04			159,135	396,413	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026616-03			33,782	149,516	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026616-04			30,588	375,535	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS028430-01A1				16,068	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS027417-02	UNIVERSITY OF COLORADO	5 R01 HS027417-02		86,320	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS027419-01A1	UNIVERSITY OF COLORADO	1 R01 HS027419-01A1		55,556	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R13 HS027769-01	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	1 R13 HS027769-01		21,156	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS026742-02	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 HS026742-02		1,600	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS026742-03	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 HS026742-03		8,266	2,887,992	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	1 R01 HL161635-01				183,868	183,868	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R44 MH115528-02	ADAPTIVE TECHNOLOGY CONSULTING, LLC	2 R44 MH115528-02		137,953	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 UG3 MH120102-02	CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH)	5 UG3 MH120102-02		7,805	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 UG3 MH120102-03	CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH)	5 UG3 MH120102-03		188,467	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R21 MH121165-02	CASE WESTERN RESERVE UNIVERSITY	5 R21 MH121165-02		9,776	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123262-02	CITY UNIVERSITY OF NEW YORK (CUNY)	5 R01 MH123262-02		29,003	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH120588-01A1	INDIANA UNIVERSITY	1 R01 MH120588-01A1		96,370	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K23 MH116339-06			2,011	227,445	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K23 MH122737-02				159,454	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K18 MH122755-02				130,815	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K08 MH126166-02				164,812	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K24 MH126280-01A1				87,621	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 K23 MH126313-02				128,979	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 HM118233-04	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HM118233-04		16,355	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH118233-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 MH118233-03		139,876	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH124851-01	MASSACHUSETTS GENERAL HOSPITAL	1 R01 MH124851-01		\$ 46,654	\$ 16,223,612	RESEARCH AND DEVELOPMENT	\$ 493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121407-02	PORTLAND STATE UNIVERSITY	5 R01 MH121407-02		11,319	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121407-03	PORTLAND STATE UNIVERSITY	5 R01 MH121407-03		20,942	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH070560-13				573,742	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH102272-08				535,706	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107435-05				1,523	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R01 MH107435-06				268,590	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111599-05				362,299	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111776-04			\$ 35,364	35,364	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111877-04				109,355	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113362-05			61,606	588,397	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113438-03			7,377	148,586	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113478-05			134,065	735,312	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH114906-04			197,584	495,040	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH115000-03			165,132	360,929	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH116058-03			305,070	628,489	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH116269-04				1,010,264	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH118273-04			206,732	1,130,010	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH118539-02				72,777	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH119817-03				330,206	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R33 MH120149-03			6,636	377,243	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R56 MH120736-02			102,953	491,949	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121438-02			365,274	577,315	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121455-02			76,761	599,200	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH121620-03			55,761	772,370	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R61 MH122464-02			54,614	700,898	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R61 MH123029-02			100,546	352,039	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 RF1 MH123201-01A1			94,011	365,848	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123563-03			58,766	452,682	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123662-02			54,247	812,546	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R34 MH124496-2			19,130	93,514	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH126272-01				234,816	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH127018-02			86,372	445,385	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH127228-01				286,042	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH128790-01				73,474	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107467-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 MH107467-05		462	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH120122-03	UNIVERSITY OF COLORADO	5 R01 MH120122-03		118,263	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R34 MH123584-01	UNIVERSITY OF ILLINOIS	1 R34 MH123584-01		15,287	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	3 R01 MH120124-02S2	UNIVERSITY OF MICHIGAN	3 R01 MH120124-02S2		34,807	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R56 MH120826-01A1	UNIVERSITY OF NEW MEXICO	1 R56 MH120826-01A1	8,607	56,312	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-05	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-05		436	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH127317-02	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	5 R01 MH127317-02		11,053	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-02	UNIVERSITY OF WISCONSIN	5 U01 MH112913-02		400	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-04	UNIVERSITY OF WISCONSIN	5 U01 MH112913-04		49,187	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123687-02	VANDERBILT UNIVERSITY	5 R01 MH123687-02		95,951	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 RF1 MH123971-01	VANDERBILT UNIVERSITY	1 RF1 MH123971-01		66,203	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH124671-01	VANDERBILT UNIVERSITY	1 R01 MH124671-01		35,824	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 RF1 MH125933-01	VANDERBILT UNIVERSITY	1 RF1 MH125933-01		868	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 T32 MH065215-17	VANDERBILT UNIVERSITY	5 T32 MH065215-17		58,999	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 T32 MH065215-18	VANDERBILT UNIVERSITY	5 T32 MH065215-18		15,694	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH123155-01A1	YALE UNIVERSITY	1 R01 MH123155-01A1		52,259	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH123155-02	YALE UNIVERSITY	5 R01 MH123155-02		14,193	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-02	UNIVERSITY OF WISCONSIN	5 U01 MH112913-02		(400)	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111776-04				(27,742)	16,223,612	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES_PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	5 H79 TI081358-03				\$ 72,818	\$ 72,818	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ADVANCED NURSING EDUCATION GRANT PROGRAM	93.247	5 T14 HP33119-03-00	VANDERBILT UNIVERSITY	5 T14 HP33119-03-00		368,090	368,090	RESEARCH AND DEVELOPMENT	493,731,962
EARLY HEARING DETECTION AND INTERVENTION	93.251	65942:ST TN	TN DEPARTMENT OF HEALTH	65942:ST TN		109,182	109,182	RESEARCH AND DEVELOPMENT	493,731,962
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4B HS30752-05				62,912	425,010	N/A	—
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4B HS30752-06-00				362,098	425,010	N/A	—
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	1 U01 OH012271-01-00	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	1 U01 OH012271-01-00		88,442	88,889	RESEARCH AND DEVELOPMENT	493,731,962
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	5 R21 OH011452-02-00	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R21 OH011452-02-00		447	88,889	RESEARCH AND DEVELOPMENT	493,731,962
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	6 NH23 IP922617-02-05				31,772	31,772	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA020780-10	BOSTON MEDICAL CENTER	5 U01 AA020780-10		29,620	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA020780-10	BOSTON MEDICAL CENTER	5 U01 AA020780-10		19,772	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	7 R03 AA026099-03	OCHSNER CLINIC FOUNDATION	7 R03 AA026099-03		961	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	1 P01 AA029542-01			\$ 197,803	548,408	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA026186-05			14,348	221,347	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026222-04			296,389	330,239	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026222-05			335,491	670,200	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026209-04	UNIVERSITY OF BRISTOL	5 U01 AA026209-04		1,028	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA025337-02	UNIVERSITY OF FLORIDA	5 R01 AA025337-02		40,665	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA027654-03	UNIVERSITY OF IOWA	5 R01 AA027654-03		51,838	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026224-05	YALE UNIVERSITY	5 U01 AA026224-05		17,596	1,931,674	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 K23 DA047476-04				166,987	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 K01 DA050740-03				185,795	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 K01 DA051683-01A1				136,909	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA040630-05				56,298	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2 R01 DA040630-06A1				425,500	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 R01 DA045729-04			5,123	133,243	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 R01 DA045729-04S1				45,234	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA050334-02			3,404	462,962	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA015831-19S1	THE MCLEAN HOSPITAL CORPORATION	3 UG1 DA015831-19S1		(31,246)	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2 UG1 DA013732-22S1	UNIVERSITY OF CINCINNATI	2 UG1 DA013732-22S1	9,999	311,118	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	2 UG1 DA013732-23S1	UNIVERSITY OF CINCINNATI	2 UG1 DA013732-23S1	1,031	160,964	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 U01 DA055347-01	VANDERBILT UNIVERSITY	1 U01 DA055347-01		153,922	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA015831-20S2	YALE UNIVERSITY	3 UG1 DA015831-20S2		242,011	2,449,697	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 K01 EB030039-02				154,498	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB018992-04				984	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB018992-06			31,446	134,963	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB024525-04			16,879	540,431	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB025258-03			34,713	157,839	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB026991-02			1,554	90,930	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R03 EB029078-02				58,036	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB029443-01A1			3,963	300,901	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB029639-03			52,016	217,074	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB031954-01			18,953	111,874	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 T32 EB001628-18				\$ 901	\$ 3,673,838	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 T32 EB001628-19				377,413	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 U18 EB029351-01			\$ 370,429	1,080,771	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB014308-04	VANDERBILT UNIVERSITY	5 R01 EB014308-04		14,570	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB014308-08	VANDERBILT UNIVERSITY	5 R01 EB014308-08		24,400	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB014308-08	VANDERBILT UNIVERSITY	5 R01 EB014308-08		12,275	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB016695-08	VANDERBILT UNIVERSITY	5 R01 EB016695-08		116,495	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2 R01 EB017230-05A1	VANDERBILT UNIVERSITY	2 R01 EB017230-05A1		15,744	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2 R01 EB017230-05A1	VANDERBILT UNIVERSITY	2 R01 EB017230-05A1		9,126	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB023717-02	VANDERBILT UNIVERSITY	5 R01 EB023717-02		1,934	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB026901-01A1	VANDERBILT UNIVERSITY	1 R01 EB026901-01A1		67,081	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB027498-02	VANDERBILT UNIVERSITY	5 R01 EB027498-02		55,348	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R21 EB027881-01A1	VANDERBILT UNIVERSITY	1 R21 EB027881-01A1		34,767	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB027881-02	VANDERBILT UNIVERSITY	5 R21 EB027881-02		15,466	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB028615-01	VANDERBILT UNIVERSITY	1 R01 EB028615-01		29,166	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB028690-02	VANDERBILT UNIVERSITY	5 R01 EB028690-02		25,007	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB030414-02	VANDERBILT UNIVERSITY	5 R01 EB030414-02		25,844	3,673,838	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL PUBLIC HEALTH IMPROVEMENT INITIATIVE	93.292	1 K01 MH125073-01A1	VANDERBILT UNIVERSITY	1 K01 MH125073-01A1		3,650	3,650	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD013493-05	DUKE UNIVERSITY	5 R01 MD013493-05		8,706	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD013493-04	DUKE UNIVERSITY	5 R01 MD013493-04		25,610	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-35	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-35		19,161	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-35	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-35		25,696	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-35	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-35		7,805	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1 P50 MD017347-01			260,620	483,755	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD015396-02				188,229	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD012397-03	SAN DIEGO STATE UNIVERSITY	5 U54 MD012397-03		(308)	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD012397-04	SAN DIEGO STATE UNIVERSITY	5 U54 MD012397-04		18,972	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD010722-05			\$ 349,020	\$ 658,154	\$ 1,476,321	RESEARCH AND DEVELOPMENT	\$ 493,731,962
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R21 MD015159-02	VANDERBILT UNIVERSITY	5 R21 MD015159-02		40,541	1,476,321	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 GM132769-03	ALABAMA STATE UNIVERSITY	5 U01 GM132769-03		66,050	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023320-05	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 UH3 OD023320-05		(606)	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023320-06	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 UH3 OD023320-06		44,670	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023320-07	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 UH3 OD023320-07		207,391	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023268-05	BRIGHAM AND WOMEN'S HOSPITAL	5 UH3 OD023268-05		647	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023268-06	BRIGHAM AND WOMEN'S HOSPITAL	5 UH3 OD023268-06		3,263	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	1 DP2 HD098859-01			21,199	661,033	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	3 DP5 OD029586-01S1				13,355	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 DP5 OD029586-02				576,784	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	3 DP5 OD029586-02S1				75,415	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-05	DUKE UNIVERSITY	5 U2C OD023375-05		14,407	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-05	DUKE UNIVERSITY	5 U2C OD023375-05		21,971	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-06	DUKE UNIVERSITY	5 U2C OD023375-06		12,943	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-06	DUKE UNIVERSITY	5 U2C OD023375-06		91,408	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	4 U24 OD023319-05	NORTHWESTERN UNIVERSITY	4 U24 OD023319-05		12,164	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	4 U24 OD023319-06	NORTHWESTERN UNIVERSITY	4 U24 OD023319-06		65,362	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	1 OT2 OD032581-01				57,713	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	1 OT2 OD032581-01				735,668	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	3 R01 DK115545-04S1				69	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	4 UH3 CA241685-03			171,620	694,521	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 HG007674-08				532	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 HG007674-09			16,805	1,263,692	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	3 U01 HG007674-09S1				66,528	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	1 OT2 OD032581-01	UNIVERSITY OF NORTH TEXAS	1 OT2 OD032581-01		396,428	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U24 GM132217-02	UNIVERSITY OF NORTH TEXAS	5 U24 GM132217-02		1,744	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 GM132133-02	UNIVERSITY OF PITTSBURGH	5 U01 GM132133-02		8,387	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023271-05	UNIVERSITY OF WASHINGTON	5 UH3 OD023271-05		17,114	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023271-06	UNIVERSITY OF WASHINGTON	5 UH3 OD023271-06		87,456	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023282-04	UNIVERSITY OF WISCONSIN	5 UH3 OD023282-04		369	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023282-05	UNIVERSITY OF WISCONSIN	5 UH3 OD023282-05	32,975	418,396	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023282-06	UNIVERSITY OF WISCONSIN	5 UH3 OD023282-06		2,012,308	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023196-03				(105,049)	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023196-04			7,019,894	21,556,727	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023196-05			11,642	14,460,149	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	1 U54 DK120058-02	VANDERBILT UNIVERSITY	1 U54 DK120058-02		(91)	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 DK120058-02	VANDERBILT UNIVERSITY	5 U54 DK120058-02		(25)	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	1 U54 DK120058-03	VANDERBILT UNIVERSITY	1 U54 DK120058-03		271,040	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 DK120058-04	VANDERBILT UNIVERSITY	5 U54 DK120058-04		45,722	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 DK120058-04	VANDERBILT UNIVERSITY	5 U54 DK120058-04		32,351	43,888,006	RESEARCH AND DEVELOPMENT	493,731,962
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001234-02-00				5,099	116,246	RESEARCH AND DEVELOPMENT	493,731,962
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001234-03-00				22,678	116,246	RESEARCH AND DEVELOPMENT	493,731,962
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001235-02-00				16,035	116,246	RESEARCH AND DEVELOPMENT	493,731,962
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001235-03-00				72,434	116,246	RESEARCH AND DEVELOPMENT	493,731,962
EMERGING INFECTIONS PROGRAMS	93.317	59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		1,691,772	3,314,398	RESEARCH AND DEVELOPMENT	493,731,962
EMERGING INFECTIONS PROGRAMS	93.317	59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		1,622,534	3,314,398	RESEARCH AND DEVELOPMENT	493,731,962
EMERGING INFECTIONS PROGRAMS	93.317	59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		92	3,314,398	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318	6NU50CK000586-01-00				\$ 3,356	\$ 127,727	RESEARCH AND DEVELOPMENT	\$ 493,731,962
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318	1 NU3 HCK000006-01-00				124,371	127,727	RESEARCH AND DEVELOPMENT	493,731,962
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	93.323	67997:ST TN	TN DEPARTMENT OF HEALTH	67997:ST TN		(33,945)	(33,945)	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-05	DUKE UNIVERSITY	5 U24 TR001608-05		4,537	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-05S1	DUKE UNIVERSITY	5 U24 TR001608-05S1		22,859	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U24 TR001608-05S4	DUKE UNIVERSITY	3 U24 TR001608-05S4		7,602	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U24 TR001608-05S4	DUKE UNIVERSITY	3 U24 TR001608-05S4		16,711	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U24 TR001608-05S4	DUKE UNIVERSITY	3 U24 TR001608-05S4		135,569	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-06	DUKE UNIVERSITY	5 U24 TR001608-06		1,531,013	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-06S1	DUKE UNIVERSITY	5 U24 TR001608-06S1		388,024	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U24 TR001608-06S4	DUKE UNIVERSITY	3 U24 TR001608-06S4		2,042,592	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-02	DUKE UNIVERSITY	5 U01 TR001803-02		83,070	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-05	DUKE UNIVERSITY	5 U01 TR001803-05		3,883	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-04			\$ 63,344	63,345	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-05			237,840	618,658	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	2 KL2 TR002245-06				182,854	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U01 TR003206-02	ROCKEFELLER UNIVERSITY	1 U01 TR003206-02		121,975	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR003206-03	ROCKEFELLER UNIVERSITY	5 U01 TR003206-03		24,987	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 R21TR003942-01				169,543	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-03			1,832	3,937	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-03				828	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-05				255,144	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	2 TL1 TR002244-06				77,953	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001812-05	UNIVERSITY OF MASSACHUSETTS	5 U01 TR001812-05		19,204	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001579-05			54,887	79,805	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U24 TR001579-05S1				504,229	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	4 U24 TR001579-06			125,095	4,923,632	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 UL1 TR002243-04S3			8,185,059	9,394,738	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 UL1 TR002243-05			568,673	5,856,332	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	2 U54 TR002243-06				2,801,856	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002398-02			67,353	334,303	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U34 TR003298-01				63,755	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	4 UH3 TR002097-05	VANDERBILT UNIVERSITY	4 UH3 TR002097-05		240,088	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002383-03	VANDERBILT UNIVERSITY	5 U01 TR002383-03		9,835	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002383-04	VANDERBILT UNIVERSITY	5 U01 TR002383-04		126,835	30,109,696	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1 S10 OD025092-01A1				(85,754)	867,294	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1 S10 OD025085-01A1				549,442	867,294	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1 S10 OD030338-01				202,166	867,294	RESEARCH AND DEVELOPMENT	493,731,962
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1 S10 OD030436-01				201,440	867,294	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	5 U01 CA232829-01A1			\$ 126,188	\$ 748,944	\$ 3,400,432	RESEARCH AND DEVELOPMENT	\$ 493,731,962
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1 U2C CA233291-01			678,853	1,893,429	3,400,432	RESEARCH AND DEVELOPMENT	493,731,962
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	5 U01 CA254832-01			93,385	212,511	3,400,432	RESEARCH AND DEVELOPMENT	493,731,962
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	5 U01 CA254832-02			60,408	545,548	3,400,432	RESEARCH AND DEVELOPMENT	493,731,962
NURSING RESEARCH	93.361	5 R01 NR015079-09				431,837	460,988	RESEARCH AND DEVELOPMENT	493,731,962
NURSING RESEARCH	93.361	1 R01 NR017622-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NR017622-01A1		608	460,988	RESEARCH AND DEVELOPMENT	493,731,962
NURSING RESEARCH	93.361	5 R01 NR017622-03	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 NR017622-03		28,543	460,988	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA242740-01A1	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	1 U01 CA242740-01A1		5,787	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA242740-02	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 U01 CA242740-02		28,771	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 R01 CA172253-06	BAPTIST HOSPITAL SYSTEM DBA BH1	2 R01 CA172253-06		9,307	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4 UH3 CA243120-03	BOSTON CHILDREN'S HOSPITAL	4 UH3 CA243120-03		27,199	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U24 CA248010-01A1	BOSTON CHILDREN'S HOSPITAL	1 U24 CA248010-01A1		15,919	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U24 CA248010-02	BOSTON CHILDREN'S HOSPITAL	5 U24 CA248010-02		97,899	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R37 CA262299-01	BRIGHAM AND WOMEN'S HOSPITAL	1 R37 CA262299-01		5,453	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA250476-01A1	BRIGHAM AND WOMEN'S HOSPITAL	1 U01 CA250476-01A1		68,795	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA250476-02	BRIGHAM AND WOMEN'S HOSPITAL	5 U01 CA250476-02		24,696	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA202979-04				478	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA220581-05	CASE WESTERN RESERVE UNIVERSITY	5 R01 CA220581-05		22,951	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 R01 CA157823-07A1	INDIANA UNIVERSITY	2 R01 CA157823-07A1		(30,571)	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 R01 CA157823-08A1	INDIANA UNIVERSITY	2 R01 CA157823-08A1		81,766	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7 U19 CA203654-04	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)	7 U19 CA203654-04		4,153	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7 U19 CA203654-05	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)	7 U19 CA203654-05		13,192	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	7 U19 CA203654-05	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (FRANCE)	7 U19 CA203654-05		11,562	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA247283-01	JOHNS HOPKINS UNIVERSITY	1 U01 CA247283-01		1	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	4 K00 CA253718-03				50,623	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA226086-05	MEDICAL UNIVERSITY OF SOUTH CAROLINA	5 R01 CA226086-05		30,998	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R00 CA230205-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 R00 CA230205-04		31,283	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3 R00 CA230205-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	3 R00 CA230205-04		108,490	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA204113-05	NEW YORK UNIVERSITY	5 R01 CA204113-05		220,179	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	NORTHWESTERN UNIVERSITY	HHSN261201200035I		158,545	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	NORTHWESTERN UNIVERSITY	HHSN261201200035I		96,573	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA255016-01A1	OREGON HEALTH & SCIENCE UNIVERSITY	1 R01 CA255016-01A1		16,307	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA028842-34			19,472	262,700	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA116087-13				1,654	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA116087-14			123,004	738,755	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA116087-15			2,541	460,980	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA077955-26				460,051	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA188214-06				76,034	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA189152-06			97,144	97,144	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA190612-06			\$ 27,466	\$ 84,332	\$ 15,156,508	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA198482-06				39,620	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA200999-05				143,831	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA202936-05			11,168	43,976	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA202981-05			198,252	820,315	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA203012-05			103,095	175,632	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA204819-05			12,527	243,882	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207466-04				405,200	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA225005-04			260,823	583,180	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R37 CA227130-04			34,135	691,123	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA230352-04			336,808	666,767	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA232516-04			19,714	1,008,982	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA235553-04				699,749	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R37 CA237452-03			24,623	343,120	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA237895-03				607,755	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA240093-03			139,013	751,038	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R21 CA243036-02				164,295	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA247987-02			4,994	515,359	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA249863-02			37,825	603,314	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA251758-01A1			59,960	258,964	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA228156-03	ROSWELL PARK CANCER INSTITUTE	5 R01 CA228156-03		127,536	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 UM1 CA182910-06				91,000	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA202979-05			6,451	11,432	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 U01 CA202979-06				1,496,938	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 UG3 CA260318-01				613,860	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 U01 CA262678-01A1				37,329	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 UG3 CA265846-01			5,483	428,905	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA260615-01	UNIVERSITY OF CALIFORNIA, SYSTEMWIDE	1 R01 CA260615-01		17,301	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 P01 CA138336-10	UNIVERSITY OF HAWAII	5 P01 CA138336-10		15,792	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207401-04	UNIVERSITY OF KENTUCKY	5 R01 CA207401-04		79,212	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA209798-04	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 CA209798-04		12,826	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA255318-01A1	UNIVERSITY OF WISCONSIN	1 R01 CA255318-01A1		72,437	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA164605-08	VANDERBILT UNIVERSITY	5 R01 CA164605-08		29,347	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	2 R01 CA200709-06A1	VANDERBILT UNIVERSITY	2 R01 CA200709-06A1		31,215	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1 R01 CA247833-01	VANDERBILT UNIVERSITY	1 R01 CA247833-01		92,511	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA224276-03	VANDERBILT UNIVERSITY	5 U01 CA224276-03		22,686	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 U01 CA224276-04	VANDERBILT UNIVERSITY	5 U01 CA224276-04		95,413	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 UG1 CA189824-08	WAKE FOREST UNIVERSITY	5 UG1 CA189824-08		35,972	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R37 CA246175-02	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R37 CA246175-02		14,256	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207401-04			1,280	1,280	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA207401-04				(1,280)	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5 R01 CA189152-06				(217,568)	15,156,508	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA249992-01A1	CASE WESTERN RESERVE UNIVERSITY	1 R01 CA249992-01A1		11,537	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA249992-02	CASE WESTERN RESERVE UNIVERSITY	5 R01 CA249992-02		16,736	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA218526-04	CEDARS-SINAI MEDICAL CENTER	5 R01 CA218526-04		48,900	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA218526-05	CEDARS-SINAI MEDICAL CENTER	5 R01 CA218526-05		102,784	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA193478-04	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 R01 CA193478-04		861	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 D43 CA270474-01				8,960	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA086368-20	FRED HUTCHINSON CANCER RESEARCH CENTER	5 U24 CA086368-20	44,517	57,602	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 U54 CA260560-01	MOUNT SINAI SCHOOL OF MEDICINE	1 U54 CA260560-01		\$ 77,692	\$ 5,277,874	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 U54 CA260560-02	MOUNT SINAI SCHOOL OF MEDICINE	1 U54 CA260560-02		173,490	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2 R01 CA159036-05A1	NEW YORK UNIVERSITY	2 R01 CA159036-05A1		58,587	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2 R44 CA203455-02A1	PRECYTE, INC	2 R44 CA203455-02A1		5,785	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA109106-16				289,167	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	7 R01 CA194024-05			\$ 57,818	148,827	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA214494-03				137,397	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA227133-04			44,394	575,900	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	7 R01 CA238686-03				13,889	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA250506-02			9,802	474,220	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R21 CA252629-01A1			8,880	194,933	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA252964-02				29,766	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA253923-02			27,495	289,124	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA239257-03	STANFORD UNIVERSITY	5 R01 CA239257-03		39,074	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA152662-10			177,177	969,314	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UM1 CA183727-06				(21)	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UM1 CA183727-08				15,013	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UM1 CA183727-09				734,627	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UM1 CA183727-10				244,834	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U01 CA231840-03			167,721	283,230	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 UG3 CA232820-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 UG3 CA232820-02		(290)	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	4 UH3 CA232820-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	4 UH3 CA232820-03		68,916	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA227466-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 CA227466-01		21	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA227466-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 CA227466-04		68,035	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA200987-05	UNIVERSITY OF MIAMI	5 R01 CA200987-05		83,355	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 U24 CA086368-18	UNIVERSITY OF MICHIGAN	5 U24 CA086368-18		9,656	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1 R01 CA212147-01A1	VANDERBILT UNIVERSITY	1 R01 CA212147-01A1		35,621	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5 R01 CA245134-03	VANDERBILT UNIVERSITY	5 R01 CA245134-03		10,332	5,277,874	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA181050-02	CHILDREN'S HOSPITAL LOS ANGELES	5 R01 CA181050-02		(118)	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA201788-04	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 R01 CA201788-04		654	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		(6,860)	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	9 R44 CA228756-02	CUMBERLAND PHARMACEUTICALS, INC.	9 R44 CA228756-02		9,204	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE EA1141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE EA1141		7,200	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE S1418	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE S1418		2,997	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:NRG-GI002	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:NRG-GI002		42	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO EA5142	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO EA5142		18,115	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO EA8141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO EA8141		(146)	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GYN GY005	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GYN GY005		256	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MD EAY131	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MD EAY131		141,645	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL S1404	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MEL S1404		11,508	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO E4512	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO E4512		\$ 2,041	\$ 4,050,493	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO S0931	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO S0931		155	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA018082-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA018082-05		553	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		954	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		57,543	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		38,832	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		(6,675)	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		3,100	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		9,000	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		2,434	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		7,348	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		2,041	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180820-08	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180820-08		13,237	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-08	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-08		19,391	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-08	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-08		11,940	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U01 CA180820-09	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U01 CA180820-09		6,610	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		11,825	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		29,330	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		2,132	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		25,371	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		14,765	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		777	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		1,297	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		496	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		3,131	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		8,108	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		2,671	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		5,374	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		1,861	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-08	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-08		6,504	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$ 2,230	\$ 4,050,493	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233259-03	EMORY UNIVERSITY	5 UG1 CA233259-03		63,537	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233259-04	EMORY UNIVERSITY	5 UG1 CA233259-04		20,309	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA118953-12	FRED HUTCHINSON CANCER RESEARCH CENTER	5 R01 CA118953-12		15,163	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U01 CA236229-03	FRED HUTCHINSON CANCER RESEARCH CENTER	5 U01 CA236229-03		10,792	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 U01 CA253166-01	FRED HUTCHINSON CANCER RESEARCH CENTER	1 U01 CA253166-01		49,283	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U01 CA253166-02	FRED HUTCHINSON CANCER RESEARCH CENTER	5 U01 CA253166-02		55,183	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 P01 CA129243-13	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 P01 CA129243-13		27,524	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 P01 CA129243-14	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 P01 CA129243-14		45,347	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R41 CA257262-01A1	MTI BIOTECH	1 R41 CA257262-01A1		155,137	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180868-09	NRG ONCOLOGY FOUNDATION	5 U10 CA180868-09		4,909	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA213201-03			\$ 186,699	456,973	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R21 CA226562-02			35,747	126,950	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA227481-04			2,742	347,188	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA248505-02				281,872	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R03 CA252807-01				69,025	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R01 CA262287-01				151,974	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180888-08	SOUTHWEST ONCOLOGY GROUP	5 U10 CA180888-08		2,155	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180868-09				4,591	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-07				184,590	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	7 U10 CA180886-08				44,722	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	7 U10 CA180886-08				27,001	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	7 U10 CA180886-08				12,439	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-02				20,425	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-03				191,891	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-04				99,595	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 U01 CA253560-01			262	262	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U01 CA253560-02			135,569	326,368	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 U01 CA253560-03				33,894	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R37 CA245157-01A1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	1 R37 CA245157-01A1		72,675	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R37 CA245157-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R37 CA245157-02		26,721	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	4 R00 CA218892-02	UNIVERSITY OF HAWAII	4 R00 CA218892-02		1,714	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R00 CA218892-04	UNIVERSITY OF HAWAII	5 R00 CA218892-04		20,573	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA243511-04	UNIVERSITY OF WASHINGTON	5 R01 CA243511-04		36,438	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA116021-18	VANDERBILT UNIVERSITY	5 R01 CA116021-18		75,382	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA214043-05	VANDERBILT UNIVERSITY	5 R01 CA214043-05		43,506	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R01 CA224241-01A1	VANDERBILT UNIVERSITY	1 R01 CA224241-01A1		20,731	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	5 R01 CA243326-03	VANDERBILT UNIVERSITY	5 R01 CA243326-03		49,210	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R01 CA260958-01A1	VANDERBILT UNIVERSITY	1 R01 CA260958-01A1		6,330	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 R01 CA260958-01A1	VANDERBILT UNIVERSITY	1 R01 CA260958-01A1		22,655	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-06	YALE UNIVERSITY	2 UM1 CA186689-06		6,002	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-06	YALE UNIVERSITY	2 UM1 CA186689-06		5,981	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-06	YALE UNIVERSITY	2 UM1 CA186689-06		174	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-06	YALE UNIVERSITY	2 UM1 CA186689-06		833	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-07	YALE UNIVERSITY	2 UM1 CA186689-07		245,152	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	2 UM1 CA186689-06	YALE UNIVERSITY	2 UM1 CA186689-06		118,681	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER TREATMENT RESEARCH	93.395	1 U01 CA253560-01				(237)	4,050,493	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	HHSN261200800001E	LEIDOS BIOMEDICAL RESEARCH, INC. (FORMERLY SAIC-FREDERICK)	HHSN261200800001E		893	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-04		\$ 58,187	\$ 6,603,776	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-05	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-05		55,619	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA095004-16				102,067	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA193219-07				249,956	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-04				670	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-05				680,916	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-06				193,498	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA200681-05				24,175	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA211695-06			\$ 10,521	252,637	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA217987-05			46,458	213,359	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA227833-04			175,837	270,625	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA235016-04			54,921	889,019	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	1 R37 CA244970-01A1				498,983	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA249424-03			141,547	314,990	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA250051-03				512,697	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA252964-01A1				238,572	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA263614-01A1				64,023	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA163056-11				279,270	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA196405-06			165,381	565,683	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 UG3 CA241685-02			(2,230)	3,732	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA233581-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 CA233581-04		44,678	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA233581-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 CA233581-03		24,391	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA194215-05	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	5 U24 CA194215-05		88,532	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 P01 CA229123-03	VANDERBILT UNIVERSITY	5 P01 CA229123-03		894,896	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA226833-04	VANDERBILT UNIVERSITY	5 R01 CA226833-04		64,447	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA255446-02	VANDERBILT UNIVERSITY	5 R01 CA255446-02		17,261	6,603,776	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	2 P30 CA068485-25			1,282,438	2,432,381	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 P30 CA068485-26			809,666	6,029,026	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	3 P30 CA068485-26S1				47,145	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	3 P30 CA068485-26S2				8,877	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA098131-18			336,871	608,296	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA098131-19			186,690	1,640,609	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA236733-02			289,195	322,458	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA236733-03			861,915	2,283,605	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA236733-04			15,924	35,049	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA163072-11			55,173	404,113	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	2 U54 CA163072-12			94,675	779,367	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-03	VANDERBILT UNIVERSITY	5 U54 CA217450-03		(383)	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-04	VANDERBILT UNIVERSITY	5 U54 CA217450-04		183,709	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-05	VANDERBILT UNIVERSITY	5 U54 CA217450-05		53,188	14,827,440	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	1 F32 CA254070-01				14,895	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 F32 CA254070-02				51,927	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K12 CA090625-20				20,379	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K12 CA090625-21				59,852	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	2 K12 CA090625-22A1				3,004	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K25 CA176219-06				13,795	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K23 CA204726-05				7,676	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K07 CA225404-05				143,171	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K00 CA234920-05				93,340	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K08 CA240901-02				244,944	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K08 CA241351-03				183,769	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K01 CA245231-02				28,810	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K99 CA248822-01				48,180	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 K99 CA248822-02				47,376	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER RESEARCH MANPOWER	93.398	4 R00 CA215360-04				\$ 65,392	\$ 2,279,464	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CANCER RESEARCH MANPOWER	93.398	2 T32 CA106183-17				680	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	2 T32 CA106183-18				394,837	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-08				1,627	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-10				68,721	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-11				254,575	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA217834-03				27,673	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA217834-04				332,945	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009582-34	VANDERBILT UNIVERSITY	5 T32 CA009582-34		4,306	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-32	VANDERBILT UNIVERSITY	5 T32 CA009592-32		5,740	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-33	VANDERBILT UNIVERSITY	5 T32 CA009592-33		10,418	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-33	VANDERBILT UNIVERSITY	5 T32 CA009592-33		58,094	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009592-34	VANDERBILT UNIVERSITY	5 T32 CA009592-34		953	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-13	VANDERBILT UNIVERSITY	5 T32 CA119925-13		35,702	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-13	VANDERBILT UNIVERSITY	5 T32 CA119925-13		35,700	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-14	VANDERBILT UNIVERSITY	5 T32 CA119925-14		20,983	2,279,464	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	2 UG1 CA189955-06	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-06		4,095	99,048	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	2 UG1 CA189955-07	CHILDREN'S HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-07		2,223	99,048	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	2 UG1 CA189828-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 UG1 CA189828-06		5,943	99,048	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	5 UG1 CA189828-07	EASTERN COOPERATIVE ONCOLOGY GROUP	5 UG1 CA189828-07		4,623	99,048	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	5 UG1 CA189828-08	EASTERN COOPERATIVE ONCOLOGY GROUP	5 UG1 CA189828-08		52,590	99,048	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	7 UG1 CA189955-08				24,954	99,048	RESEARCH AND DEVELOPMENT	493,731,962
CANCER CONTROL	93.399	5 UG1 CA189824-07	WAKE FOREST UNIVERSITY	5 UG1 CA189824-07		4,620	99,048	RESEARCH AND DEVELOPMENT	493,731,962
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	775 2020 007	ACADEMYHEALTH	775 2020 007		2,446	91,688	RESEARCH AND DEVELOPMENT	493,731,962
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	NU38OT000316	THE TASK FORCE FOR GLOBAL HEALTH	NU38OT000316		89,242	91,688	RESEARCH AND DEVELOPMENT	493,731,962
IMPROVING THE HEALTH OF AMERICANS THROUGH PREVENTION AND MANAGEMENT OF DIABETES AND HEART DISEASE AND STROKE	93.426	72501:ST TN	TN DEPARTMENT OF HEALTH	72501:ST TN		14,890	14,890	RESEARCH AND DEVELOPMENT	493,731,962
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0002-02-00	VANDERBILT UNIVERSITY	90RTEM0002-02-00		1,328	22,373	RESEARCH AND DEVELOPMENT	493,731,962
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0002-02-00	VANDERBILT UNIVERSITY	90RTEM0002-02-00		885	22,373	RESEARCH AND DEVELOPMENT	493,731,962
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0002-03-00	VANDERBILT UNIVERSITY	90RTEM0002-03-00		2,885	22,373	RESEARCH AND DEVELOPMENT	493,731,962
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0003-03-00	VANDERBILT UNIVERSITY	90RTEM0003-03-00		17,275	22,373	RESEARCH AND DEVELOPMENT	493,731,962
COVID-19 HRSA COVID-19 CLAIMS REIMBURSEMENT FOR THE UNINSURED PROGRAM AND THE COVID-19 COVERAGE ASSISTANCE FUND	93.461	COVID-19 UNINSURED				5,809,048	5,809,048	N/A	—
ALZHEIMER'S DISEASE PROGRAM INITIATIVE (ADPI)	93.470	65462:ST TN	STATE OF TENNESSEE COMMISSION ON AGING AND DISABILITY	65462:ST TN		44,508	44,508	RESEARCH AND DEVELOPMENT	493,731,962
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	65663:ST TN	TN DEPARTMENT OF HEALTH	65663:ST TN		70,791	99,175	N/A	—
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	68711:ST TN	TN DEPARTMENT OF HEALTH	68711:ST TN		18,218	99,175	N/A	—
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	72869:ST TN	TN DEPARTMENT OF HEALTH	72869:ST TN		10,166	99,175	N/A	—
COVID-19 PROVIDER RELIEF FUND AND AMERICAN RESCUE PLAN (ARP) RURAL DISTRIBUTION	93.498	COVID-19				58,653,058	58,653,058	N/A	—

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CHILD CARE AND DEVELOPMENT BLOCK GRANT	93.575	COVID-19 CHILD CARE				\$ 224,112	\$ 224,112	CCDF CLUSTER	\$ 224,112
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	67852:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	67852:ST TN	\$ 42,653	44,217	550,342	N/A	—
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	69637:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	69637:ST TN	13,500	42,355	550,342	N/A	—
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	71344:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	71344:ST TN	57,347	449,167	550,342	N/A	—
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	73268:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	73268:ST TN		13,344	550,342	N/A	—
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	74802:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	74802:ST TN		1,259	550,342	N/A	—
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90D NHC0001-01-00	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	90D NHC0001-01-00		5,522	30,869	N/A	—
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90D NHC0001-03-00	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	90D NHC0001-03-00		25,347	30,869	N/A	—
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDC50014-01-00				40,506	669,564	N/A	—
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0077-01-00			147,154	148,787	669,564	N/A	—
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0080-01-00				7,275	669,564	N/A	—
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC077-02-00			72,231	472,996	669,564	N/A	—
FOSTER CARE_TITLE IV-E	93.658	56787:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	56787:ST TN		80,281	80,281	N/A	—
MATERNAL OPIOID MISUSE MODEL (A)	93.687	65326:ST TN	TN BUREAU OF TENNCARE	65326:ST TN		466,412	978,790	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL OPIOID MISUSE MODEL (A)	93.687	65326:ST TN	TN BUREAU OF TENNCARE	65326:ST TN		512,378	978,790	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL ASSISTANCE PROGRAM	93.778	CDC-BCBS	BLUECROSS BLUESHIELD OF TENNESSEE HEALTH FOUNDATION, INC.	CDC-BCBS		760,624	5,291,744	MEDICAID CLUSTER	5,291,744
MEDICAL ASSISTANCE PROGRAM	93.778	46264:ST TN	TN BUREAU OF TENNCARE	46264:ST TN		(2,752)	5,291,744	MEDICAID CLUSTER	5,291,744
MEDICAL ASSISTANCE PROGRAM	93.778	71331:ST TN	TN BUREAU OF TENNCARE	71331:ST TN		1,136,369	5,291,744	MEDICAID CLUSTER	5,291,744
MEDICAL ASSISTANCE PROGRAM	93.778	46264:ST TN	TN DEPARTMENT OF HEALTH	46264:ST TN		(46)	5,291,744	MEDICAID CLUSTER	5,291,744
MEDICAL ASSISTANCE PROGRAM	93.778	65729:ST TN	TN DEPARTMENT OF HEALTH	65729:ST TN	10,140	529,545	5,291,744	MEDICAID CLUSTER	5,291,744
MEDICAL ASSISTANCE PROGRAM	93.778	53068:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	53068:ST TN	92,633	2,867,563	5,291,744	MEDICAID CLUSTER	5,291,744
MEDICAL ASSISTANCE PROGRAM	93.778	74121:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	74121:ST TN		441	5,291,744	MEDICAID CLUSTER	5,291,744
OPIOID STR	93.788	33901:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	33901:ST TN		70,515	1,311,799	N/A	—
OPIOID STR	93.788	62292:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	62292:ST TN		86,437	1,311,799	N/A	—
OPIOID STR	93.788	65038:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	65038:ST TN		22,013	1,311,799	N/A	—
OPIOID STR	93.788	65428:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	65428:ST TN		20,248	1,311,799	N/A	—
OPIOID STR	93.788	70172:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	70172:ST TN		272,879	1,311,799	N/A	—

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
OPIOID STR	93.788	72607:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	72607:ST TN		\$ 839,688	\$ 1,311,799	N/A	\$ —
OPIOID STR	93.788	65038:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	65038:ST TN		19	1,311,799	N/A	—
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL140443-02	BOSTON CHILDREN'S HOSPITAL	1 R21 HL140443-02		184	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146134-03	BOSTON CHILDREN'S HOSPITAL	5 R01 HL146134-03		31,471	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146134-04	BOSTON CHILDREN'S HOSPITAL	5 R01 HL146134-04		28,182	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148439-02	BRIGHAM AND WOMEN'S HOSPITAL	1 R01 HL148439-02		151,566	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U01 HL123336-01	BRIGHAM AND WOMEN'S HOSPITAL	1 U01 HL123336-01		8,449	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL158071-01A1	CASE WESTERN RESERVE UNIVERSITY	1 R01 HL158071-01A1		90,975	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U2C HL156291-01	CHILDREN'S HOSPITAL OF PHILADELPHIA	1 U2C HL156291-01		17,307	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U2C HL156291-02	CHILDREN'S HOSPITAL OF PHILADELPHIA	5 U2C HL156291-02		119,387	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151604-01	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	1 R01 HL151604-01		(11,235)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL151604-02	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	5 R01 HL151604-02		189,631	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL149680-02	COLUMBIA UNIVERSITY	7 R01 HL149680-02		137	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL137166-01			\$ 11,826	11,826	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 DP2 HL137166-02			1,181	479,762	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL152426-01				585,303	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U10 HL084904-12	DUKE UNIVERSITY	5 U10 HL084904-12		12,466	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL143927-02				(250)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL144081-03				660	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151152-01A1	FRED HUTCHINSON CANCER RESEARCH CENTER	1 R01 HL151152-01A1		11,961	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL151152-02	FRED HUTCHINSON CANCER RESEARCH CENTER	5 R01 HL151152-02		63,958	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148137-02	HARVARD UNIVERSITY	1 R01 HL148137-02		93,796	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL094786-08			14,743	59,718	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144846-04			21,100	526,956	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K08 HL145075-03				126,120	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL128928-04				703	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL130497-06				18,469	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K12 HL133117-05				123,009	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL135461-05				85,490	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	3 K01 HL135461-05S1				33,905	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL140278-05				91,860	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL145345-03				92,443	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL148640-03				147,379	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K23 HL151871-02				169,618	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K08 HL153786-02				167,267	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K08 HL153789-02				59,007	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K08 HL153956-02				135,677	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K24 HL155891-01A1			1,985	46,034	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K23 HL156759-01A1				123,546	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K99 HL159594-01				107,659	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL111821-10	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL111821-10		75,975	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL151838-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL151838-03		62,966	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL151841-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL151841-03		74,915	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 U10 HL068270-15	NEW ENGLAND RESEARCH INSTITUTES	4 U10 HL068270-15		\$ 338	\$ 32,593,011	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 U10 HL068270-15	NEW ENGLAND RESEARCH INSTITUTES	4 U10 HL068270-15		(33,218)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL105444-11	NEW YORK UNIVERSITY	5 R25 HL105444-11		(720)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL116263-04				128	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 P01 HL116263-06A1			\$ 286,094	1,429,234	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL116263-07				1,032,817	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL128203-05			1,054,391	1,529,980	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL129941-05			220,877	645,696	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL145721-05				189,293	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL070715-17				340,503	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 R56 HL081707-12A1				37,263	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL096223-11				8,446	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL121139-05				(134)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL124935-06				101,706	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL125426-06				5,840	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128386-04				(51)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128996-05			(200)	375	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-05			48,534	311,717	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133127-02			7,701	277,850	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133786-04				188,790	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133860-04			5,912	5,912	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134895-04				253,505	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL135011-05			36,299	360,706	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R00 HL135442-05			29,064	135,008	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL138519-04				617	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-03			12,425	12,425	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-04			8,371	435,238	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-05			6,982	428,539	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL140074-05				385,350	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL140145-04			1,007	296,390	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL140375-02				(113)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL140382-02			34,398	43,233	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL141466-03				56,242	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL142583-03				489,950	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL142856-04				645,584	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R38 HL143619-04				480,361	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144568-03				645,052	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL144941-02				473,554	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144943-04			24,640	575,886	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL144980-03				473,154	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL144980-04				262,801	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL145293-01A1				(107,481)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL145293-02			53,531	600,147	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL145293-03				165,113	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146524-04				278,894	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146654-03			19,446	493,658	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R21 HL147831-03				77,786	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL148244-03				435,247	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL148661-02			81,944	81,944	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL148661-03			426,699	535,496	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL149386-01				6,870	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-02				4,166	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-03				447,515	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-04				33,067	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149779-03			16,969	583,132	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149826-03				865,226	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149948-03			455,912	832,925	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R56 HL150186-01A1			86,650	360,304	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL151523-03				\$ 685,432	\$ 32,593,011	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL153607-01A1			\$ 185,586	1,530,419	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL153607-02				90,117	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R03 HL154243-02				86,034	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R03 HL155041-02				90,621	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL155197-01A1				208,226	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R34 HL155400-02				246,279	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL155523-01				377,113	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R61 HL155810-01			67,288	458,647	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL155990-01				253,930	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL156021-01A1				344,952	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL156021-02				116,541	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL157378-02				338,017	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL157583-02			13,701	367,969	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL157584-01				721,342	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL158884-01				138,159	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL158918-01A1				13,750	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL158976-02			265,717	565,894	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL159487-02				516,083	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL160863-01				265,782	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL160970-01				90,975	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL160975-01A1				293	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL161095-01				249,368	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL161516-01				47,284	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	9 R01 HL163854-06				52,514	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL163960-01				14,040	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL164675-01				3,830	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	3 R01 HL123968-08S1	STANFORD UNIVERSITY	3 R01 HL123968-08S1		2,738	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	3 R01 HL141851-03S1	STANFORD UNIVERSITY	3 R01 HL141851-03S1		2,654	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL139968-03	STATE UNIVERSITY OF NEW YORK (SUNY)	5 R01 HL139968-03		24,411	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R44 HL132746-01A1	THERMEDICAL	1 R44 HL132746-01A1		15,448	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL105334-11				486,269	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL105334-10				1,307	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL120338-06	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 HL120338-06		(6)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R34 HL153566-02	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 R34 HL153566-02		2,627	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K24 HL112827-09	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 K24 HL112827-09		10,791	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL129856-06	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 HL129856-06		38,836	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL155990-02	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	7 R01 HL155990-02		9,927	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL145817-03	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 R25 HL145817-03		14,580	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	3 OT3 HL142481-03	UNIVERSITY OF CALIFORNIA, SANTA CRUZ	3 OT3 HL142481-03		7,521	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL147171-02	UNIVERSITY OF CINCINNATI	5 R01 HL147171-02		29,503	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL153118-01	UNIVERSITY OF CINCINNATI	1 R01 HL153118-01		59,108	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151659-01A1	UNIVERSITY OF FLORIDA	1 R01 HL151659-01A1		29,930	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL152081-03	UNIVERSITY OF KENTUCKY	5 R01 HL152081-03		39,096	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL136679-02	UNIVERSITY OF MINNESOTA	5 R01 HL136679-02		14,321	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL150053-02	UNIVERSITY OF MINNESOTA	5 R01 HL150053-02		91,574	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL153179-01A1	UNIVERSITY OF MINNESOTA	1 R01 HL153179-01A1		40,865	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 OT3 HL147154-01	UNIVERSITY OF NORTH CAROLINA	1 OT3 HL147154-01		13,207	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL142302-04	UNIVERSITY OF NORTH CAROLINA	5 R01 HL142302-04		572,172	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134905-05	UNIVERSITY OF PENNSYLVANIA	5 R01 HL134905-05		11,717	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134905-05	UNIVERSITY OF PENNSYLVANIA	5 R01 HL134905-05		\$ 12,517	\$ 32,593,011	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL136824-03	UNIVERSITY OF PITTSBURGH	7 R01 HL136824-03		2,533	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL147818-22	UNIVERSITY OF PITTSBURGH	5 R01 HL147818-22		237,413	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151223-02	VANDERBILT UNIVERSITY	1 R01 HL151223-02		89,298	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL156034-01A1	VANDERBILT UNIVERSITY	1 R01 HL156034-01A1		65,307	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-40	VANDERBILT UNIVERSITY	5 T32 HL007411-40		15,513	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-41	VANDERBILT UNIVERSITY	5 T32 HL007411-41		59,662	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-41	VANDERBILT UNIVERSITY	5 T32 HL007411-41		61,800	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-41	VANDERBILT UNIVERSITY	5 T32 HL007411-41		62,867	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-03	VANDERBILT UNIVERSITY	5 T32 HL144446-03		66,706	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-03	VANDERBILT UNIVERSITY	5 T32 HL144446-03		54,540	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-03	VANDERBILT UNIVERSITY	5 T32 HL144446-03		61,419	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL144446-04	VANDERBILT UNIVERSITY	5 T32 HL144446-04		2,652	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 R44 HL140669-02	VOLUMETRIX LLC	4 R44 HL140669-02		(25,832)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL156991-01	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 HL156991-01		18,590	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 UG3 HL145269-01A1	WAYNE STATE UNIVERSITY	1 UG3 HL145269-01A1		(112)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL138357-03	YALE UNIVERSITY	5 R01 HL138357-03		12,386	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL137166-01				(28,262)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133860-04				(1,285)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-03				(416)	32,593,011	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 U01 HL152976-01	BOSTON UNIVERSITY	1 U01 HL152976-01		39,245	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL152976-02	BOSTON UNIVERSITY	5 U01 HL152976-02		98,899	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL116473-09	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 HL116473-09		17,608	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL125177-05	CLEVELAND CLINIC FOUNDATION	5 U01 HL125177-05		(286)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL125177-06	CLEVELAND CLINIC FOUNDATION	5 U01 HL125177-06		31,891	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL125177-06	CLEVELAND CLINIC FOUNDATION	5 U01 HL125177-06		30,179	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL161847-01	CORNELL UNIVERSITY	1 OT2 HL161847-01		7,204	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL161847-01	CORNELL UNIVERSITY	1 OT2 HL161847-01		65,396	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL145561-03	CORNELL UNIVERSITY	5 U01 HL145561-03		12,625	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL145561-04	CORNELL UNIVERSITY	5 U01 HL145561-04		8,188	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL157130-01A1	DARTMOUTH COLLEGE	1 R01 HL157130-01A1		131,974	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL156812-01	DUKE UNIVERSITY	1 OT2 HL156812-01		85,613	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R61 HL147833-02	DUKE UNIVERSITY	5 R61 HL147833-02		3,114	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 UG3 HL147011-01A1	FRED HUTCHINSON CANCER RESEARCH CENTER	1 UG3 HL147011-01A1		2,729	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 UG3 HL147011-01A1	FRED HUTCHINSON CANCER RESEARCH CENTER	1 UG3 HL147011-01A1		1,295	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	4 UH3 HL147011-02	FRED HUTCHINSON CANCER RESEARCH CENTER	4 UH3 HL147011-02		4,223	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL149422-03	HARVARD UNIVERSITY	5 R01 HL149422-03		3,193	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL150070-01A1	JOHNS HOPKINS UNIVERSITY	1 R01 HL150070-01A1		(2,676)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL150070-02	JOHNS HOPKINS UNIVERSITY	5 R01 HL150070-02		25,652	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 UG3 HL151458-01A1	JOHNS HOPKINS UNIVERSITY	1 UG3 HL151458-01A1		5,912	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	2 K24 HL103836-06				22,598	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K24 HL127301-06				8,093	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	2 K24 HL127301-07A1				53,810	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K08 HL133484-04				71,605	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K08 HL136888-05				96,520	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	3 K08 HL136888-05S1				21,905	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K23 HL141539-05				152,442	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K08 HL143051-03				154,728	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K23 HL143053-05				158,703	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K12 HL143956-03				1,296	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K12 HL143956-04				369,407	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 K23 HL148638-03				175,216	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
LUNG DISEASES RESEARCH	93.838	5 K01 HL149989-03				\$ 127,827	\$ 16,729,987	RESEARCH AND DEVELOPMENT	\$ 493,731,962
LUNG DISEASES RESEARCH	93.838	5 K24 HL150312-02				(264)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 K23 HL153584-01				187,856	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 K01 HL157755-01				136,850	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL156812-01	MASSACHUSETTS GENERAL HOSPITAL	1 OT2 HL156812-01		42,701	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL156812-01	MASSACHUSETTS GENERAL HOSPITAL	1 OT2 HL156812-01		135,948	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-06		43,892	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	3 U01 HL 123009-06S1	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL 123009-06S1		(1,721)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	3 U01 HL123009-06S2	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S2	\$ 26,175	33,766	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	3 U01 HL123009-06S2	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S2	24,326	34,117	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-07	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-07		80,406	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-07	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-07		19,874	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL156812-01	MEHARRY MEDICAL COLLEGE	1 OT2 HL156812-01		17,113	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	7 K24 HL150312-03	MOUNT SINAI SCHOOL OF MEDICINE	7 K24 HL150312-03		8,359	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL132338-05	MOUNT SINAI SCHOOL OF MEDICINE	5 R01 HL132338-05		53,835	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	7 R01 HL132338-06	MOUNT SINAI SCHOOL OF MEDICINE	7 R01 HL132338-06		18,921	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R41 HL158393-01	MTI BIOTECH	1 R41 HL158393-01		120,177	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 OT2 HL161847-01	NEW YORK UNIVERSITY	1 OT2 HL161847-01		15,626	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL159250-01	NORTHWESTERN UNIVERSITY	1 R01 HL159250-01		7,388	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL113326-08	OKLAHOMA MEDICAL RESEARCH FOUNDATION	5 R01 HL113326-08		33,339	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	2 P30 DK020593-45				418,398	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-10			27,975	720,489	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 P01 HL108800-10			54,193	63,368	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 P01 HL108800-11			66,091	1,440,254	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL095797-13				612,434	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL122554-08				687,717	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL126176-06			30,775	213,114	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL132338-05			49,446	49,446	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL134802-04				317,794	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL134802-05				270,548	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL135849-04			20,776	20,776	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL136664-04			7,550	7,550	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	2 R01 HL136664-05A1				716,969	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL136748-04				222,142	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL140231-03			33,596	41,553	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL140231-04			170,276	616,887	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R56 HL141567-01A1				12,120	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5R01 HL142720-03				661,792	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R38 HL143619-03				(2,426)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL146401-03				343,161	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL146588-04			209,245	601,587	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R56 HL149129-01A1			6,265	611,985	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R35 HL150783-01			1,933	1,933	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R35 HL150783-02			10,699	497,273	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R35 HL150783-03				65,922	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL151016-03				485,692	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R61 HL151951-01				48,493	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	4 R33 HL151951-02				792,878	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
LUNG DISEASES RESEARCH	93.838	5 R01 HL152210-02				\$ 4,365	\$ 16,729,987	RESEARCH AND DEVELOPMENT	\$ 493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL153246-03			\$ 114,101	744,839	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R03 HL154287-02				95,317	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL157373-02				465,323	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL158906-01				300,200	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL152083-02	STANFORD UNIVERSITY	5 R01 HL152083-02		98,468	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-13				4,925	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-14				548	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-15				(1,659)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-16			107,838	427,185	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	2 T32 HL087738-17				7,268	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 T32 HL094296-13				(18,988)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 T32 HL094296-14				406,441	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL145372-02	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	5 R01 HL145372-02		175,519	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL123033-07			11,907	165,465	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R35 HL140026-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R35 HL140026-04		51,437	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R35 HL140026-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R35 HL140026-05		53,847	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL157533-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 HL157533-01A1		16,926	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 UG1 HL139119-06	UNIVERSITY OF KANSAS MEDICAL CENTER	5 UG1 HL139119-06		39,141	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U24 HL145265-02	UNIVERSITY OF MICHIGAN	5 U24 HL145265-02		4,996	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U24 HL138998-05	UNIVERSITY OF NORTH CAROLINA	5 U24 HL138998-05		3,834	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL155159-01A1	UNIVERSITY OF PENNSYLVANIA	1 R01 HL155159-01A1		10,460	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R01 HL159886-01	UNIVERSITY OF PENNSYLVANIA	1 R01 HL159886-01		22,306	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL159886-02	UNIVERSITY OF PENNSYLVANIA	5 R01 HL159886-02		658	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL135144-05	UNIVERSITY OF PITTSBURGH	5 R01 HL135144-05		64,972	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	20FED20000031PSE	VETERANS AFFAIRS	20FED20000031PSE	28,000	45,512	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	2 R44 HL140709-02	VIRTUOSO SURGICAL	2 R44 HL140709-02		1,906	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL130876-05	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 HL130876-05		26,016	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 U01 HL130045-05	WASHINGTON UNIVERSITY IN ST. LOUIS	5 U01 HL130045-05		19,341	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL132338-05				(891)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL135849-04				(12,350)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	5 R01 HL136664-04				(4,364)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
LUNG DISEASES RESEARCH	93.838	1 R35 HL150783-01				(3,136)	16,729,987	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL143402-03	CASE WESTERN RESERVE UNIVERSITY	5 U01 HL143402-03		94,193	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		5,486	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL128566-05	EMORY UNIVERSITY	5 U01 HL128566-05		1,530	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K23 HL138291-05				193,439	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K24 HL147017-03				105,302	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K08 HL150282-04				179,465	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 UG1 HL138645-04	MOUNT SINAI SCHOOL OF MEDICINE	5 UG1 HL138645-04		3,039	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 UG1 HL138645-05	MOUNT SINAI SCHOOL OF MEDICINE	5 UG1 HL138645-05		21,000	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL131731-02	NATIONAL MARROW DONOR PROGRAM	5 R01 HL131731-02		856	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 U24 HL138660-01	NATIONAL MARROW DONOR PROGRAM	1 U24 HL138660-01		1,922	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 U24 HL138660-01	NATIONAL MARROW DONOR PROGRAM	1 U24 HL138660-01		5,175	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U24 HL138660-05	NATIONAL MARROW DONOR PROGRAM	5 U24 HL138660-05		\$ 2,358	\$ 3,992,926	RESEARCH AND DEVELOPMENT	\$ 493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	7 K23 HL141447-04	OHIO STATE UNIVERSITY	7 K23 HL141447-04		21,397	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 OT3 HL147810-01			\$ 105,713	446,086	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL101972-11	OREGON HEALTH & SCIENCE UNIVERSITY	2 R01 HL101972-11		64,790	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL144113-04	OREGON HEALTH & SCIENCE UNIVERSITY	5 R01 HL144113-04		81,972	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL124159-09				706,216	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL130018-04				122,977	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL133559-04				230,519	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R35 HL140025-04				237,016	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R35 HL140025-05				514,014	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL141943-05				389,819	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 R01 HL155207-01A1				85,133	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 R61 HL156508-01				44,784	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL133817-05	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	5 U01 HL133817-05		103,082	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 U01 HL156620-01			44,438	224,948	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL156620-02				104,073	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	7 R01 HL133896-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	7 R01 HL133896-04		(15,559)	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL118979-05	UNIVERSITY OF MINNESOTA	2 R01 HL118979-05		17,894	3,992,926	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 K12 HL137943-05			57,040	698,996	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 UG3 HL154297-01	NORTHWESTERN UNIVERSITY	1 UG3 HL154297-01		3,890	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 UG3 HL154297-02	NORTHWESTERN UNIVERSITY	5 UG3 HL154297-02		21,497	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 R01 HL146781-01	OHIO STATE UNIVERSITY	1 R01 HL146781-01		24,010	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 OT2 HL156812-01	RESEARCH TRIANGLE INSTITUTE	1 OT2 HL156812-01	12,880,228	23,288,278	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 OT2 HL156812-01	RESEARCH TRIANGLE INSTITUTE	1 OT2 HL156812-01	74,109	782,764	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 R01 HL157596-01			104,230	503,058	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 U01 HL142103-03	SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH	5 U01 HL142103-03		2,177	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 U01 HL142103-04	SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH	5 U01 HL142103-04		12,610	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 R01 HL154153-01	UNIVERSITY OF PITTSBURGH	1 R01 HL154153-01		4,871	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 R01 HL154153-05	UNIVERSITY OF PITTSBURGH	5 R01 HL154153-05		112,702	25,454,853	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR055557-12	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 AR055557-12		34,063	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR074131-02	CASE WESTERN RESERVE UNIVERSITY	5 R01 AR074131-02		5,631	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR074131-03	CASE WESTERN RESERVE UNIVERSITY	5 R01 AR074131-03		62,827	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR075422-03	CASE WESTERN RESERVE UNIVERSITY	5 R01 AR075422-03		\$ 302,160	\$ 3,032,739	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR053684-14	CLEVELAND CLINIC FOUNDATION	5 R01 AR053684-14		63,204	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073874-04	EMORY UNIVERSITY	5 R01 AR073874-04		48,205	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4 UH3 AR077360-02	JOHNS HOPKINS UNIVERSITY	4 UH3 AR077360-02		10,714	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 K01 AR072123-05				125,989	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 K08 AR072757-05				136,397	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR060846-08			\$ 221,254	429,929	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR063157-08				278,793	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073001-03				139,473	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R21 AR073133-02				2,158	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7 R01 AR073196-05				156,768	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073764-04				209,136	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073831-02			31,361	31,361	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R21 AR074261-02				1	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR076516-02				435,394	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R13 AR078623-01				22,776	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R21 AR080372-01				26,973	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R01 AR080629-01				43,618	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073773-03	STANFORD UNIVERSITY	5 R01 AR073773-03		23,955	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3 P50 AR060772-08S1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	3 P50 AR060772-08S1		31,962	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 P50 AR060772-10	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 P50 AR060772-10		41,403	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4 UH3 AR076387-02	UNIVERSITY OF IOWA	4 UH3 AR076387-02		7,335	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	4 UG3 AR076387-03	UNIVERSITY OF IOWA	4 UG3 AR076387-03		85,083	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR073486-03	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 AR073486-03		13,432	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 R01 AR074989-02	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	5 R01 AR074989-02		90,567	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-08	VANDERBILT UNIVERSITY	5 T32 AR059039-08		967	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-09	VANDERBILT UNIVERSITY	5 T32 AR059039-09		31,933	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-10	VANDERBILT UNIVERSITY	5 T32 AR059039-10		58,315	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5 T32 AR059039-11	VANDERBILT UNIVERSITY	5 T32 AR059039-11		11,805	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2 T32 AR059039-11	VANDERBILT UNIVERSITY	2 T32 AR059039-11		5,120	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	2 T32 AR059039-11	VANDERBILT UNIVERSITY	2 T32 AR059039-11		65,292	3,032,739	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK118471-04	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 R18 DK118471-04		119,808	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK076169-13	AUGUSTA UNIVERSITY	5 U24 DK076169-13		48,943	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK097771-08	AUGUSTA UNIVERSITY	5 U24 DK097771-08		1,042	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK115255-04	AUGUSTA UNIVERSITY	5 U24 DK115255-04		72,857	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK128187-01A1	BAYLOR COLLEGE	1 R01 DK128187-01A1		37,671	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115392-04	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK115392-04	\$	70,105	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115392-05	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK115392-05		20,729	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116898-03	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK116898-03		2,073	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116898-04	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 DK116898-04		30,228	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK116723-01A1	CASE WESTERN RESERVE UNIVERSITY	1 R01 DK116723-01A1		9,094	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK094157-10	CASE WESTERN RESERVE UNIVERSITY	5 U01 DK094157-10		30	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK094157-11	CASE WESTERN RESERVE UNIVERSITY	5 U01 DK094157-11		194,376	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U24 DK098085-03	CITY OF HOPE	2 U24 DK098085-03		23,092	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U24 DK098085-03	CITY OF HOPE	2 U24 DK098085-03		115,848	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 UC4 DK098085-04	CITY OF HOPE	2 UC4 DK098085-04		52,083	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113201-03	DARTMOUTH COLLEGE	5 R01 DK113201-03	\$	10,358	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113201-04	DARTMOUTH COLLEGE	5 R01 DK113201-04		91,610	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK056942-17				198,386	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-18				10	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093660-11				385,064	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U24 DK065176-19	DUKE UNIVERSITY	5 U24 DK065176-19		98,919	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK116520-04				140	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 F32 DK127679-01A1				54,970	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK127679-02				10,084	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 F32 DK128970-02				66,436	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK098246-09	GEORGE WASHINGTON UNIVERSITY	5 U01 DK098246-09		20,680	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK098246-10	GEORGE WASHINGTON UNIVERSITY	5 U01 DK098246-10		24,235	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK120598-01A1	HARVARD PILGRIM HEALTH CARE	1 R01 DK120598-01A1		56,340	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK110375-06	JOHNS HOPKINS UNIVERSITY	5 R01 DK110375-06		236,751	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK103910-06				(134)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK106511-05				1	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK114566-04				174,085	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK117969-03				76,850	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK118118-04				185,890	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK118192-04				168,053	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK120631-03				\$ 108,963	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 K23 DK123392-01A1				184,495	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK123495-03				153,270	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K08 DK124686-02				10,293	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 K23 DK131341-01				51,117	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK088327-08	MASSACHUSETTS GENERAL HOSPITAL	2 R01 DK088327-08		111,384	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK123019-01A1	MASSACHUSETTS GENERAL HOSPITAL	1 R01 DK123019-01A1		88,375	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 U01 DK104833-06S1	MEDICAL UNIVERSITY OF SOUTH CAROLINA	3 U01 DK104833-06S1		10,282	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100866-07	NATIONWIDE CHILDREN'S HOSPITAL	2 U01 DK100866-07		8,015	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-42S1			\$ 302,490	430,183	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-44			457,547	2,064,899	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 P30 DK020593-44S1			14,036	56,439	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-19			10,079	10,079	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-20			171,310	1,184,346	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 P30 DK058404-21				33,666	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK092986-11			25,402	261,970	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-04				49,882	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-05			117,774	1,031,355	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P20 DK123967-02			17,898	144,341	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK131104-01				269,949	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3T32DK007061-48S1				68,272	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113423-04				245,973	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK018381-49				664,273	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK048370-25				26,863	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK048370-26			100,599	492,591	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK051265-25A1				304,015	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 R01 DK051610-25				(3,392)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK051610-26			95,360	464,684	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK058587-22				550,925	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK062794- 18				598,371	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK065138-18				\$ 89,783	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK066358-13			\$ 8,270	133,614	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK069921-16A1				507,705	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK081134-11			48,013	461,663	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK081646-13				270,898	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093501-10			8,712	8,712	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093501-12			328,574	771,557	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK095785-10				473,748	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK099467-09				487,253	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK101332-08			9,982	370,733	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK101791-05				204	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK103067-06				(893)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK103935-06			18,234	70,000	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105550-10			11,596	101,341	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK106755-06			32,723	32,723	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108968-05				(24,877)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK109102-06				(5,321)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK109102-08			19,329	740,613	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK110166-05			163,044	581,162	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111554-05			17,700	255,118	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111671-05				259,254	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK112262-06				449,043	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK112688-04				2,794	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115545-04			72,345	608,285	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116625-04			54,000	505,445	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116957-04			540,595	637,970	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116964-05				377,084	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117144-05				649,684	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117875-04			26,513	206,921	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK118407-02				363,134	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK119212-04				\$ 294,414	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 R01 DK119282-03S1			\$ 6,779	185,397	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK119282-04			30,600	710,587	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	4 R00 DK119413-03				200,679	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R03 DK119735-02				7,573	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120025-04				323,616	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120626-03				519,711	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120814-02			15,688	188,800	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK120821-03			197,140	318,247	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK121101-03				404,227	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK121316-04				384,340	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK122075-03				482,276	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK122147-03			65,447	516,506	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK123373-03				626,976	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R03 DK123489-02				38,895	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK124845-02			185,113	819,360	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK125794-01A1				251,593	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK125895-03			20,081	517,673	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK126721-02			10,079	741,588	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R56 DK126890-01				63,881	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK126890-01A1				165,858	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R21 DK127075-01				239,151	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK127178-01A1				285,461	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK127912-02			42,579	155,480	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK128190-01A1				216,779	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK128200-02			3,213	690,577	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK128293-01A1			22,608	294,561	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R56 DK128337-01				113,521	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK129202-01A1				26,638	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R03 DK129559-01A1				38	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK129624-01			\$ 13,222	\$ 190,401	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK131070-01				232,984	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R56 DK131101-01				90,719	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK131129-01				285,297	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK131529-01				109,323	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK132669-01				55,470	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R25 DK096999-10				130,997	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123743-02	STANFORD UNIVERSITY	1 U01 DK123743-02		13,337	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123743-03	STANFORD UNIVERSITY	1 U01 DK123743-03		136,719	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK114485-01A1	STATE UNIVERSITY OF NEW YORK (SUNY)	1 R01 DK114485-01A1		7,095	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007061-47				(2,398)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 T32 DK007061-48				326,591	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-41				(512)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-42				91,701	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-43				65,501	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 T32 DK007569-32				2,294	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007569-33				294,586	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007673-28				318	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007673-29				350,908	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007673-30				69	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK124385-02	THE WISTAR INSTITUTE	5 R01 DK124385-02		18,025	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-06				47,610	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 UC4 DK112232-01			743,585	837,252	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-03				1,128	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-04			75,758	419,883	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-05				85,292	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-04			9,832	266,359	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-05			(605)	2,016	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123716-01				374,405	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK123716-02			476,252	679,573	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK123716-03			\$ 351,577	\$ 631,934	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK123821-01			213,469	523,784	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U34 DK123895-02				223,307	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 U01 DK129989-01				122,237	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK079337-13S1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 P30 DK079337-13S1		2,523	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113980-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 DK113980-04	15,004	55,656	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113980-05	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 DK113980-05		27,448	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 RC2 DK118640-01A1	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1 RC2 DK118640-01A1	19,250	536,793	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK122797-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 DK122797-01		97,970	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK129793-01	UNIVERSITY OF CALIFORNIA, DAVIS	1 R01 DK129793-01		163,587	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 R01 DL128803-02	UNIVERSITY OF CALIFORNIA, SAN DIEGO	7 R01 DL128803-02		1,317	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120429-02	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 U01 DK120429-02		6,060	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120429-04	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 U01 DK120429-04		10,850	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U54 DK118612-03	UNIVERSITY OF CHICAGO	5 U54 DK118612-03		(4,436)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U54 DK118612-04	UNIVERSITY OF CHICAGO	5 U54 DK118612-04		105,735	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U54 DK118612-05	UNIVERSITY OF CHICAGO	5 U54 DK118612-05		3,038	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK123330-01A1	UNIVERSITY OF CINCINNATI	1 R01 DK123330-01A1		13,039	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120456-03	UNIVERSITY OF MIAMI	5 U01 DK120456-03	13,150	21,655	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK120456-04	UNIVERSITY OF MIAMI	5 U01 DK120456-04	9,129	298,937	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK121709-01A1	UNIVERSITY OF MICHIGAN	1 R01 DK121709-01A1		24,071	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100867-08	UNIVERSITY OF NORTH CAROLINA	2 U01 DK100867-08		(11,540)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK100867-09	UNIVERSITY OF NORTH CAROLINA	2 U01 DK100867-09		29,240	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK090964-10	UNIVERSITY OF OKLAHOMA	5 R24 DK090964-10		52	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK087635-11A1	UNIVERSITY OF PENNSYLVANIA	2 R01 DK087635-11A1		(1,830)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK087635-12	UNIVERSITY OF PENNSYLVANIA	5 R01 DK087635-12		8,532	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK087635-12	UNIVERSITY OF PENNSYLVANIA	5 R01 DK087635-12		6,128	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK087635-13	UNIVERSITY OF PENNSYLVANIA	5 R01 DK087635-13		8,806	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK105821-06	UNIVERSITY OF PENNSYLVANIA	2 R01 DK105821-06		31,436	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 U01 DK112217-02A1	UNIVERSITY OF PENNSYLVANIA	2 U01 DK112217-02A1	4,980	576,224	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1U01 DK126654-01	UNIVERSITY OF PENNSYLVANIA	1U01 DK126654-01		85,796	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK126654-02	UNIVERSITY OF PENNSYLVANIA	5 U01 DK126654-02		\$ 39,719	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R18 DK118460-02	UNIVERSITY OF PITTSBURGH	5 R18 DK118460-02		9,118	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 U01 DK123812-01S1	UNIVERSITY OF PITTSBURGH	3 U01 DK123812-01S1		18,148	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 UC2 DK126122-02	UNIVERSITY OF PITTSBURGH	1 UC2 DK126122-02		189,820	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK132948-01	UNIVERSITY OF SOUTH CAROLINA	1 R01 DK132948-01		3,003	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK085465-07	UNIVERSITY OF SOUTH FLORIDA	5 U01 DK085465-07		67,208	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK106993-03	UNIVERSITY OF SOUTH FLORIDA	5 U01 DK106993-03		270,892	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK127084-01A1	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	1 R01 DK127084-01A1		33,168	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 R01 DK108159-06	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	7 R01 DK108159-06		5,250	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK127589-01	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS	1 R01 DK127589-01		14,591	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK124719-01A1	UNIVERSITY OF UTAH	1 R01 DK124719-01A1		12,776	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK124063-01	UNIVERSITY OF WASHINGTON	1 R01 DK124063-01		255,290	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK050277-24	VANDERBILT UNIVERSITY	2 R01 DK050277-24		96,775	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK059402-20	VANDERBILT UNIVERSITY	5 R01 DK059402-20		3,193	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK103831-07	VANDERBILT UNIVERSITY	5 R01 DK103831-07		83,756	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK117147-01A1	VANDERBILT UNIVERSITY	1 R01 DK117147-01A1		175,483	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117147-04	VANDERBILT UNIVERSITY	5 R01 DK117147-04		155,669	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK119508-02	VANDERBILT UNIVERSITY	1 R01 DK119508-02		15,387	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK128710-02	VANDERBILT UNIVERSITY	5 R01 DK128710-02		3,861	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007563-34	VANDERBILT UNIVERSITY	5 T32 DK007563-34		57,278	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007563-34	VANDERBILT UNIVERSITY	5 T32 DK007563-34		26,069	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK101003-08	VANDERBILT UNIVERSITY	5 T32 DK101003-08		40,157	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U2C DK059637-20	VANDERBILT UNIVERSITY	5 U2C DK059637-20		184	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 U2C DK059637-20S1	VANDERBILT UNIVERSITY	3 U2C DK059637-20S1		66,717	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK108968-06A1	WASHINGTON UNIVERSITY IN ST. LOUIS	2 R01 DK108968-06A1		9,811	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-19				(8,704)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093501-10				(3,174)	41,847,801	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK106755-06				\$ (10,185)	\$ 41,847,801	RESEARCH AND DEVELOPMENT	\$ 493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 K12 NS080223-09	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 K12 NS080223-09		(14)	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 K12 NS080223-10	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 K12 NS080223-10		139,050	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS116148-01A1	CHILDREN'S NATIONAL MEDICAL CENTER	1 R01 NS116148-01A1		15,361	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS116148-02	CHILDREN'S NATIONAL MEDICAL CENTER	5 R01 NS116148-02		22,058	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R44 NS117214-01A1	CND LIFE SCIENCES	1 R44 NS117214-01A1		35,428	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R21 NS116434-01A1	DARTMOUTH-HITCHOCK CLINIC	1 R21 NS116434-01A1		61,555	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U24 NS114416-01	DUKE UNIVERSITY	1 U24 NS114416-01		15,334	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 K23 NS113858-03				(3,481)	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS105746-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS105746-02		885	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS102371-04	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS102371-04		18,667	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS105746-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS105746-03		32,199	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS105746-04	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS105746-04		11,447	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS088312-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS088312-01		6,830	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS088312-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS088312-01		17,633	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS080168-05	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH	5 U01 NS080168-05		31,692	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS094041-05			\$ 33,517	43,088	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS078680-11			6,430	573,615	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2 R01 NS092961-08			10,549	629,364	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS093669-06			83,938	146,500	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS096127-06				141,107	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097763-05				268,654	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097783-05				(43,123)	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	3 R01 NS100980-01				626,480	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104149-04				229,595	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS107424-04				432,681	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R21 NS107877-02				64,177	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS108445-03			30,000	326,992	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS109114-05			\$ 14,425	\$ 339,455	\$ 10,342,028	RESEARCH AND DEVELOPMENT	\$ 493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS110130-04			11,762	357,333	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS110661-03			137,245	606,321	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R03 NS111486-01				18,426	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS112252-04			268,138	748,965	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113171-02				(26,364)	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113171-03			585,346	1,114,574	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113171-04				20,797	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS113832-03			185,465	405,118	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS117816-02			2,900	308,043	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS118483-03				32,356	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS118483-03			244,314	613,681	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS121718-01A1				50,131	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R41 NS122656-01A1				57,036	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS123281-01A1				28,296	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-20			141,216	145,873	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104339-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 NS104339-04		9,549	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104339-05	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 NS104339-05		16,570	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS112171-02	UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCE	1 R01 NS112171-02		7,572	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS104094-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NS104094-01		7,634	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS096173-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NS096173-01A1		64,185	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104094-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 NS104094-05		1,790	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS092764-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 U01 NS092764-05		18,505	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7 K23 NS113858-04	UNIVERSITY OF CINCINNATI	7 K23 NS113858-04		9,981	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS095869-02	UNIVERSITY OF CINCINNATI	5 U01 NS095869-02		19,689	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS100699-01A1	UNIVERSITY OF CINCINNATI	1 U01 NS100699-01A1		11,734	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS106513-02	UNIVERSITY OF CINCINNATI	5 U01 NS106513-02		2,556	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS110728-01	UNIVERSITY OF CINCINNATI	1 U01 NS110728-01		16,118	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS100996-02	UNIVERSITY OF LOUISVILLE	1 R01 NS100996-02		27,395	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 RF1 NS113285-01	UNIVERSITY OF NORTH CAROLINA	1 RF1 NS113285-01	\$ 24,462	\$ 180,785	\$ 10,342,028	RESEARCH AND DEVELOPMENT	\$ 493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS107486-02	UNIVERSITY OF UTAH	1 U01 NS107486-02		3,168	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS107486-03	UNIVERSITY OF UTAH	1 U01 NS107486-03		16,212	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U24 NS107128-03				16,645	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U24 NS107128-04				343,780	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 UF1 NS107666-01			208,152	369,493	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS104497-01	VANDERBILT UNIVERSITY	1 R01 NS104497-01		2,337	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4 R33 NS109521-02	VANDERBILT UNIVERSITY	4 R33 NS109521-02		15,729	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS110665-02	VANDERBILT UNIVERSITY	5 R01 NS110665-02		9,603	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R61 NS112445-01A1	VANDERBILT UNIVERSITY	1 R61 NS112445-01A1		164,688	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS118580-01	VANDERBILT UNIVERSITY	1 R01 NS118580-01		157,815	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS120518-01	VANDERBILT UNIVERSITY	1 R01 NS120518-01		32,634	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS107281-03	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 NS107281-03		152,046	10,342,028	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI007474-26				188	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R56 AI076121-10A1			6,707	6,707	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI095227-10				35	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI147765-04			736,113	1,217,597	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 U01 AI096299-13	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	2 U01 AI096299-13		26,506	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI096299-14	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	5 U01 AI096299-14		5,395	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 G11 AI169624-01	AURUM INSTITUTE NPC	1 G11 AI169624-01		974	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-07S1	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-07S1		16	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UM1 AI109565-08	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	2 UM1 AI109565-08		475,543	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-08	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-08		156,825	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-08	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-08		(10,673)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-08S1	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-08S1		250,837	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI109565-08S1	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	3 UM1 AI109565-08S1		109,552	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI109565-08S3	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	3 UM1 AI109565-08S3		112,050	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134430-05	BOSTON UNIVERSITY	5 R01 AI134430-05		67,161	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI150295-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 AI150295-02		7,232	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI150295-03	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 AI150295-03		36,683	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI126612-01A1	CHILDREN'S HOSPITAL LOS ANGELES	1 U01 AI126612-01A1		\$ 824	\$ 65,280,286	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U54 AI117804-08	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	5 U54 AI117804-08		12,967	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U54 AI117804-07	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	5 U54 AI117804-07		2,549	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI143370-03	DUKE UNIVERSITY	5 R01 AI143370-03		18,227	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI104681-09	DUKE UNIVERSITY	5 UM1 AI104681-09		15,247	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI104815-09	DUKE UNIVERSITY	5 UM1 AI104815-09		15,247	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI104681-10	DUKE UNIVERSITY	5 UM1 AI104681-10		23,206	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI104681-10	DUKE UNIVERSITY	5 UM1 AI104681-10		23,206	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139406-04	EMORY UNIVERSITY	5 R01 AI139406-04		12,260	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 UM1 AI148684-02	EMORY UNIVERSITY	1 UM1 AI148684-02		15,716	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AL148684-03	EMORY UNIVERSITY	5 UM1 AL148684-03		23,272	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI148684-03	EMORY UNIVERSITY	5 UM1 AI148684-03		21,979	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 F32 AI157215-01				20,824	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 F32 AI157215-02				53,306	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 F32 AI161860-01				67,753	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068619-12	FAMILY HEALTH INTERNATIONAL	5 UM1 AI068619-12	\$ 167,973	167,973	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		58,623	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		76,629	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI068614-14S1	FRED HUTCHINSON CANCER RESEARCH CENTER	3 UM1 AI068614-14S1		18,859	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI068614-14S1	FRED HUTCHINSON CANCER RESEARCH CENTER	3 UM1 AI068614-14S1		696,486	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-16	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-16		51,683	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI068614-15S1	FRED HUTCHINSON CANCER RESEARCH CENTER	3 UM1 AI068614-15S1		22,029	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-16	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-16		21,463	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P30 AI117970-07	GEORGE WASHINGTON UNIVERSITY	5 P30 AI117970-07		11,609	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142764-03	HENRY M. JACKSON FOUNDATION	5 U19 AI142764-03	50,842	525,574	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142764-04	HENRY M. JACKSON FOUNDATION	5 U19 AI142764-04		105,351	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R41 AI148019-01	IDBIOLOGICS, LLC	1 R41 AI148019-01		7,661	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 R01 AI134036-06	INDIANA UNIVERSITY	7 R01 AI134036-06		2,291	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI077653-11	INDOOR BIOTECHNOLOGIES, INC.	5 R01 AI077653-11		69,548	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI127469-05	JOHNS HOPKINS UNIVERSITY	5 R01 AI127469-05		43,354	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UMI AI068632-15	JOHNS HOPKINS UNIVERSITY	2 UMI AI068632-15		4,050	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069918-15	JOHNS HOPKINS UNIVERSITY	5 U01 AI069918-15		\$ 40	\$ 65,280,286	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069918-17	JOHNS HOPKINS UNIVERSITY	5 U01 AI069918-17		23,537	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM2 AI130836-06	JOHNS HOPKINS UNIVERSITY	5 UM2 AI130836-06		6,586	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 U01 AI69918-16	JOHNS HOPKINS UNIVERSITY	2 U01 AI69918-16		122,167	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K08 AI106420-06			\$ 2,152	2,152	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI120875-06				84,909	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K01 AI131895-05				119,046	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI141621-03				176,131	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K24 AI148459-02				139,699	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K08 AI150352-04				57,537	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K08 AI151100-03				170,162	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K99 AI154672-01				11,723	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K23 AI156132-02				183,127	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K23 AI168496-01				59,455	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-02	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-02		229	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U19 AI142790-03	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	1 U19 AI142790-03		697,770	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142790-04	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	5 U19 AI142790-04		84,438	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI136816-04	MASSACHUSETTS GENERAL HOSPITAL	5 U01 AI136816-04		10,153	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AL136740-01A1	MEHARRY MEDICAL COLLEGE	1 R01 AL136740-01A1		67,468	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI128418-01A1	OHIO STATE UNIVERSITY	1 R21 AI128418-01A1		1	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI157037-01	OREGON HEALTH & SCIENCE UNIVERSITY	1 R01 AI157037-01		9,706	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI157037-02	OREGON HEALTH & SCIENCE UNIVERSITY	5 R01 AI157037-02		40,041	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 P30 AI110527-06				(2,160)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P30 AI110527-07			903,099	2,361,868	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P30 AI110527-08				288,028	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI127828-05			306,385	468,708	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI131722-05			61,517	442,490	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI039657-25			76,319	386,984	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI051448-20				380,694	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	6 R01 AI069233-12				(313)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI073843-13				449,648	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI077505-11				(126)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI077505-12			364,834	906,437	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI093234-10			207,888	439,418	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI095755-11			3,071	20,147	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R01 AI095755-13				433,022	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI101171-11			350,248	595,839	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI101171-11S1				3,867	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI108197-10				278,754	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI108197-10S1			520,647	642,754	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI113292-06				336	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI114816-06			477	477	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI118932-06			(12,166)	4,767	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI118932-08			101,216	425,889	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI120790-04			29,616	272,166	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI124456-05				185,283	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R24 AI124872-06			45,461	45,461	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R24 AI124872-08			148,620	981,324	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI125642-05			\$ 174,263	\$ 481,136	\$ 65,280,286	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI130459-05				152,574	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI131722-04S1			1,798	1,798	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI131722-05S1			152,408	616,790	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI131771-05			364,122	626,706	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI132560-05				221,343	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134036-05			59,087	236,271	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI136526-03			342,109	401,408	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI137082-03			96,294	359,774	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI138581-04			380,624	696,327	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI139012-01:02			13,950	13,950	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI139021-02				(296)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139046-03				314,351	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139172-04			(7,175)	1,139,215	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI141448-03				478,213	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI142042-02			785	1,353	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI142095-04				506,513	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI142321-02				96,405	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R21 AI142321-02S1				117,631	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI143710-04			20,045	325,940	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI144193-01:02				2,812	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI145265-04				744,797	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI145397-02				35,728	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI145686-02			38,880	120,304	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI145992-03			539,797	1,021,961	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI146698-02				35,506	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI147768-02				299	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI149207-02				169,329	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI149262-02				131,102	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI149303-02				153,533	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI149722-03			119,786	525,645	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI150302-02			58,305	152,384	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI150384-02				93,480	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R34 AI150532-01			806	53,143	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI150701-03				512,382	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI151210-03			67,264	257,080	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI152693-02			34,929	680,284	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI153167-03				663,003	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI153769-02				188,476	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI154016-02				170,708	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI154064-02			22,947	92,870	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI155646-02			62,086	421,433	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI155668-02			358,295	700,680	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI156292-01			11,363	180,926	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI158605-02			122,928	264,024	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI163586-01A1				46,502	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R03 AI163835-01				82,216	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI164107-01A1				880	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI164147-01				2,760	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI164587-01A1				21,440	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1R21AI164760-01				137,471	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R13 AI164791-01				11,000	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI166584-01A1				35,527	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI166870-01				4,312	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI168468-01				5,385	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI168832-01				17,808	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R44 AI152670-02				1,038	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI157843-01A1			33,950	314,371	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R03 DK129626-01				23,133	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI137523-04	STANFORD UNIVERSITY	5 R01 AI137523-04		307,004	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 U01 AI135950-03S1	STANFORD UNIVERSITY	3 U01 AI135950-03S1		\$ 72,084	\$ 65,280,286	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 U01 AI135950-03S2	STANFORD UNIVERSITY	3 U01 AI135950-03S2		216,348	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 T32 AI007474-27A1				112,455	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI095202-11				10,937	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 T32 AI095202-12				287,119	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI069439-15				71	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 UM1 AI069439-16			\$ 410,090	1,259,786	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI069439-17			160,277	1,337,544	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069923-16			158,400	159,140	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 U01 AI069923-17			982,135	2,059,182	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069923-18			6,507	218,518	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI095227-11			54,549	82,312	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 U19 AI095227-11S2			18,998	1,025,362	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 U19 AI095227-12			130,965	1,104,962	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI095227-13				49,002	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI117905-05			14,310	14,310	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI125135-03			(14,835)	(14,835)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI132004-02				(16,560)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI132004-03			29,599	83,358	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI148452-01S2				2,969,090	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI148452-02			123,554	313,948	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI148452-02S1				5,872	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI148452-02S2			1,802,360	2,881,360	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 UM1 AI148452-02S3			3,976,343	5,735,113	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI148452-03			1,851,043	2,281,585	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI150739-02			537,608	1,039,925	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI150739-03			12,740	168,837	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI152967-01			(10,152)	(10,152)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI152967-02			87,206	1,015,765	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI154659-01			8,908	13,056	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI154659-02			189,288	2,039,323	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI154659-03				165,747	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI155299-01				640,778	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI155299-02				192,290	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI167789-01				183,112	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI68614-14				217,273	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R24 AI067039-16	UNIVERSITY OF ALABAMA AT BIRMINGHAM	2 R24 AI067039-16		241,755	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134648-05	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 AI134648-05		38,923	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142759-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U19 AI142759-02		(17)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142759-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U19 AI142759-03		313,057	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142759-04	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U19 AI142759-04		202,476	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U54 AI150225-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 AI150225-02		1,079	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI106701-09	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI106701-09		54,494	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI153827-01A1	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	1 R01 AI153827-01A1		17,720	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI153827-02	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 R01 AI153827-02		7,454	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-15		5,274	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-15		4,771	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-15		\$ 5,740	\$ 65,280,286	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-15	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-15		156,523	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-16	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-16		5,467	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-16	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-16		5,992	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-16	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-16		8,470	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI106701-08	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI106701-08		266,727	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UMI AI068636-16	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UMI AI068636-16		154,251	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 P01 AI106695-06	UNIVERSITY OF CALIFORNIA, BERKELEY	2 P01 AI106695-06		35,760	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 P01 AI106695-07	UNIVERSITY OF CALIFORNIA, BERKELEY	2 P01 AI106695-07		433,455	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI149255-01	UNIVERSITY OF CALIFORNIA, IRVINE	1 R21 AI149255-01		33,676	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI070535-15	UNIVERSITY OF CALIFORNIA, SAN DIEGO	5 U19 AI070535-15		11,904	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 U19 AI070535-16	UNIVERSITY OF CALIFORNIA, SAN DIEGO	2 U19 AI070535-16		67,293	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI152183-02	UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	5 R01 AI152183-02		165,465	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI152869-01A1	UNIVERSITY OF MICHIGAN	1 R21 AI152869-01A1		18,967	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI132178-03S1	UNIVERSITY OF NORTH CAROLINA	3 R01 AI132178-03S1		16,313	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI132178-04S1	UNIVERSITY OF NORTH CAROLINA	3 R01 AI132178-04S1		115,708	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI132178-05	UNIVERSITY OF NORTH CAROLINA	5 R01 AI132178-05		282,061	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI108884-08	UNIVERSITY OF NOTRE DAME	5 R01 AI108884-08		18,943	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI169767-01	UNIVERSITY OF PENNSYLVANIA	1 U01 AI169767-01		7,077	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 P01 AI139449-02	UNIVERSITY OF TEXAS	5 P01 AI139449-02		140,119	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI141661-04	UNIVERSITY OF TEXAS	5 R01 AI141661-04		106,394	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142785-03	UNIVERSITY OF TEXAS	5 U19 AI142785-03		833,373	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142785-04	UNIVERSITY OF TEXAS	5 U19 AI142785-04		151,975	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI148707-03	UNIVERSITY OF WISCONSIN	5 R01 AI148707-03		429,461	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI114271-07	UNIVERSITY OF WISCONSIN	5 UM1 AI114271-07		3,238	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 UM1 AI160040-01	UNIVERSITY OF WISCONSIN	1 UM1 AI160040-01		25,975	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI160040-02	UNIVERSITY OF WISCONSIN	5 UM1 AI160040-02		9,928	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R56 AI46096-01A1	VANDERBILT UNIVERSITY	1 R56 AI46096-01A1		3,940	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI157827-01	VANDERBILT UNIVERSITY	1 R01 AI157827-01		371,629	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI112541-07	VANDERBILT UNIVERSITY	5 T32 AI112541-07		5,734	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI138932-02	VANDERBILT UNIVERSITY	5 T32 AI138932-02		\$ 25,847	\$ 65,280,286	RESEARCH AND DEVELOPMENT	\$ 493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI138932-03	VANDERBILT UNIVERSITY	5 T32 AI138932-03		54,392	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R43 AI149906-02	VIRTICI,LLC.	5 R43 AI149906-02		23,613	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI073755-15	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 AI073755-15		122,050	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI157155-02	WASHINGTON UNIVERSITY IN ST. LOUIS	5 R01 AI157155-02		510,028	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI161022-01A1	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 AI161022-01A1		55,678	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI114816-06			\$ (477)	–	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2 R56 AI076121-10A1				(6,012)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 K08 AI106420-06				(2,019)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R24 AI124872-06				(39,300)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3 R01 AI131722-04S1				(38,532)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI117905-05				(27,314)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI152967-01				(11,077)	65,280,286	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM129783-03	CHILDREN'S MERCY HOSPITAL CINCINNATI	5 R01 GM129783-03		18,667	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM126943-03	MEDICAL CENTER	5 R35 GM126943-03		7,785	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM117473-04	DUKE UNIVERSITY	5 R01 GM117473-04		3,702	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	2 R01 GM119197-05A1	EAST TENNESSEE STATE UNIVERSITY	2 R01 GM119197-05A1		209,988	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM119197-01	EAST TENNESSEE STATE UNIVERSITY	1 R01 GM119197-01		19,774	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 F32 GM139303-01				(122)	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 F32 GM139303-02				68,770	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 F32 GM142246-01				45,450	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K23 GM117395-05			(11,689)	55,644	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K08 GM123445-04				37,739	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K23 GM129662-04				170,727	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 K23 GM134482-02				178,981	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM130715-01A1	MARSHFIELD CLINIC RESEARCH FOUNDATION	1 R01 GM130715-01A1		14,628	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R41 GM139497-01A1	MERU BIOTECHNOLOGIES	1 R41 GM139497-01A1		10,258	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 P50 GM115305-06				1,807	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM112871-06				138,133	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM115353-04				(9,158)	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM120484-05			16,409	217,533	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM120523-05				206,963	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM121711-05				272,293	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM124109-05				167,371	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM124685-05			19,345	531,239	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	3 R35 GM124685-05S1			90,700	90,700	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM126062-04			48,069	463,754	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM126535-04				435,889	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM130791-03			15,645	460,667	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM131770-03				297,820	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM132204-03				335,441	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM132592-03				281,727	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM133169-03			104,308	569,065	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM137083-02				16,026	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM138191-02				367,138	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM138873-02				165,950	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM139891-02				391,762	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R35 GM141927-02				204,182	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R21 GM144915-01				93,478	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R35 GM145375-01				\$ 19,007	\$ 7,971,882	RESEARCH AND DEVELOPMENT	\$ 493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM140287-01	SCRIPPS RESEARCH INSTITUTE	1 R01 GM140287-01		37,334	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM140287-02	SCRIPPS RESEARCH INSTITUTE	5 R01 GM140287-02		50,895	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM007569-45			\$ (22,650)	(22,650)	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM007569-46			22,650	603,606	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM108554-08				(674)	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM108554-09				203,112	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 T32 GM135094-01A1				68,460	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 P50 AI150481-14	UNIVERSITY OF PITTSBURGH	5 P50 AI150481-14		75,795	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 P50 AI150481-15	UNIVERSITY OF PITTSBURGH	5 P50 AI150481-15		336,833	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R01 GM140464-01	UNIVERSITY OF WISCONSIN	1 R01 GM140464-01		5,653	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM140464-02	UNIVERSITY OF WISCONSIN	5 R01 GM140464-02		25,929	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R25 GM134979-01A1	VANDERBILT UNIVERSITY	1 R25 GM134979-01A1		1,277	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R25 GM134979-02	VANDERBILT UNIVERSITY	5 R25 GM134979-02		5,753	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM076592-11	VANDERBILT UNIVERSITY	5 R01 GM076592-11		1,988	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 R01 GM076592-13	VANDERBILT UNIVERSITY	5 R01 GM076592-13		12,234	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 R35 GM125028-01	VANDERBILT UNIVERSITY	1 R35 GM125028-01		2,445	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 T32 GM139800-01	VANDERBILT UNIVERSITY	1 T32 GM139800-01		1,090	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 T32 GM139800-01	VANDERBILT UNIVERSITY	1 T32 GM139800-01		701	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1 T32 GM139800-01	VANDERBILT UNIVERSITY	1 T32 GM139800-01		3,987	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM139800-02	VANDERBILT UNIVERSITY	5 T32 GM139800-02		7,655	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5 T32 GM007569-45				(10,319)	7,971,882	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD083181-02	BAYLOR COLLEGE	5 R01 HD083181-02		13,616	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7 K12 HD000850-37	CORNELL UNIVERSITY	7 K12 HD000850-37		1,173	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HHSN275201000003I	DUKE UNIVERSITY	HHSN275201000003I		1,032	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD107103-01	DUKE UNIVERSITY	1 R01 HD107103-01		846	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 F32 HD100087-01A1				22,560	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD092505-01A1	GEORGIA REGENTS UNIVERSITY/MEDICAL COLLEGE OF GA	1 R01 HD092505-01A1		18,195	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD097992-02			166,433	323,257	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD100685-01	IOWA STATE UNIVERSITY	1 R21 HD100685-01		4,201	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD096147-04	JOHNS HOPKINS UNIVERSITY	5 R01 HD096147-04		185,417	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD043483-20				33,376	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 K12 HD087023-07				375,826	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD087023-08				117,083	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 K23 HD104183-01A1				122,493	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD043483-21				190,409	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R44 HD084151-05	MIYAZAKI ENTERPRISES,LLC	5 R44 HD084151-05		26,469	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4 UH3 HD096920-03	NORTHWESTERN UNIVERSITY	4 UH3 HD096920-03		4,924	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4 UH3 HD096920-04	NORTHWESTERN UNIVERSITY	4 UH3 HD096920-04		10,069	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 P50 HD103537-01			\$ 237,347	\$ 253,422	\$ 10,660,000	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 P50 HD103537-02			316,154	1,559,156	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 P50 HD103537-03				74,973	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 P50 HD106446-01			16,912	655,637	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3 P50 HD106446-01S1:2				6,381	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD071089-09			338,177	466,765	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081121-06			(4,371)	11,652	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084461-06				313,555	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084500-06				67,939	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD086792-05				3,293	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD088662-05			2,571	264,758	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD090061-05			92,537	444,687	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD093671-05			60,314	380,266	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD094946-04				425,518	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD097344-04				380,724	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD098213-03				506,939	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD098719-02				662,923	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD099777-02			85,540	512,944	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD100458-03			84,424	937,232	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD103348-02			69,731	208,164	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD104983-02				155,633	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD105304-01				48,192	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD106578-02				30,786	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U01 HD076733-06			46,508	207,495	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD083211-06			(5,487)	–	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-13	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-13		100,202	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-15	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-15		21,665	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD024356-26	UNIVERSITY OF CALIFORNIA, DAVIS	2 R01 HD024356-26		(578)	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD024356-26	UNIVERSITY OF CALIFORNIA, DAVIS	5 R01 HD024356-26		96,757	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD093933-03	UNIVERSITY OF KANSAS	5 R01 HD093933-03		1,992	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD098867-01A1	UNIVERSITY OF PENNSYLVANIA	1 R01 HD098867-01A1		\$ 11,455	\$ 10,660,000	RESEARCH AND DEVELOPMENT	\$ 493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD102318-01	UNIVERSITY OF PENNSYLVANIA	1 R01 HD102318-01		11,455	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 K12 HD047349-18	UNIVERSITY OF UTAH	2 K12 HD047349-18		12,123	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD097757-01A1	VANDERBILT UNIVERSITY	1 R21 HD097757-01A1		6,959	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD098454-01A1	VANDERBILT UNIVERSITY	1 R21 HD098454-01A1		1,902	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD102752-01	VANDERBILT UNIVERSITY	1 R01 HD102752-01		156,260	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R61 HD099742-01	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R61 HD099742-01		43,718	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4 R33 HD099742-03	WASHINGTON UNIVERSITY IN ST. LOUIS	4 R33 HD099742-03		166,110	10,660,000	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 K76 AG060001-03				319,703	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG061518-04			\$ 279,044	794,709	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG056368-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 AG056368-02		287	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	2 P01 AG027296-12	BROWN UNIVERSITY	2 P01 AG027296-12		42,719	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG059417-02	CALIFORNIA PACIFIC MEDICAL CENTER	5 R01 AG059417-02		34,196	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R56 AG061522-01A1	DARTMOUTH COLLEGE	1 R56 AG061522-01A1		151,998	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 U19 AG065188-01	DUKE UNIVERSITY	1 U19 AG065188-01		112,478	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 U19 AG065188-02	DUKE UNIVERSITY	5 U19 AG065188-02		10,878	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 U19 AG065188-02	DUKE UNIVERSITY	5 U19 AG065188-02		58,314	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 F32 AG062045-02				8,586	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 RF1 AG059869-01	JOHNS HOPKINS UNIVERSITY	1 RF1 AG059869-01		69,025	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 K23 AG045966-06				21,382	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	2 K24 AG046373-09				166,038	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 K01 AG058700-05				105,205	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 K24 AG064114-2				181,379	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 K01 AG066971-02				119,952	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 K76 AG068436-03				262,077	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 K23 AG070320-01A1				167,012	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 K23 AG072030-02				207,081	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 K01 AG073584-01				97,872	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 K01 AG077038-01				972	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	3 R01 AG053582-05S1	MASSACHUSETTS GENERAL HOSPITAL	3 R01 AG053582-05S1		214,369	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 U19 AG063911-02	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH	1 U19 AG063911-02		47,172	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R44 AG055184-01	METABOLIC TECHNOLOGIES, INC.	1 R44 AG055184-01		6,872	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R24 AG064025-02	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	1 R24 AG064025-02		5,334	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R24 AG064025-03	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	1 R24 AG064025-03		50,062	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG059861-04	OHIO STATE UNIVERSITY	5 R01 AG059861-04		36,361	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 P20 AG068082-01			38,952	122,909	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 P20 AG068082-02			29,597	637,560	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	3 P20 AG068082-02S1				25,860	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	6 R01 AG034962-07				42,951	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG034962-08				(3,412)	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG034962-09			22,151	2,306,685	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG047992-06			1,195,687	1,195,687	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	2 R56 AG047992-07A1				\$ 48,857	\$ 23,642,735	RESEARCH AND DEVELOPMENT	\$ 493,731,962
AGING RESEARCH	93.866	5 R01 AG048915-04				209,059	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG053264-06			\$ 2,387	151,439	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG056534-05			49,238	562,894	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG058639-01A1			592	592	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG058639-02				(4,787)	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG058639-03			830,368	3,201,715	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG058856-04				376,699	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG059716-05			420,596	973,652	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R21 AG059941-02				24,599	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG061138-04			78,462	696,428	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG061161-03			16,254	841,010	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG061351-01			173,537	385,838	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG062499-04			57,468	986,069	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG062574-03				27,523	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG062826-03			12,254	678,720	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R21 AG063126-02				164,575	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG065249-02				541,093	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG065550-02				554,885	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R03 AG065643-02				70,941	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R21 AG065859-01				216,836	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R56 AG068026-01A1				412,323	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG068606-02			21,797	465,261	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG069795-02			111,194	450,314	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R21 AG070859-01				228,545	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG071439-02				139,666	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG073439-01			140,253	368,652	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG073633-01A1				4,423	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R21 AG075643-01				1,644	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG076785-01				66,550	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 RF1 AG063755-01	THE JACKSON LABORATORY	1 RF1 AG063755-01		107,687	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG074012-01	THE JACKSON LABORATORY	1 R01 AG074012-01		175,387	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG076129-01	THE JACKSON LABORATORY	1 R01 AG076129-01		12,106	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 U24 AG074855-01			660,087	1,375,757	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG054366-03	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 R01 AG054366-03		510	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 P30 AG024968-19	UNIVERSITY OF SOUTHERN CALIFORNIA	5 P30 AG024968-19		9,267	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	6 R01 AG047992-02	UNIVERSITY OF SOUTHERN CALIFORNIA	6 R01 AG047992-02		(3,325)	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG054029-02	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R01 AG054029-02		5,366	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG061848-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 R01 AG061848-01		26,420	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R61 AG066543-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 R61 AG066543-01		85,287	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R61 AG066543-02	UNIVERSITY OF SOUTHERN CALIFORNIA	5 R61 AG066543-02		50,951	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	2 U19 AG024904-11	UNIVERSITY OF SOUTHERN CALIFORNIA	2 U19 AG024904-11		31,965	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 U01 AG068057-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 U01 AG068057-01		27,309	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 U01 AG068057-02	UNIVERSITY OF SOUTHERN CALIFORNIA	5 U01 AG068057-02		49,645	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG061325-02	UNIVERSITY OF TENNESSEE	5 R01 AG061325-02		170,054	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG006159-01	UNIVERSITY OF VERMONT	1 R01 AG006159-01		631,609	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R21 AG072101-01	UNIVERSITY OF VERMONT	1 R21 AG072101-01		3,054	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG064800-03	UNIVERSITY OF WASHINGTON	5 R01 AG064800-03		33,770	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG060754-01	VANDERBILT UNIVERSITY	5 R01 AG060754-01		36,959	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG062685-01A1	VANDERBILT UNIVERSITY	1 R01 AG062685-01A1		19,265	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	1 R01 AG064950-01	VANDERBILT UNIVERSITY	1 R01 AG064950-01		\$ 84,751	\$ 23,642,735	RESEARCH AND DEVELOPMENT	\$ 493,731,962
AGING RESEARCH	93.866	1 R01 AG064950-01	VANDERBILT UNIVERSITY	1 R01 AG064950-01		6,716	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG064950-02	VANDERBILT UNIVERSITY	5 R01 AG064950-02		9,546	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG069900-01	VANDERBILT UNIVERSITY	1 R01 AG069900-01		231,724	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R21 AG071975-01A1	VANDERBILT UNIVERSITY	1 R21 AG071975-01A1		8,774	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R21 AG072188-01A1	VANDERBILT UNIVERSITY	1 R21 AG072188-01A1		8,817	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 T32 AG058024-03	VANDERBILT UNIVERSITY	5 T32 AG058024-03		25,449	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 T32 AG058524-03	VANDERBILT UNIVERSITY	5 T32 AG058524-03		5,246	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 T32 AG058524-03	VANDERBILT UNIVERSITY	5 T32 AG058524-03		50,878	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 T32 AG058524-03	VANDERBILT UNIVERSITY	5 T32 AG058524-03		(1,305)	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 T32 AG058524-04	VANDERBILT UNIVERSITY	5 T32 AG058524-04		23,941	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 T32 AG058524-04	VANDERBILT UNIVERSITY	5 T32 AG058524-04		13,729	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R44 AG058268-03	XYKEN	5 R44 AG058268-03		32,239	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	5 R01 AG047992-06				(173,090)	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
AGING RESEARCH	93.866	1 R01 AG058639-01A1				(11)	23,642,735	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U10 EY011751-22	JAEB CENTER FOR HEALTH RESEARCH	5 U10 EY011751-22		99,877	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		2,774	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		12,064	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 UG1 EY028091-04	JOHNS HOPKINS UNIVERSITY	5 UG1 EY028091-04		4,191	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U10 EY024527-04	JOHNS HOPKINS UNIVERSITY	5 U10 EY024527-04		3,390	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 UG1 EY028091-03	JOHNS HOPKINS UNIVERSITY	5 UG1 EY028091-03		(2,464)	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 K08 EY027464-05				140,859	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 K08 EY029006-05				184,948	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 K08 EY032620-02				208,304	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	1 U10 EY026869-01	NEW YORK UNIVERSITY	1 U10 EY026869-01		38	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	2 P30 EY008126-32			\$ 2,194	2,270	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 P30 EY008126-33			135,788	195,633	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 P30 EY008126-34			238,090	541,145	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY013760-15				342,209	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY017427-12				119,744	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	2 R01 EY020894-10			3,809	197,238	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY022349-11			128,625	476,272	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY023240-05				(92)	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY023397-10				414,180	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	7 R01 EY024063-04				756	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY024373-05				1,991	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY027746-05				276,365	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY028133-04			269,782	454,180	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY029298-03				1,093	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY029693-03			6,202	369,373	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY031315-02				323,437	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R21 EY032592-02			123,758	225,614	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R21 EY032724-02				195,009	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	1 R21 EY033473-01				107,482	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U24 EY029903-03	STANFORD UNIVERSITY	5 U24 EY029903-03		126,785	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U24 EY029903-04	STANFORD UNIVERSITY	5 U24 EY029903-04		229,463	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U24 EY029893-02			3,118	3,118	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U24 EY029893-03			76,529	138,777	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U24 EY029893-04			864,457	1,137,580	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	3 U24 EY029893-04S1				101,206	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 UG1 EY029658-03	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 UG1 EY029658-03		2,691	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 UG1 EY031651-02	UNIVERSITY OF PITTSBURGH	5 UG1 EY031651-02		22,433	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY002686-43	VANDERBILT UNIVERSITY	5 R01 EY002686-43		10,472	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY002686-44	VANDERBILT UNIVERSITY	5 R01 EY002686-44		7,672	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	1 R01 EY013769-01	VANDERBILT UNIVERSITY	1 R01 EY013769-01		1,922	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 R01 EY027729-04	VANDERBILT UNIVERSITY	5 R01 EY027729-04		137,097	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
VISION RESEARCH	93.867	5 R01 EY030490-02	VANDERBILT UNIVERSITY	5 R01 EY030490-02		\$ 1,922	\$ 7,024,951	RESEARCH AND DEVELOPMENT	\$ 493,731,962
VISION RESEARCH	93.867	1 R01 EY032670-01	VANDERBILT UNIVERSITY	1 R01 EY032670-01		48,251	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 T32 EY021453-10	VANDERBILT UNIVERSITY	5 T32 EY021453-10		5,293	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	1 U54 EY032442-01	VANDERBILT UNIVERSITY	1 U54 EY032442-01		51,806	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
VISION RESEARCH	93.867	5 U54 EY032442-02	VANDERBILT UNIVERSITY	5 U54 EY032442-02		100,583	7,024,951	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 U19 AG063911-03	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH	5 U19 AG063911-03		89,158	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM010685-12				599,474	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM012854-03				357,199	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	7 R01 LM012964-04			\$ 35,926	226,784	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	1 R21 LM013807-01A1				41,370	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	9 R01 LM013712-05A1	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9 R01 LM013712-05A1		9,397	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	2 R01 LM012806-05	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	2 R01 LM012806-05		22,468	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-18	VANDERBILT UNIVERSITY	5 T15 LM007450-18		(4,512)	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-19	VANDERBILT UNIVERSITY	5 T15 LM007450-19		11,811	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-19	VANDERBILT UNIVERSITY	5 T15 LM007450-19		141,364	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-20	VANDERBILT UNIVERSITY	5 T15 LM007450-20		31,183	1,525,696	RESEARCH AND DEVELOPMENT	493,731,962
GRANTS FOR PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	5 T0BHP33102-03-00	MEHARRY MEDICAL COLLEGE	5 T0BHP33102-03-00		18,069	18,069	RESEARCH AND DEVELOPMENT	493,731,962
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	249104:ST TN	TN DEPARTMENT OF HEALTH	249104:ST TN		42,980	42,980	N/A	—
CANCER PREVENTION AND CONTROL PROGRAMS FOR STATE, TERRITORIAL AND TRIBAL ORGANIZATIONS	93.898	65897:ST TN	TN DEPARTMENT OF HEALTH	65897:ST TN		118,635	118,635	RESEARCH AND DEVELOPMENT	493,731,962
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	42015:METRO	METRO-NASH. AND DAVIDSON COUNTY,TENNESSEE	42015:METRO		617,687	819,138	N/A	—
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	6485124:METRO	METRO-NASH. AND DAVIDSON COUNTY,TENNESSEE	6485124:METRO		201,451	819,138	N/A	—
HIV CARE FORMULA GRANTS	93.917	65998:ST TN	TN DEPARTMENT OF HEALTH	65998:ST TN		269,963	989,316	N/A	—
HIV CARE FORMULA GRANTS	93.917	65998:ST TN	TN DEPARTMENT OF HEALTH	65998:ST TN		719,353	989,316	N/A	—
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76 HA30761-05-00				4,001	640,670	N/A	—
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	4 H76 HA30761-05				535,637	640,670	N/A	—
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76 HA30761-06-00				101,032	640,670	N/A	—
HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS	93.941	6 U01 PS005240-01-01			19,761	187,868	187,868	RESEARCH AND DEVELOPMENT	493,731,962
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	70822:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	70822:ST TN		95,436	133,519	N/A	—
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	72568:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	72568:ST TN		38,083	133,519	N/A	—
PPHF GERIATRIC EDUCATION CENTERS	93.969	6 U1Q HP33085-02-01			45,027	45,460	543,671	RESEARCH AND DEVELOPMENT	493,731,962
PPHF GERIATRIC EDUCATION CENTERS	93.969	5 U1Q HP33085-03-00			249,595	494,271	543,671	RESEARCH AND DEVELOPMENT	493,731,962
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 T1M HP39068-01-00			3,648	3,940	543,671	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009337-10			178,433	178,433	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	3 D43 TW009337-11S2			499,315	826,456	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009745-08			87,011	146,399	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009745-09			166,097	222,376	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW011544-02			39,959	96,379	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW011544-03			5,128	67,972	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 D43 TW011949-01			25,757	99,326	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 D43 TW012268-01				17,049	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 G11 TW011529-01				(1,469)	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 G11 TW011529-02			67,393	125,714	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 G11 TW011529-03				\$ 1,031	\$ 2,640,620	RESEARCH AND DEVELOPMENT	\$ 493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 G11 TW011819-01			\$ 22,631	52,406	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 G11 TW011819-02				10,116	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R25 TW009722-09			64,029	112,118	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R25 TW009722-10			105,803	153,565	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R21 TW011327-02			3,583	77,981	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)									
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW010559-04		5 D43 TW010559-04		49,145	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	2 D43 TW009744-07A1	UNIVERSITY OF ZAMBIA	2 D43 TW009744-07A1		63,011	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 R25 TW011219-02	UNIVERSITY OF ZAMBIA	1 R25 TW011219-02		(773)	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 R25 TW011219-03	UNIVERSITY OF ZAMBIA	1 R25 TW011219-03		5,698	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 U2R TW011248-01				114	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 U2R TW011248-03			186,650	329,761	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 U2R TW011248-04				8,137	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009337-10				(325)	2,640,620	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	57826:ST TN	TN DEPARTMENT OF HEALTH	57826:ST TN		(1,185)	608,595	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	65891:ST TN	TN DEPARTMENT OF HEALTH	65891:ST TN		236,620	608,595	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	65891:ST TN	TN DEPARTMENT OF HEALTH	65891:ST TN		(804)	608,595	RESEARCH AND DEVELOPMENT	493,731,962
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	67188:ST TN	TN DEPARTMENT OF HEALTH	67188:ST TN		373,964	608,595	N/A	—
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION	93.998	1 NU53 DD000010-02-00				287,865	526,277	N/A	—
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION	93.998	5 NU53DD000010-04-00				238,412	526,277	N/A	—
200-2012-50430	93.RD	200-2012-50430				296,167	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
200-2012-50430	93.RD	200-2012-50430				1,160,087	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
200-2016-91801	93.RD	200-2016-91801			7,568,904	9,827,880	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30120C07637	93.RD	75D30120C07637			102,600	397,208	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30121C10094	93.RD	75D30121C10094				1,727,313	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30121C11513	93.RD	75D30121C11513				989,029	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30121C11656	93.RD	75D30121C11656			1,045,618	3,069,464	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30122C12914	93.RD	75D30122C12914			2,895,578	4,424,842	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30122C13379	93.RD	75D30122C13379				13,196	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75FCMC19D0093	93.RD	75FCMC19D0093				48,242	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N91021C00046	93.RD	75N91021C00046				19,879	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N91021P00623	93.RD	75N91021P00623				33,452	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N91021P00873	93.RD	75N91021P00873				46,470	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00074	93.RD	75N93019C00074				17,381	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00074	93.RD	75N93019C00074			30,090	481,154	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00074	93.RD	75N93019C00074			25,189	311,712	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00074	93.RD	75N93019C00074				379,081	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N95D19P00178	93.RD	75N95D19P00178				19,336	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N95D21P00135	93.RD	75N95D21P00135				7,876	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N97019P00279	93.RD	75N97019P00279				78,213	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D301-19-C-05584	93.RD	75D301-19-C-05584	BOSTON CHILDREN'S HOSPITAL	75D301-19-C-05584		4,152	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30120C07725	93.RD	75D30120C07725	BOSTON CHILDREN'S HOSPITAL	75D30120C07725		241,120	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30121C10297	93.RD	75D30121C10297	BOSTON CHILDREN'S HOSPITAL	75D30121C10297		184,776	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	BRIGHAM AND WOMEN'S HOSPITAL	75F40119D10037		543,100	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	BRIGHAM AND WOMEN'S HOSPITAL	75F40119D10037		82,866	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	BRIGHAM AND WOMEN'S HOSPITAL	75F40119D10037		201,078	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
200-211-41276	93.RD	200-211-41276	DUKE UNIVERSITY	200-211-41276	32,781	44,581	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		52,212	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		\$ 747	\$ 27,049,092	RESEARCH AND DEVELOPMENT	\$ 493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		42,620	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		20,182	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		7,460	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		13,417	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		53,454	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		273,244	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		19,059	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		31,659	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119D10037	93.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		67,681	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSF223201400030I	93.RD	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		44,596	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHS-CAOD-2021-NHLBI-00	93.RD	HHS-CAOD-2021-NHLBI-00				32,051	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				101,263	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				2,086	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				7,602	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				9,539	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				18,897	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				5,546	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				(476)	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				5,404	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201300023I	93.RD	HHSN272201300023I				(476)	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93020C00027	93.RD	75N93020C00027	IDBIOLOGICS, LLC	75N93020C00027		1,837	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N993020C00027	93.RD	75N993020C00027	IDBIOLOGICS, LLC	75N993020C00027		29,184	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00073	93.RD	75N93019C00073	INTEGRAL MOLECULAR	75N93019C00073		148,160	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00073	93.RD	75N93019C00073	INTEGRAL MOLECULAR	75N93019C00073		161,811	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019D00031	93.RD	75N93019D00031	JOHNS HOPKINS UNIVERSITY	75N93019D00031		339,751	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N91019D00024	93.RD	75N91019D00024	LEIDOS BIOMEDICAL RESEARCH, INC. (FORMERLY SAIC-FREDERICK)	75N91019D00024		75,159	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75D30121C10168	93.RD	75D30121C10168	MEDICAL UNIVERSITY OF SOUTH CAROLINA	75D30121C10168		9,856	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N91020C00046	93.RD	75N91020C00046	OUTCOMES4ME	75N91020C00046		15,996	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSP233201500024I	93.RD	HHSP233201500024I	RESEARCH TRIANGLE INSTITUTE	HHSP233201500024I		69,719	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
HHSN272201600018C	93.RD	HHSN272201600018C	UNIVERSITY OF ALABAMA AT BIRMINGHAM	HHSN272201600018C		1,948	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75Q80120D00018	93.RD	75Q80120D00018	UNIVERSITY OF CHICAGO	75Q80120D00018		59,024	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75F40119C10090	93.RD	75F40119C10090	UNIVERSITY OF COLORADO	75F40119C10090		33,532	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00052	93.RD	75N93019C00052	UNIVERSITY OF GEORGIA	75N93019C00052		249,161	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N3019C00055	93.RD	75N3019C00055	UNIVERSITY OF MARYLAND	75N3019C00055		27,643	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00055	93.RD	75N93019C00055	UNIVERSITY OF MARYLAND	75N93019C00055		125,905	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
4I-WDR5-MLL1	93.RD	4I-WDR5-MLL1	VANDERBILT UNIVERSITY	4I-WDR5-MLL1		1,467	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
4I-WDR5-MLL1	93.RD	4I-WDR5-MLL1	VANDERBILT UNIVERSITY	4I-WDR5-MLL1		3,954	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE (CONTINUED)
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
75N91019D00024	93.RD	75N91019D00024	VANDERBILT UNIVERSITY	75N91019D00024		\$ 33,770	\$ 27,049,092	RESEARCH AND DEVELOPMENT	\$ 493,731,962
75N93019C00062	93.RD	75N93019C00062	WASHINGTON UNIVERSITY IN ST. LOUIS	75N93019C00062		101,273	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
75N93019C00062	93.RD	75N93019C00062	WASHINGTON UNIVERSITY IN ST. LOUIS	75N93019C00062		102,520	27,049,092	RESEARCH AND DEVELOPMENT	493,731,962
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$ 106,686,421	\$ 594,055,606			
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT									
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	720-656-18-C-00001				261,137	398,089	N/A	—
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	AID-OAA-A-11-00012	THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE	AID-OAA-A-11-00012	30,158	136,952	398,089	N/A	—
USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT	98.012	720-OAA-18-CA-00019			55,122	106,581	231,832	N/A	—
USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT	98.012	720-OAA-21-CA-00010	YALE UNIVERSITY	720-OAA-21-CA-00010		125,251	231,832	N/A	—
TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT					85,280	629,921			
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$ 110,708,104	\$ 621,616,008			

Please Note:
Italicized award lines indicate pass-through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

VANDERBILT UNIVERSITY MEDICAL CENTER
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE
Fiscal Period 7/1/2021 - 6/30/2022

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$ 110,708,104	\$ 621,616,008			
STATE FINANCIAL ASSISTANCE									
PSYLTDHDDFET MW				6442:STTN BOP	—	100,772			
DOC (BOP) RISK ASSESSMENTS				6442:STTN BOP	—	23,265			
COMMUNITY FORENSIC-JUV CT EVALUATIONS				6442:STTN CFJCE	—	98,107			
54788:COVID 19 HOTLINE SUPPORT				54788:ST TN	—	(163)			
54788:COVID 19 HOTLINE SUPPORT				54788:ST TN	—	147,268			
55782:VU:TENNESSEE BLUEPRINT				55782:ST TN-VU	—	4,408			
57826:CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE CYSHCN				57826:ST TN	—	(991)			
233330:QUALITY IMPROVEMENT COLLABORATIVE FOR COVID-19 P				233330:ST TN	—	582,140			
64198:COMPREHENSIVE CARE CLINIC FOR STATE APPROVED CLIENTS				64198:ST TN	—	(1,294)			
64198:COMPREHENSIVE CARE CLINIC FOR STATE APPROVED CLIENTS				64198:ST TN	—	101,944			
215466:THE ENHANCEMENT GOALS OF CARE DISCUSSIONS IN TN LTC FACIL				215466:ST TN	—	27,401			
56787:CPS ASSESSMENT TRACK TRAINING ACADEMY				56787:ST TN	—	151,987			
65891:GENETIC SCREENING, TESTING, COUNSELING-STATE FUND				65891:ST TN	—	(54)			
65891:GENETIC SCREENING, TESTING, COUNSELING-STATE FUND				65891:ST TN	—	751,807			
34001-99205:CLOVER BOTTOM NEUROLOGY SPASTICITY CLINICS				34001-9925:ST TN	—	23,206			
62967:MED-ASSISTED TREATMENT SERVICES				62967:MED-ASSISTED TRT	—	22,183			
67188:POISON CONTROL SERVICES				67188:ST TN	—	374,928			
63811:SAFE BABY COURTS-STATE				63811:ST TN	—	56,466			
70659:TENNESSEE INTEGRATED COURT SCREENING AND REFERRAL PROJ				70659:ST TN	—	53,948			
64491:STRATEGIC TRAINING, ANALYSIS AND RESOURCES FOR				64491:ST TN	—	337,740			
INTERNAL CAR SEAT PROGRAM				STATE OF TENNESSEE	—	4,390			
DISSEMINATION OF MOTIVATIONAL INTERVIEWING IN CHILD WELFARE				ST OF TN-CASEY FAMILY	—	32,164			
TOTAL STATE FINANCIAL ASSISTANCE					—	2,891,622			
TOTAL EXPENDITURE OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE					\$ 110,708,104	\$ 624,507,630			

Please Note:

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

Vanderbilt University Medical Center
Notes to the Schedule of Expenditures of Federal Awards
and State Financial Assistance
For the Year Ended June 30, 2022

1. Significant Accounting Policies Used in Preparing the Schedule of Expenditures of Federal Awards (SEFA)

The accompanying Schedule of Expenditures of Federal Awards and State Financial Assistance (the Schedule) includes the activity of Vanderbilt University Medical Center (VUMC) under programs of the federal government and of the State of Tennessee for the year ended June 30, 2022. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the State of Tennessee Audit Manual. For purposes of the Schedule, federal and state awards include all grants, contracts, and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all subawards to VUMC by organizations pursuant to federal grants, contracts, and similar agreements, and agencies and departments of the Tennessee state government, including federal awards passed through by the state of Tennessee.

2. 10% De Minimis Cost Rate

VUMC did not use the de minimis cost rate.

3. Summary of Significant Accounting Policies for the Schedule

For purposes of the Schedule, expenditures for federal and state programs are recognized on the accrual basis, which is consistent with accounting principles generally accepted in the United States of America. Expenditures for federal and state awards of VUMC are determined using the cost accounting principles and procedures set forth in the Uniform Guidance and the State of Tennessee Audit Manual. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498) Reporting Periods 2 and 3

The Schedule includes \$58.7 million received from the Department of Health and Human Services (HHS) between July 1, 2020 and June 30, 2021, under the Provider Relief Fund (PRF) program of Assistance Listing No. 93.498. In accordance with guidance from HHS, the amounts from Fiscal 2022 are presented as Periods 2 and 3 in the HHS Reporting Portal. Such amounts were recognized as other operating revenue in VUMC's consolidated financial statements in the accompanying consolidated statement of operations and changes in net assets for the year ended June 30, 2022. Due to the PRF Reporting Portal requirements, these amounts are not the total PRF received and/or recognized by VUMC as other operating revenue in VUMC's consolidated financial statements for the year ended June 30, 2022.

The amount presented on the Schedule for PRF is for the fiscal year ended June 30, 2022. The amount presented reconciles to the PRF information reported to HHS as follows:

Name of Reporting Entity for HHS Reporting Periods 2 and 3 Provider Relief Fund Report	Reporting Entity Tax Identification Number (TIN)	Type of Distributi on	Total Other Provider Relief Fund Expenses Reported	Total Lost Revenues Reported	Total
Vanderbilt University Medical Center	352528741	General	\$ 6,359,220	\$ 43,473,028	\$ 49,832,248
Vanderbilt University Medical Center	352528741	Targeted	—	8,820,810	8,820,810
Total			<u>\$ 6,359,220</u>	<u>\$ 52,293,838</u>	<u>\$ 58,653,058</u>

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Senior Management and the Board of Directors
Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheet as of June 30, 2022, and the related consolidated statements of operations, changes in net assets and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated September 30, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Vanderbilt University Medical Center's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Vanderbilt University Medical Center's internal control. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Vanderbilt University Medical Center's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

September 30, 2022

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors
Vanderbilt University Medical Center

Report of Independent Auditors on Compliance for Each Major Federal Program

Qualified and Unmodified Opinions

We have audited Vanderbilt University Medical Center's compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of Vanderbilt University Medical Center's major federal programs for the year ended June 30, 2022. Vanderbilt University Medical Center's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Qualified Opinion on COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

In our opinion, except for the noncompliance described in the Basis for Qualified and Unmodified Opinions section of our report, Vanderbilt University Medical Center complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on *COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund* for the year ended June 30, 2022.

Unmodified Opinion on Each of the Other Major Federal Programs

In our opinion, Vanderbilt University Medical Center complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its other major federal programs identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs for the year ended June 30, 2022.

Basis for Qualified and Unmodified Opinions

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Vanderbilt University Medical Center and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program. Our audit does not provide a legal determination of Vanderbilt University Medical Center's compliance with the compliance requirements referred to above.

Matter Giving Rise to Qualified Opinion on COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Vanderbilt University Medical Center did not comply with requirements regarding Assistance Listing 93.461, *COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund*, as described in finding 2022-001 for A. Activities Allowed or Unallowed, E. Eligibility, and N. Special Tests and Provisions.

Compliance with such requirements is necessary, in our opinion, for Vanderbilt University Medical Center to comply with requirements applicable to that program.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to Vanderbilt University Medical Center's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Vanderbilt University Medical Center's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Vanderbilt University Medical Center's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Vanderbilt University Medical Center's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Vanderbilt University Medical Center's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Vanderbilt University Medical Center's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

Our audit of the major federal program identified as Assistance Listing No. 93.461 included certain audit procedures for the compliance requirement associated with activities allowed or unallowed that were limited to tests of compliance that reimbursements received, or expected to be received, related to health services allowed under this federal program. Our audit of compliance was not designed to test or provide assurance on the determination of whether a service was medically necessary, obtained through a legally appropriate referral, properly performed, rendered in a quality manner from a clinical perspective, adequately supervised, accurately documented and classified (i.e., that the correct medical bill code assigned represents the health service performed), or rendered and billed by non-sanctioned individuals. Performing procedures related to these matters is not within our professional expertise. Additional information on the nature of our procedures is available in the AICPA Audit and Accounting Guide, *Health Care Entities*. Our audit procedures for the compliance requirement associated with eligibility were limited to tests of compliance that services reimbursed, or expected to be reimbursed, were for individuals who received a temporary member identification number from the third-party service provider used by HRSA to identify a lack of active health care coverage.

The results of our auditing procedures disclosed another instance of noncompliance which is required to be reported in accordance with the Uniform Guidance, and which is described in the accompanying schedule of findings and questioned costs:

Finding No.	Assistance Listing No.	Program Name	Compliance Requirement
2022-002	93.067	Global AIDS	L. Reporting

Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on Vanderbilt University Medical Center's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be material weaknesses.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. We consider the following deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses.

Finding No.	Assistance Listing No.	Program Name	Compliance Requirement
2022-001	93.461	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	A. Activities Allowed or Unallowed E. Eligibility N. Special Tests and Provisions
2022-002	93.067	Global AIDS	L. Reporting
2022-003	93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	A. Activities Allowed or Unallowed L. Reporting

A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance yet important enough to merit attention by those charged with governance.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on Vanderbilt University Medical Center's response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst & Young LLP

February 3, 2023

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2022

Section I – Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

_____ Yes X No

Significant deficiency(ies) identified?

_____ Yes X None reported

Noncompliance material to financial statements noted?

_____ Yes X No

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified?

 X Yes _____ No

Significant deficiency(ies) identified?

_____ Yes X None reported

Type of auditor’s report issued on compliance for major federal programs:

Assistance Listing #	Name of Major Federal Program or Cluster	Type of Opinion on Major Program
Various	Research & Development Cluster	Unmodified
93.067	Global AIDS	Unmodified
93.461	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	Qualified
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	Unmodified
21.027	COVID-19 Coronavirus State and Local Fiscal Recovery Funds	Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 X Yes _____ No

Identification of major federal programs:

Assistance Listing number(s)	Name of Federal Program or Cluster
Various	Research & Development Cluster
93.067	Global AIDS
93.461	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
21.027	COVID-19 Coronavirus State and Local Fiscal Recovery Funds

Dollar threshold used to distinguish between Type A and Type B programs:

\$ 3,000,000

Auditee qualified as low-risk auditee?

_____ Yes X No

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Section II – Financial Statement Findings

No findings reported.

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Section III – Federal Award Findings and Questioned Costs

Finding 2022-001

Identification of the federal program:

Federal Grantor: United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Pass-Through Award Period of Performance: 07/01/2021–06/30/2022

Criteria or specific requirement (including statutory, regulatory, or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Health and Human Services (HHS) – Health Resources and Services and Administrative (HRSA) issued Terms and Conditions for Participation in the HRSA COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program (T&Cs) outlining requirements that recipients of funding from the HRSA COVID-19 Uninsured Program must comply with, including the following sections: Testing Services, Treatment Services and Vaccine Administration, and General Provisions in FY2020 Consolidated Appropriations.

Per the HRSA T&Cs and further clarified in the HRSA FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration, the FAQ states the following:

“If a provider tests for COVID-19 as part of pre-operative or other medical treatment unrelated to COVID-19, is the test eligible for reimbursement? For the HRSA COVID-19 Uninsured Program, COVID-19 testing is eligible for reimbursement if one of the following diagnoses codes is included in any position on the claim:

- Z03.818 – Encounter for observation for suspected exposure to other biological agents ruled out (possible exposure to COVID-19)
- Z11.59 – Encounter for screening for other viral diseases (asymptomatic)
- Z20.828 – Contact with and (suspected) exposure to other viral communicable (confirmed exposure to COVID-19)
- Z11.52 – Encounter for screening for COVID-19 (asymptomatic)
- Z20.822 – Contact with and (suspected) exposure to COVID-19
- Z86.16 – Personal history of COVID-19

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Related treatment visits and services are not eligible for reimbursement given the primary reason for treatment is not COVID-19.”

Condition:

Vanderbilt University Medical Center (VUMC) did not retain audit evidence to support the report logic that was developed to extract patients from the patient billing systems that were identified as having an allowable COVID-19 testing and treatment diagnosis code and eligible for reimbursement under this federal program. In addition, supporting documentation was not retained to validate who had access to modify and run the script, what changes were made to the script and how any changes to the script were tested and implemented during the fiscal year based on changes to HRSA guidance, and how management validated the completeness and accuracy of the data extracted by the script.

For certain emergency department, physician office visits, and inpatient claims that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, VUMC erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

Cause:

Management did not develop and maintain effective internal control over report writing, program changes, and user access. VUMC did not have internal controls in place to ensure claims billed to the HRSA COVID-19 Uninsured Program were in accordance with HRSA Uninsured Program regulations.

Effect or potential effect:

The key report used to identify eligible federal program participants could be inaccurate or incomplete.

VUMC did not have internal controls in place to formally document its compliance with the HRSA COVID-19 Uninsured Program’s allowability and eligibility requirements. Outpatient encounters that included a COVID-19 testing diagnosis code, where the primary treatment diagnosis code was not COVID-19 related, were not reviewed for allowability and eligibility prior to submission to HRSA to verify treatment costs were allowable under the HRSA COVID-19 Uninsured Program.

Questioned costs:

\$336,536

Context:

Management performed an analysis over claims submitted to HRSA related to services with dates of service from July 1, 2021 through June 30, 2022, indicating that 1,013 patient accounts totaling \$336,536 related to certain claims where COVID-19 was not the primary diagnosis were inappropriately billed to HRSA. The \$336,536 was refunded to HRSA in August 2022.

Total federal expenditures for Assistance Listing 93.461 totaled \$5,809,048 for the year ended June 30, 2022.

Identification as a repeat finding, if applicable:

2021-001

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Recommendation:

The Uninsured Program ended in 2022; therefore, the development of internal controls is not required. However, if the program were to continue, VUMC should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement. VUMC should retain evidence of internal controls related to access and change management over the report. Management should implement a quality review process of eligible claims identified on a monthly basis to ensure that patients identified meet the required eligibility requirements.

Views of responsible officials:

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program, and therefore, remediation of internal controls is no longer applicable.

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Finding 2022-002

Identification of the federal program:

Federal Grantor: U.S. Department of Health and Human Services

Assistance Listing No.: 93.067, Global AIDS

Award Number: 5 NU2 GGH001943-04-00 and 6 NU2 GGH001943-05-00

Award Year: 2021–2022

Criteria or specific requirement (including statutory, regulatory, or other citation):

2 CFR 200.303 requires that a non-federal entity “must (a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States and the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Under the requirements of the Federal Funding Accountability and Transparency Act (Pub. L. No. 109-282) (Transparency Act) that are codified in 2 CFR Part 170, recipients (i.e., direct recipients) of grants or cooperative agreements who make first tier subawards of \$30,000 or more are required to register in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) and report subaward data through FSRS.

Condition:

VUMC is a prime recipient of funding from the Centers for Disease Control and Prevention related to the Global AIDS grant and made first tier subawards of greater than \$30,000. VUMC filed a single report in FSRS for the total of all its subawards instead of filing a separate report for each subaward.

Cause:

Policies and procedures and internal controls were not in place to ensure compliance with the Transparency Act.

Effect or potential effect:

VUMC did not comply with the Transparency Act and report all required information in FSRS.

Questioned costs:

\$0

Context:

VUMC made first tier subawards to 22 subrecipients totaling \$3,885,454 in federal expenditures. Total Global AIDS expenditures totaled \$41,208,584. Subaward reports were not independently reported in the FSRS.

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Identification as a repeat finding, if applicable:

2021-002

Recommendation:

We recommend that VUMC implement internal controls and a review process to ensure that subrecipients are appropriately entered into FSRS.

Views of responsible officials:

VUMC is a prime recipient of funding from the Centers for Disease Control and Prevention related to the Global AIDS grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient, as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global AIDS subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Finding 2022-003

Identification of the federal program:

Federal Grantor: U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

Assistance Listing: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

Award Year: 2021–2022

Criteria or specific requirement (including statutory, regulatory, or other citation):

2 CFR Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

Management did not retain supporting documentation over its review and approval of the lost revenue calculation and expenses reported in the HHS portal.

Cause:

Management represented it performed a review and approval of the lost revenue calculation, COVID-19 expenses, and HHS portal submission of lost revenue; however, adequate supporting documentation to evidence that the internal controls were sufficiently designed and operating effectively was not maintained.

Effect or potential effect:

A lack of internal controls over the review of the lost revenue calculation, COVID-19 expenses, and the data submitted in the HHS portal could result in a misstatement of the amounts reported in the HHS portal.

Questioned costs:

\$0

Context:

VUMC had two submissions to HRSA during FY22, which included expenses and lost revenue. Total federal expenditures for Assistance Listing No. 93.498 totaled \$58,653,058 for the year ended June 30, 2022.

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)
For the Year Ended June 30, 2022

Identification as a repeat finding, if applicable:

2021-003

Recommendation:

Management should implement internal controls over the review and approval of the data used to calculate lost revenue and expenses and the report of lost revenue in the HHS portal.

Views of responsible officials:

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control; however, management understands that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2023 Ernst & Young LLP.
All Rights Reserved.

ey.com

**Vanderbilt University Medical Center
Management's Corrective Action Plan
For the Year Ended June 30, 2022**

Finding 2022-001

Federal Grantor: United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program, and therefore, remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year-end 2023.

Finding 2022-002

Federal Grantor: U.S. Department of Health and Human Services

Assistance Listing No.: 93.067, Global AIDS

Award Number: 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from the Centers for Disease Control and Prevention related to the Global AIDS grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient, as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global AIDS subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year-end 2023.



**Vanderbilt University Medical Center
Management's Corrective Action Plan (continued)
For the Year Ended June 30, 2022**

Finding 2022-003

Federal Grantor: U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.498, COVID-19 Provider Relief Fund and American Rescue Plan (ARP)
Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control; however, Management understands that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year-end 2023.



**Summary Schedule of Prior Year Audit Findings
FOR THE Year Ended June 30, 2021**

Finding 2021-001

Federal Grantor: United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)
Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program, and therefore, remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year-end 2023.

Status: Refunds were paid in fiscal year 2023.

Finding 2021-002

Federal Agency: U.S. Department of Health and Human Services
Assistance Listing No.: 93.067, Global AIDS
Award Number: 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from the Centers for Disease Control and Prevention related to the Global AIDS grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient, as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global AIDS subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year-end 2023.

Status: The corrective action plan will be implemented by fiscal year-end 2023.

**Finding 2021-003**

Federal Agency: U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP)
Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control; however, Management understands that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year-end 2023.

Status: The corrective action plan will be implemented by fiscal year-end 2023.

2020-001 – SUSPENSION AND DEBARMENT

Federal Program Information:	Federal Agency and Program Name	Assistance Listing No.
	Global AIDS	93.067
	Grant Award 5 NU2 GGH001943-04-00	
	Grant Award 6 NU2 GGH001943-03-10	

Finding:

During our testing of 40 transactions, totaling \$337,363 for suspension and debarment of the Global AIDS program, we noted that for 11 transactions, totaling \$20,269, there was a lack of supporting documentation demonstrating that management was monitoring the contractors to ensure they were not suspended or debarred when the purchase was made; this was determined to be a systemic issue. Vanderbilt University Medical Center does not have adequately designed internal controls and policies and procedures in place to ensure that contractors are being properly monitored for suspension and debarment.

Status:

The corrective action plan was taken.